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about this Publication
In 2008, Harm Reduction International released the Global State of Harm Reduction, a report that 
mapped responses to drug-related HIV and hepatitis C epidemics around the world for the first time. 
The data gathered for the report provided a critical baseline against which progress could be measured 
in terms of the international, regional and national recognition of harm reduction in policy and practice. 
Since then, the biennial report has become a key publication for researchers, policymakers, civil society 
organisations and advocates, mapping harm reduction policy adoption and programme implementation 
globally.
The Global State of Harm Reduction 2014 continues to map the response to drug-related HIV, viral 
hepatitis and tuberculosis. It also integrates updated information on harm reduction services into each 
regional chapter, including on needle and syringe programmes (NSPs) and opioid substitution therapy 
(OST) provision; harm reduction services in the prison setting; access to antiretroviral therapy for people 
who inject drugs; regional overdose responses; policy developments; civil society developments; and 
information relating to funding for harm reduction.
This report, and other global state of harm reduction resources, are designed to provide reference 
tools for  wide range of audiences, such as international donor organisations, multilateral and bilateral 
agencies, civil society and non-governmental organisation, including organisations of people who use 
drugs, as well as researchers and the media.
If you would like to find out more about Harm Reduction International
and how you can support our work, please contact us at:
Harm Reduction International
Unit 2C09, South Bank Technopark
90 London Road, London, SE1 6LN
Phone:  +44 (0)207 7171 592
Email: info@ihra.net
Web: www.ihra.net
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AHRN Asian Harm Reduction Network 
AIVL Australian Injecting and Illicit Drug Users’ League 
AIDS Acquired immunodeficiency syndrome 
ANPUD Asian Network of People who use Drugs 
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CPR Cardiopulmonary resuscitation 
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EMCDDA European Monitoring Centre for Drugs and Drug 
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GDP Gross Domestic Product 
GFATM Global Fund to Fight AIDS, Tuberculosis and 
Malaria 
GP General practitioner 
GTZ Deutsche Gesellschaft für Technische 
Zusammenarbeit 
HAT Heroin assisted treatment 
HBV Hepatitis B virus 
HBsAG Marker in the blood indicating active HBV 
infection 
HCV Hepatitis C virus 
HIV Human immunodeficiency virus 
HLS High Level Segment 
IDU Injecting drug use 
IHRA International Harm Reduction Association 
INCB International Narcotics Control Board 
INPUD International Network of People who Use Drugs 
MENA Middle East and North Africa 
MENAHRA Middle East and North African Harm Reduction 
Network 
MDT Mandatory drug testing 
MMT Methadone maintenance treatment 
MSM Men who have sex with men 
NASA National AIDS Spending assessment 
NGO Non-governmental organisation 
NIDU Non-injecting drug use 
NSP Needle and syringe exchange programme 
OST Opioid substitution therapy 
PAHO Pan American Health Organization (WHO) 
PEPFAR President’s Emergency Plan for AIDS Relief 
PICTs Pacific Island Countries and Territories 
PNEP Prison needle and syringe exchange programme 
SAHRN Sub-Saharan African Harm Reduction Network 
SAMHSA US Substance Abuse and Mental Health Services 
Administration 
SIF Supervised or safer injecting facility 
STI Sexually transmitted infection 
SPC Secretariat of the Pacific Community 
TB Tuberculosis
UAE United Arab Emirates 
UK United Kingdom of Great Britain and Northern 
Ireland 
UN United Nations 
UNAIDS Joint United Nations Programme on HIV/AIDS 
UNDP United Nations Development Programme 
UNESCO United Nations Economic, Social and Cultural 
Organization 
UNFPA United Nations Population Fund 
UNGASS United Nations General Assembly Special Session
UNICEF United Nations Children’s Fund 
UNODC United Nations Office on Drugs and Crime 
MENARO 
UNODC
Middle East and North Africa Regional Office 
US United States of America 
VCT Voluntary HIV counselling and testing 
WFP World Food Programme (UN) 
WHO World Health Organization
Abbreviations and acronyms
For the last few decades, those of us in the fight 
against AIDS have rallied together around two 
powerful words: Ending AIDS. Today, we are closer to 
that goal than we have ever been.
And yet, alongside this optimism and hope, there’s 
another set of words that undermines so much of our 
work: Left Behind. 
In most communities, people who inject drugs 
don’t have access to syringes to prevent infections, 
opioid substitution treatment, or naloxone to prevent 
overdose.  Moreover, people who use drugs are 
denied basic health services. They have no access 
to non-judgmental primary care, mental health and 
drug treatment services, and the support they need to 
maintain stable, healthy lives.  
And yet, harm reduction has been proven time 
and again to be extremely effective in curbing HIV 
transmission. In settings where comprehensive harm 
reduction has been implemented, HIV rates among 
people who inject drugs are low—in some cases, 
almost negligible.
This is why the Elton John AIDS Foundation invests 
heavily in harm reduction programming as a core 
priority in our grant making, and we are deeply proud 
of the achievements of our grantees.  In the United 
States, for example, it is calculated that the grantees 
of the Syringe Access Fund, in which we are a lead 
funding partner, reach more than 30,000 people every 
year, with over one million clean syringes and other 
harm reduction services.  This effort in the United 
States is gradually reducing the number of people 
acquiring HIV through injection drug use.  
The Elton John AIDS Foundation was a proud sponsor 
of the International Harm Reduction Conference in 
Vilnius in 2013.  We are also proud to support the 
work of Harm Reduction International in producing 
this valuable report.  And at every opportunity in 
our foundation’s global communications, we profile 
and applaud the many harm reduction workers and 
activists who are at the front lines of this struggle. 
But our efforts alone are not enough. Too many 
people are being left behind and left out—in the 
Americas, in Africa, in Asia, in Eastern Europe.  And 
there continues to be a dangerous shortfall in funding 
for harm reduction to reach the people who need help 
the most. 
Every person left behind is a fellow human being 
– someone’s child, someone’s parent, someone’s 
friend, someone’s partner.  Every one of them has a 
right to life and to health.  Every one of them deserves 
compassion, and dignity, and love.
As we look back on all of the important progress 
we’ve made in recent years, we must remember that 
‘Ending AIDS’ must be much more than a slogan.  It 
must be a realistic vision, grounded in science, and 
funded and implemented in a manner that will reach 
all who are in need. That is why this report is so 
critical.  Because to truly End AIDS, we must make 
sure that no one gets Left Behind.
Foreword by David Furnish
David Furnish
Chair, Elton John AIDS Foundation
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This fourth edition of the Global State of Harm 
Reduction is released at a critical juncture in the 
evolution of the harm reduction response to the use of 
illicit drugs.  
The cost effectiveness and power of harm reduction 
as a means of realising the right to the highest 
attainable standard of health for people who use 
drugs - as a rights affirming, community empowering 
response to our needs - has never been more widely 
recognised. The core harm reduction interventions of 
the ‘comprehensive package’, including the provision 
of sterile needles and syringes and opioid substitution 
therapy (OST), have been clearly demonstrated to 
effectively prevent the transmission of blood borne 
viruses amongst people who inject drugs. 
Yet the funding gap to support harm reduction 
programming and bring it to the scale needed has 
never been more stark. Investment in harm reduction 
as part of overall prevention spending is nowhere 
near proportionate to the incidence of new HIV 
cases amongst people who inject drugs, illustrating 
that donor priorities are out of alignment with the 
epidemiological trend and burden of HIV disease. HIV 
is an epidemic increasingly concentrated amongst 
the key populations (who collectively account for 
approximately half of new infections globally).  
Yet changing donor priorities, and an inability, or 
lack of willingness, to pay on the part of national 
governments means harm reduction programmes 
are either downsizing, not receiving investment 
proportionate to infection rates amongst people who 
inject drugs, running at a level that is nowhere near 
the necessary scale or simply not being provided as 
multilateral donors withdraw.
The severity of the hepatitis C crisis amongst 
people who inject drugs is more acute than HIV by 
several orders of magnitude. Yet harm reduction has 
been so tightly tied to HIV-led imperatives that few 
programmes have been incentivised to provide the 
level or range of equipment or services needed to 
prevent the hepatitis C virus from being inadvertently 
spread. Access to HCV diagnostics, treatment and 
care is scandalously lacking, with people who inject 
drugs denied access to treatment in most countries. 
This is not to speak of the obscene prices being 
demanded for the new generation of direct acting 
antiviral drugs. 
Since the publication of the last Global State of Harm 
Reduction, we have seen several notable statements 
making clear the direct causative connection between 
criminalisation and repressive drug control policies, 
and the systemic human rights abuses to which 
people who use drugs are subject. We have seen 
very welcome World Health Organization (WHO) 
recommendations calling for peer distribution and use 
of naloxone to reduce opioid overdoses, a singularly 
empowering recommendation for the drug using 
community, and a recognition of the central role that 
we can and must play in getting vital services into the 
hands of our community. This closes the cycle that 
saw harm reduction emerge initially from drug user 
activists, to a new recognition that services, if they are 
to be truly accessible, acceptable, and appropriate 
must be returned through a process of power-shifting 
to the communities they serve. This reclamation of 
harm reduction services by the drug using community 
is a process of empowerment, and a recognition of 
the vital role that we play in protecting our health, and 
defending our rights. The success of this agenda, 
however, is contingent upon investment in community 
systems strengthening and empowered organisations, 
networks, and communities of people who use drugs.
Whilst, the retreat from investment in harm reduction 
places the lives, health, and rights of millions of 
people who use drugs around the world in jeopardy, 
the international drug users’ movement has never 
been stronger, having successfully fought to occupy 
our rightful place as a vital partner in every debate 
that impacts upon our lives and health on the 
global, regional and national stages. The wealth of 
knowledge contained in this new edition of the Global 
State of Harm Reduction will be a welcome addition 
to the advocacy armoury of drug user activists 
everywhere, and its publication is warmly welcomed. 
Foreword by Dr Eliot Ross Albers
Dr Eliot Ross Albers
Executive Director  
International Network of People who use Drugs
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About the Global State of  
Harm Reduction 2014
In 2008, Harm Reduction International released 
the Global State of Harm Reduction, a report that 
mapped responses to drug-related HIV and hepatitis 
C epidemics around the world for the first time.(1) 
The data gathered for the report provided a critical 
baseline against which progress could be measured 
in terms of the international, regional and national 
recognition of harm reduction in policy and practice. 
Since then, the biennial report has become a key 
publication for researchers, policymakers, civil 
society organisations and advocates, mapping 
harm reduction policy adoption and programme 
implementation globally. 
In the second and third editions, the Global State of 
Harm Reduction 2010: Key Issues for Broadening the 
Response(2) and The Global State of Harm Reduction 
2012: Towards an Integrated Response,(3) important 
harm reduction issues were explored in a series 
of chapters on key topics, such as the response 
to amphetamine-related harms, harm reduction in 
prisons, effective harm reduction services for women 
who inject drugs, and access to harm reduction 
services by young people. 
The Global State of Harm Reduction 2014 continues 
to map the response to drug-related HIV, viral 
hepatitis and tuberculosis. It also integrates updated 
information on harm reduction services into each 
regional chapter, including on needle and syringe 
programmes (NSPs) and opioid substitution therapy 
(OST) provision; harm reduction services in the prison 
setting; access to antiretroviral therapy for people 
who inject drugs; regional overdose responses; 
policy developments; civil society developments; and 
information relating to funding for harm reduction.      
This report and other Global State of Harm Reduction 
resources can be found at www.ihra.net 
Methodology
The information presented in the two sections of 
the report has been gathered using existing data 
sources, including research papers and reports from 
multilateral agencies, international non-governmental 
organisations, civil society and harm reduction 
networks, organisations of people who use drugs, and 
expert and academic opinion from those working on 
HIV, drug use and harm reduction. Harm Reduction 
International has also enlisted support from regional 
harm reduction networks and researchers to gather 
qualitative information on key developmentsi and 
to review population size estimates, data on the 
epidemiology of HIV and viral hepatitis among people 
who inject drugs, and the extent of NSP and OST 
provision.
Quantitative data for the tables at the beginning of 
each chapter in Section 2 have been obtained from a 
variety of sources and are referenced in each regional 
update. These data reflect the most recent available 
estimates for each country at the time of the data 
collection exercise (June to October 2014). Where 
no source was available, the data were unpublished 
or their reliability were questioned by civil society 
organisations, researchers or other experts, we have 
sought expert opinion to identify additional sources 
and verify their reliability. 
Where information in the tables is dated, we have 
provided footnotes with a year of estimate. Unless 
Harm Reduction International has been able to 
identify more recent data, prevalence figures for viral 
hepatitis have been sourced from the review of reviews 
published by Nelson and colleagues in 2011.(4) Data 
from Western Europe and some countries in Eurasia 
has been sourced from the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) 2014 
Statistical Bulletin, unless otherwise stated in the text. 
Footnotes and references are provided for all estimates 
reported, together with any discrepancies in the data.
Figures published through international reporting systems, 
such as those undertaken by the United Nations Office on 
Drugs and Crime (UNODC), the World Health Organization 
and the Joint United Nations Programme on HIV/AIDS 
(UNAIDS), may differ from those collated here due to 
the varying scopes of monitoring surveys and reliability 
criteria, and a focus on regions that may include different 
country classifications.
Regions have been largely identified using the coverage 
of regional harm reduction networks. Accordingly, this 
report examines Asia, Eurasia (Central and Eastern 
Europe and Central Asia), Western Europe, Caribbean, 
Latin America, North America, Oceania, Middle East and 
North Africa, and sub-Saharan Africa. All regional updates 
have been peer reviewed by experts in the field (see 
Acknowledgements).
Introduction
i A copy of The Global State of Harm Reduction 2014 questionnaire can be obtained by contacting info@ihra.net  
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Data quality
For global population size estimates of people who 
inject drugs and HIV epidemiology, Harm Reduction 
International has presented the UN Reference Group(5) 
data where these are the most recent available 
estimates, and provided data from other sources where 
it is reliable. These include national global AIDS progress 
reports submitted to UNAIDS in March 2014, bio-
behavioural surveillance reports, systematic reviews and 
academic studies. Other experts have been consulted for 
information on the most recent number of NSP and OST 
sites. 
We have sought input from harm reduction networks, 
researchers, academics and other experts to inform 
our reporting on the existence and coverage of harm 
reduction. Where no updates were available, data from 
The Global State of Harm Reduction 2012: Towards an 
Integrated Response(3) has been included, with footnotes 
provided on dates of estimate where necessary.
Although population size estimates for people who 
inject drugs have become available at the national level 
for several countries since 2008 (for example, through 
UNAIDS global AIDS progress reports), a systematic 
calculation of global population size estimates has not 
been conducted in the context of this report. 
Our data on epidemiology and coverage represent the 
most recent, verifiable estimates available. However, a 
lack of uniformity in measures, data collection methods 
and definitions for the estimates provided make cross-
national and regional comparisons challenging. 
The significant gaps in the data are an important 
reminder of the need for a greatly improved monitoring 
and data reporting system on HIV and drug use around 
the world. 
Limitations
The report aims to provide a global snapshot of harm 
reduction policies and programmes, and as such has 
several limitations. It does not provide an extensive 
evaluation of the quality of the services that are in place, 
although where possible, it does highlight areas of 
concern regionally. 
While The Global State of Harm Reduction 2014 aims 
to cover important areas for harm reduction, it focuses 
primarily on public health aspects of the response. The 
report does not document all the social and legal harms 
faced by people who use drugs, nor does it cover all the 
health harms related to substance use, including those 
related to alcohol and tobacco.
Report structure
Section 1 provides a global overview of harm reduction 
policy and programming.
Section 2 contains nine regional updates: Asia, 
Caribbean, Eurasia (Central and Eastern Europe and 
Central Asia), Latin America, Middle East and North 
Africa, North America, Oceania, sub-Saharan Africa and 
Western Europe. These examine developments in harm 
reduction since 2012.
References
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Response to Drug-related HIV and Hepatitis C Epidemics. London: 2008.
2. Cook C. Global State of Harm Reduction 2010: Key Issues for Broadening 
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This report is the fourth in the biennial ‘Global State 
of Harm Reduction’ series tracking developments in 
HIV and hepatitis C related harm reduction worldwide. 
The ‘Global State’ has become a go-to source for 
researchers and advocates since the first edition in 
2008 when it provided, for the first time, an at-a-
glance snapshot of global harm reduction responses. 
Throughout that time there has been slow but steady 
progress in the acceptance of harm reduction in 
national policies and in the establishment of new 
services. The response to HIV and hepatitis C related 
to unsafe injecting, however, remains poor overall.
Injecting drug use has been documented in at 
least 158 countries and territories worldwide.(1)  
Population size estimates  for people who inject 
drugs, however, are challenging to ascertain and  as 
such the global estimate for injecting drug use is a 
range of 8.9-22.4 million.(18) Similar challenges for 
HIV incidence and prevalence data are evident with 
a range of the number of people who inject drugs 
living with HIV of 0.9 – 4.8 million. (18)  It is strongly 
recommended that an independent, transparent peer 
reviewed mechanism is put in place to determine and 
review estimates related to injecting drug use and HIV.
There is urgent concern regarding the global 
target to reduce HIV incidence by 50% among 
people who inject drugs by 2015. While HIV 
incidence has declined slightly in recent years 
from 110,000 (range: 97,000 – 123,000) in 2010 to 
98,000 (range: 85,000 – 111, 000) in 2013, this is a 
reduction of only 10%(37) and indicates the necessity 
of significantly increased harm reduction service 
provision. Of the 158 countries reporting injecting 
drug use 91 of these include harm reduction in 
national policy, while needle and syringe exchange 
programmes (NSPs) and opioid substitution therapy 
(OST) are available in 90 and 80 countries or 
territories respectively (see Table 1.1.1). Two countries 
have recently introduced OST programmes (since 
2012), Burkina Faso and Turkey, and five countries 
or territories globally have newly introduced NSPs 
since 2012. Worryingly, NSP provision in prisons has 
significantly decreased since 2012, with only eight 
countries globally providing this harm reduction 
intervention.
The global state of harm reduction, however, cannot 
be represented solely by numbers. Behind the 
numbers are day to day struggles and incredibly 
complex dynamics at local, national and regional 
levels. This is why these reports have never presented 
the data alone, absent in-depth commentary on 
emerging challenges, unmet needs and policy 
developments. Crucially, The Global State of 
Harm Reduction has always been a civil society 
partnership, including developments in activism and 
service provision alongside the data. What these 
reports show, in addition to the urgent case for harm 
reduction scale up top line data, is the energy and 
innovation of civil society and community-based 
organisations.
In the few places where harm reduction has been 
brought to sufficient scale and quality it has had 
a significant impact in reducing HIV transmission. 
The core harm reduction package endorsed by 
the Joint United Nations Programme on HIV/AIDS 
(UNAIDS), the United Nations Office on Drugs and 
Crime (UNODC) and the World Health Organization 
(WHO) is vital for global responses to the epidemic. 
Nonetheless, harm reduction is facing a crisis. 
International and national funding for essential 
services is disastrously short of need in low- and 
middle-income countries. Unless fundamental 
changes are made in donor priorities, matters are set 
to worsen.
US$ 2.3 billion annually is estimated by UNAIDS to 
be required to fund HIV prevention among people 
who inject drugs in 2015.(38)  At last estimate, only 
US$ 160 million was invested by international donors; 
approximately 7% of what is required.(39) Behind 
these numbers is the spread of preventable disease 
and lives risked and lost. But again civil society is 
taking action. Networks such as the Eurasian Harm 
Reduction Network have taken a lead on advocacy 
for filling the resourcing gap, a challenge that 
disproportionately affects the Eurasian region. 
The money required is significant, but attainable. One 
tenth of the estimated annual global expenditure on 
drug enforcement - thought to exceed $100 billion (40) 
- would cover the $2.3 billion price tag four times 
over. 
Addressing this imbalance requires more than merely 
moving funds. It necessitates a change in government 
priorities in drug control as a prerequisite for those 
funds being reinvested. It is for this reason that 
harm reduction advocacy, alongside frontline service 
provision, remains absolutely essential. This also 
faces severe funding shortfalls.
The numbers present a clear public health and human 
rights challenge. They demonstrate results where 
harm reduction is scaled up, serious harms where 
it is not, and identify where major investments are 
needed. Behind those numbers are the civil society 
frontline workers and activists driving change; and a 
funding crisis in harm reduction setting the agenda for 
advocacy in the coming years. 
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111.1 Global Overview
Country or territory
Explicit supportive reference 
to harm reduction in national 
policy documents
Needle exchange programmes 
operational
Opioid substitution 
programmes operational
Drug consumption room(s)
ASIA
Afghanistan ✓ ✓ ✓ x
Bangladesh ✓ ✓ ✓ x
Cambodia ✓ ✓ ✓ x
China ✓ ✓ ✓ x
Hong Kong ✓ x ✓ x
India ✓ ✓ ✓ x
Indonesia ✓ ✓ ✓ x
Laos PDR ✓ ✓ x x
Macau ✓ ✓ ✓ x
Malaysia ✓ ✓ ✓ x
Maldives ✓ x ✓ x
Mongolia ✓ ✓ x x
Myanmar ✓ ✓ ✓ x
Nepal ✓ ✓ ✓ x
Pakistan ✓ ✓ x x
Philippines ✓ ✓ x x
Taiwan ✓ ✓ ✓ x
Thailand ✓ ✓ ✓ x
Vietnam ✓ ✓ ✓ x
EURASIA
Albania ✓ ✓ ✓ x
Armenia ✓ ✓ ✓ x
Azerbaijan x ✓ ✓ x
Belarus ✓ ✓ ✓ x
Bosnia & Herzegovina ✓ ✓ ✓ x
Bulgaria ✓ ✓ ✓ x
Croatia ✓ ✓ ✓ x
Czech Republic ✓ ✓ ✓ x
Estonia ✓ ✓ ✓ x
Georgia ✓ ✓ ✓ x
Hungary ✓ ✓ ✓ x
Kazakhstan ✓ ✓ ✓ x
Kosovo ✓ ✓ ✓ x
Kyrgyzstan ✓ ✓ ✓ x
Latvia ✓ ✓ ✓ x
Lithuania ✓ ✓ ✓ x
Macedonia ✓ ✓ ✓ x
Moldova ✓ ✓ ✓ x
Montenegro ✓ ✓ ✓ x
Poland ✓ ✓ ✓ x
Table 1.1.1: Countries or territories employing a harm reduction approach in policy or practice
The global harm reduction response
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Country or territory
Explicit supportive reference 
to harm reduction in national 
policy documents
Needle exchange programmes 
operational
Opioid substitution 
programmes operational
Drug consumption room(s)
EURASIA continued
Romania ✓ ✓ ✓ x
Russia x ✓ x x
Serbia ✓ ✓ ✓ x
Slovakia ✓ ✓ ✓ x
Slovenia ✓ ✓ ✓ x
Tajikistan ✓ ✓ ✓ x
Turkmenistan x ✓ x x
Ukraine ✓ ✓ ✓ x
Uzbekistan ✓ ✓ x x
WESTERN EUROPE
Austria ✓ ✓ ✓ x
Belgium ✓ ✓ ✓ x
Cyprus ✓ ✓ ✓ x
Denmark ✓ ✓ ✓ ✓
Finland ✓ ✓ ✓ x
France ✓ ✓ ✓ x
Germany ✓ ✓ ✓ ✓
Greece ✓ ✓ ✓ x
Iceland nk x ✓ x
Ireland ✓ ✓ ✓ x
Italy ✓ ✓ ✓ x
Luxembourg ✓ ✓ ✓ x
Malta ✓ ✓ ✓ x
Netherlands ✓ ✓ ✓ ✓
Norway ✓ ✓ ✓ ✓
Portugal ✓ ✓ ✓ x
Spain ✓ ✓ ✓ ✓
Sweden ✓ ✓ ✓ x
Switzerland ✓ ✓ ✓ ✓
Turkey ✓ x ✓ x
United Kingdom ✓ ✓ ✓ x
CARIBBEAN
Puerto Rico x ✓ ✓ x
Dominican Republic x ✓ x x
Trinidad & Tobago ✓ x x x
131.1 Global Overview
Country or territory
Explicit supportive reference 
to harm reduction in national 
policy documents
Needle exchange programmes 
operational
Opioid substitution 
programmes operational
Drug consumption room(s)
LATIN AMERICA
Argentina ✓ ✓ x x
Brazil ✓ ✓ x x
Colombia ✓ ✓ ✓ x
Mexico ✓ ✓ ✓ x
Paraguay ✓ ✓ x x
Uruguay ✓ ✓ x x
NORTH AMERICA
Canada ✓ ✓ ✓ ✓
United States ✓ ✓ ✓ x
OCEANIA
Australia ✓ ✓ ✓ ✓
New Zealand ✓ ✓ ✓ x
MIDDLE EAST AND NORTH AFRICA
Bahrain x x x x
Egypt ✓ ✓ x x
Iran ✓ ✓ ✓ x
Israel ✓ ✓ ✓ x
Jordan ✓ ✓ x x
Lebanon ✓ ✓ ✓ x
Morocco ✓ ✓ ✓ x
Palestine x ✓ x x
Syria ✓ x x x
Tunisia x ✓ x x
UAE x x ✓ x
SUB-SAHARAN AFRICA
Burkina Faso x x ✓ x
Kenya ✓ ✓ x x
Mauritius ✓ ✓ ✓ x
Senegal ✓ ✓ x x
Seychelles x x ✓ x
South Africa x ✓ ✓ x
Tanzania ✓ ✓ ✓ x
Zanzibar ✓ x x x
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Needle and syringe exchange programmes (NSPs)
In 2014, 90 countries and territories implement NSPs 
to varying degrees. Models of provision include: fixed 
and specialist NSP sites, community-based outreach, 
pharmacy provision and vending machines. Five 
countries have newly implemented NSPs since 2012 
–the Dominican Republic, Colombia, Jordan, Kenya, 
and Senegal. Newly implemented NSPs in sub-
Saharan Africa indicates a steady acceptance of the 
necessity for harm reduction services in regions which 
were previously adverse to such services.
The number of operational NSP sites and the 
coverage provided through existing services vary 
widely among countries and regions. The greatest 
increase in NSP provision has been seen in Malaysia, 
Iran and Australia, where provision has nearly doubled 
since 2012. And a total of 29 countries have scaled 
up NSP services between 2012 to 2014. These 
include: Afghanistan, India, Malaysia, Thailand, 
Armenia, Azerbaijan, Bosnia & Herzegovina, Croatia, 
Georgia, Hungary, Kyrgyzstan, Macedonia, Romania, 
Austria, Belgium, Finland, France, Germany, Greece, 
Ireland, Luxembourg, Norway, Sweden, United States, 
Australia, Egypt, Iran and Morocco. 
Generally, coverage is lower in low- and middle-
income countries than high-income countries, with 
few changes in provision since 2012 in Latin America 
and the Caribbean. However the introduction of NSP 
services in Colombia and the Dominican Republic 
is a positive step forward. Despite the increases in 
provision, existing services in many low- and middle-
income countries do not reach coverage levels 
sufficient to stabilise HIV and hepatitis C epidemics 
among populations of people who inject drugs, 
and in thirteen countries NSP provision has actually 
decreased. Pakistan saw a significant decrease in 
provision from 81 sites in 2012(2) to 34 in 2014,(3) and 
Oman’s NSP service which was operational in 2012 
now ceases to exist.
In 2014, 68 countries or territories with reported 
injecting drug use do not provide NSP services. 
Opioid substitution therapy (OST)
In 2014, 80 countries and territories implement 
OST. Methadone and buprenorphine are the most 
commonly used medications, but in some countries 
others are also provided, including slow-release 
morphine and codeine, and heroin-assisted treatment 
(HAT). Only two countries, Burkina Faso and Turkey 
have newly implemented OST since 2012. OST is also 
now available in Bahrain, but only in rehabilitation 
facilities. 
The number of sites providing OST and the proportion 
of people that receive substitution therapy, is 
substantially higher in high-income countries. Similar 
to NSP, low- and middle-income countries often have 
the fewest number of OST sites. 
In total since 2012, 25 countries have scaled up their 
provision of OST services with Vietnam doubling 
its availability of OST to people who inject drugs 
(see Chapter 2.1). However provision of OST has 
decreased in Estonia, Lithuania, Serbia, Mexico, 
and Australia. And in many countries coverage of 
existing OST programmes remains substantially 
below minimum levels recommended by international 
guidance, and improvement in scale and quality are 
urgently needed to ensure that interventions achieve 
the greatest impact.(4) 
In 2012, 78 countries with reported injecting drug use 
do not provide OST services. 
Drug Consumption Rooms
In 2014 there are now 88 drug consumption rooms 
(DCRs) operating worldwide. DCRs form a vital part 
of harm reduction services in some parts of Western 
Europe, allowing people who use drugs to inject in a 
safe space and under medical supervision. Outside 
of Europe two DCRs are in operation, one in Australia 
and one in Canada.  
In Western Europe, Denmark saw the implementation 
of five DCRs, and both Spain and Switzerland, who 
had previous DCRs in operation increased their site 
provision by six each. Between 2012-2014 a DCR 
was also opened in Greece but closed due to political 
pressures, and a reduction of DCRs has been seen in 
Germany with a decrease of 3 between 2012 to 2014, 
and the Netherlands, which saw a decrease of 10 in 
the same time period. 
Overdose
A recent systematic review found that overdose 
and AIDS related mortality are the leading cases 
of death for people who use drugs(5) and countries 
such as Sweden, which have a critically low harm 
reduction response (see Chapter 2.3) have some of 
the highest death rates among people who use drugs 
on record.(6-7) In Sub-saharan Africa naloxone, a highly 
effective opiate antagonist used to reverse the effects 
of opioid overdose, is newly available in Kenya and 
Tanzania, but the success of this provision is yet to be 
evaluated.(8)
In the United States, as of June 2014, there are 30 
states plus Washington DC that have at least one 
point of access for laypersons to obtain naloxone for 
people who use drugs, or friends and family.(9) Until 
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point of access for laypersons to obtain naloxone for 
people who use drugs, or friends and family.(9) Until 
recently naloxone distribution programmes in Canada 
existed only in Edmonton, Toronto and Ottawa. 
However, since 2012 the British Columbia Centre 
for Disease Control has overseen a rapid scale up of 
overdose prevention and response programmes this 
territory.
Australia’s medically supervised injecting centre (also 
known as a DCR – please refer to Table 2.7.1), which 
provides sterile injecting equipment alongside a range 
of additional services for people who inject drugs, has 
been found to significantly reduce calls to ambulance-
attended opioid-related overdoses in the small area of 
Sydney where it is located,(10) highlighting not only the 
necessity of naloxone in the reduction of drug-related 
deaths, but also the important function of DCRs. 
Prisons
The provision of harm reduction interventions in 
the form of NSPs and OST in prisons and other 
closed settings remains extremely limited compared 
to responses in the community. As of 2014 eight 
countries implement NSPs in prisons, and 43 
countries provide OST in the prison setting. 
NSP is markedly smaller to OST provision in prisons, 
and considering the high rates of injecting drug use 
and the complex interaction of HIV, viral hepatitis 
and tuberculosis in prison settings worldwide(12-13) 
indicates an urgent need to implement and expand 
the provision of NSP services in these settings. In 
Western Europe only Spain, Switzerland, Germany 
and Luxembourg offer NSP provision in the prison 
setting, with the service in Luxembourg under review. 
Armenia, Belarus and Romania all saw their NSP 
services in prisons closed between 2012 to 2014. 
In 2014 there is still no NSP or OST provision in Latin 
America, and provision in sub-Saharan Africa is 
limited to OST provision in male prisons in Mauritius. 
In the Middle East and North Africa NSP and OST is 
still only available in Iran. 
All countries in Western Europe, aside from Greece 
and Cyprus, provide OST for people in prison, but it is 
Malaysia that has the greatest scale-up of OST going 
from 1 prison in 2012(2) to 18 in 2014.(11) 
For the first time, The Global State of Harm Reduction 
2014 attempted to gather information on condom 
provision in prisons, and found that worryingly few 
countries or territories supply condoms to those 
incarcerated.  Coupled with the lack of NSP services 
for people who inject drugs, there is an increased 
need to amend the lack of health-based approaches 
in the prison setting.
The funding crisis for harm reduction
As a part of the Global State of Harm Reduction 
project, HRI began collecting data on donor 
investments in harm reduction in 2009. While funding 
has always been short, in recent years the outlook 
has deteriorated due to donor retreat and national 
government neglect. 
As noted above, only $160 million(38) of the $2.3 
billion(39) needed for HIV-related harm reduction was 
invested by international donors at last count. This 
situation is likely to get worse. International donor 
policy and practice is changing. Increasingly, funds 
are directed towards low-income countries with 
a high disease burden and related HIV treatment 
services. More countries are becoming ineligible 
for international donor support due to their middle-
income status, regardless of epidemiological need or 
the willingness of the national government to step in 
and cover the remaining funding gaps. This is despite 
the fact that the majority of people who inject drugs 
(approximately 75%) live in these countries.
The focus on disease burden also de-prioritises 
prevention even though the lack of access to harm 
reduction services is one of the most important 
factors driving HIV transmission in middle-income 
countries and in key regions – Central and Eastern 
Europe and Central Asia, South and South-East Asia 
and the Middle East and North Africa. 
Donor governments are increasingly relying on 
their contributions to multilateral agencies such as 
The Global Fund to Fight AIDS, Tuberculosis and 
Malaria to fulfil their commitments to key population 
programming. Yet Global Fund policy has also 
changed and now, like some of its main contributors, 
it favours investment in low-income countries with a 
high disease burden.
Meanwhile, national governments are not taking 
responsibility for their own key populations and their 
own epidemics. Even where HIV prevalence rates are 
increasing and harm reduction programme coverage 
is dismally low, many governments are not prioritising 
these programmes.
This is not due to a lack of money, but rather a 
lack of appropriate allocation of resources. At the 
same time as harm reduction services are lacking, 
these governments spend vast amounts on drug 
enforcement, too often targeting and harming the very 
people in need of support, not punishment.
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A report(14) highlighting the global crisis for harm 
reduction funding developed the following 
recommendations:
 » Keep the Global Fund global
 » Invest strategically in harm reduction
 » Increase national harm reduction investment
 » Rebalance existing resources towards health and 
harm reduction 
The Global Fund
In 2013 donor countries pledged a record US$ 
12 billion to the Global Fund.(41) Late the same 
year the Global Fund announced a major change 
in how it provides grants, launching the ‘New 
Funding Model’ to ‘enable strategic investment for 
maximum impact’ and to ‘provide implementers 
with flexible timing, better alignment with national 
strategies and predictability on the level of funding 
available’.(42) The New Funding Model moves away 
from the competitive funding rounds that had been 
implemented previously. Instead, countries are 
assigned to one of four ‘country bands’ and are given 
funding allocations based on their income level and 
disease burden.(42)
Despite the Global fund’s continued support for harm 
reduction, the New Funding Model is a demonstrable 
threat to investments in harm reduction programming, 
as many of the countries with the greatest need for 
harm reduction investment are now either ineligible 
for further funding or are not receiving any ‘new’ 
resources until at least 2017, all as a result of the 
Global Fund’s use of country income status to 
determine national allocations.(14) This is likely to lead 
to dramatic cuts to harm reduction programmes.
Bilateral donors
The New Funding Model at the Global Fund 
exemplifies the broader deprioritisation of middle-
income countries by donors, including those that 
have led the way on harm reduction resourcing. A 
clear example is the UK Department for International 
Development where, due to changes in funding 
priorities, overall bilateral funding for HIV has 
dropped by UK£ 75 million since 2010, and as a 
result the number of DFID-funded HIV programmes 
has dropped from 26 to 16.(14) All harm reduction 
programmes have closed or are due to close by the 
end of 2014, with the exception of programmes in 
Myanmar (funded through the Three Diseases Fund 
until 2016).(14)
International policy developments
United Nations Developments
At the UN level 2013 and 2014 saw the 
announcements of a UN General Assembly Special 
Session on Drugs in 2016 (the first since 1998)(43)  and 
a High Level Meeting on HIV to be held in the same 
year.(44). 2016 therefore looks set to be an important 
year for harm reduction on the international stage. 
However, negotiations relating to harm reduction 
at these events will no doubt be fraught. In March 
2014, for example, a ‘Joint Ministerial Statement’ 
was adopted at the UN Commission on Narcotic 
Drugs. As with other such consensus documents, 
harm reduction was a considerable flashpoint of 
negotiations, creating deadlock for weeks. While 
ultimately remaining in the final agreed document 
there was even considerable controversy as to 
whether previously agreed General Assembly targets 
(a 50% reduction in HIV transmission among people 
who inject drugs by 2015) could be included. The 
evidence base for harm reduction in HIV prevention 
was challenged by the Russian Federation.(45) 
In 2014, a target to ‘eliminate narcotic drug and 
substance abuse’ by 2030 appeared in the draft 
Sustainable Development Goals, illustrating clearly 
the ease with which ill-thought out and counter-
productive language about drugs enters into high 
level debates.(15) Following some advocacy around 
this language, civil society organisations across harm 
reduction, HIV and development managed to secure 
important amendments to better reflect public health 
goals. 
The ongoing inability to come to consensus on 
harm reduction at UN level (‘harm reduction’ is still 
an unacceptable term at the UN Commission on 
Narcotic Drugs), and to fully support what works in 
HIV prevention, is cause for considerable concern 
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and exposes international commitments as merely 
rhetorical. At the 2014 International AIDS Conference, 
amid visions of an end to AIDS, UNAIDS illustrated 
the gap between reality and rhetoric with its ‘Gap 
Report’. It showed clearly how people who inject 
drugs are being ‘left behind’, citing criminalisation, 
social stigma, a lack of services and a lack of funding 
as the lead causes.(16) 
International leadership on harm reduction
New targets will be needed at the 2016 high level 
meeting on HIV, but this will itself require strong 
leadership from governments that have championed 
harm reduction in the past. In recent years, however, 
that leadership has weakened in important ways. With 
continued resistance to harm reduction at national 
level and international levels stronger leadership 
from all governments that have supported these 
interventions will be vital.
The United Kingdom, in particular, has weakened in 
its leadership for harm reduction in international fora 
in part due to changing political priorities at a national 
level. During the High Level Segment ahead of the 
57th session of the CND the UK’s ministerial statement 
did not explicitly endorse harm reduction.(46)
Canada has been weak for many years under 
the Stephen Harper government, but in the past 
two years its positions at the UN have become 
increasingly extreme, working at the UN to attempt to 
block harm reduction.(17)
There remain, however, strong champions; including 
Denmark, the Netherlands and Switzerland, the latter 
funding the 2nd European Harm Reduction Conference 
in Basel.(47) While not a development of the past year, 
moreover, it is important to note in this context that 
since President Obama took office in 2008, there 
has been a clear shift in US diplomacy with regard 
to harm reduction. While the US will not agree to 
the term in UN negotiations, where once it was a 
considerable barrier to HIV agreements relating to 
harm reduction, it is now a strong advocate on the 
international stage for the scale up of core HIV and 
hepatitis C services. Indeed, the new US Drug Csar, 
Michael Botticelli, was a keynote speaker at the 2014 
Harm Reduction Conference in Baltimore, hosted by 
the Harm Reduction Coalition, illustrating important 
progress.
Within the United Nations there has been a noticeable 
improvement in the public statements of the 
Executive Director of the UN Office on Drugs and 
Crime. This was especially evident in the recent 
World Drug Report in which the Executive Director’s 
i http://supportdontpunish.org/
ii http://www.cahrproject.org/
iii http://supportdontpunish.org/photoproject
iv http://supportdontpunish.org/day-of-action-2014/
v http://idpc.net/blog/2014/07/a-global-day-of-action-for-drug-policy-reform-in-more-than-100-cities
The “Support. Don’t Punish” Campaign: a global show of force for harm reduction and 
policy reform
The “Support. Don’t Punish” campaigni is a global initiative calling for investments in proven and cost-
effective harm reduction responses for people who use drugs, for the decriminalisation of personal 
possession, and the removal of other laws that impede public health services. The campaign was 
launched in 2013 through the multi-partner Community Action on Harm Reduction project,ii and includes 
social media activities, an Interactive Photo Project,iii and a ‘Global Day of Action’ on 26th June – the 
UN’s International Day against Drug Abuse and Illicit Trafficking.
On Thursday 26th June 2014, people in more than 100 cities participated in a range of different events 
and activities – including press conferences, graffiti and art displays, protests, processions, music 
events, workshops and seminars, flash mobs, dance displays, football matches, and even a boat show 
on the Nile!iv Activists gathered in Australia, Belgium, Bolivia, Bosnia and Herzegovina, Cambodia, 
Canada, Chile, China, Colombia, Costa Rica, Denmark, Egypt, France, Georgia, Greece, Hungary, 
India, Indonesia, Ireland, Italy, Kenya, Lebanon, Macedonia, Malaysia, Mauritius, Mexico, Nepal, New 
Zealand, Nigeria, Norway, Palestine, Peru, Philippines, Poland, Puerto Rico, Romania, Russia, Senegal, 
Spain, Switzerland, Tanzania, Thailand, Tunisia, Ukraine, the United Kingdom, the USA, Viet Nam and 
Zimbabwe. The one thing that tied them all together was the campaign message – that the heightened 
risks faced by people who use drugs can no longer be ignored. Others took part on social media, with 
350 tweets per hour using the campaign hashtag at its peak.v
The momentum is clearly building now ahead of the UN General Assembly Special Session (UNGASS) 
on drugs in 2016.
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foreword was unequivocal “UNODC is committed to 
ensuring evidence-informed HIV interventions for all 
key populations. We have seen that countries that 
have adequately invested in harm reduction services 
have lowered remarkably HIV transmission among 
people who inject drugs.”(18) 
Leadership has also emerged in the form of the 
Global Commission on HIV and the Law(19) and the 
Global Commission on Drug Policy.(20) Both made up 
of high-level officials, including former presidents, the 
Commissions have made an important contribution 
to the reputation and visibility of harm reduction 
in recent years. Both have called for reforms to 
the international drug control system and for 
decriminalisation of personal use and possession to 
address drug related health harms.
International attention around viral hepatitis increased 
with a World Health Assembly resolution passed in 
May 2014 which commits the WHO and Member 
States to address the hepatitis pandemic including 
hepatitis C. Despite early opposition from several 
member states a recommendation on harm reduction 
was retained.(48) 
Regional policy developments
There have been some important developments 
within regional bodies since 2012. For example, the 
European Union adopted its drug strategy and action 
plan 2013-2020 with a renewed commitment to harm 
reduction, including in prisons.(49) This is crucial not 
only for European Commission funding priorities but 
also for EU positions as a group at the UN where 
it has traditionally led the way in improving harm 
reduction commitments.
Under the auspices of the Organization of American 
States (OAS) a team was established in 2013 to 
produce a report on ‘Scenarios for the Drug Problem 
in the Americas 2013-2025’. The final report, which 
has proven influential in the hemisphere and beyond, 
suggested four potential scenarios, with harm 
reduction being one of the lead policy principles 
underpinning the scenario planning process.(21) 
During the 5th African Union Conference of Ministers 
of Drug Control in 2012, a new Plan of Action on Drug 
Control was agreed for 2013–2017. This signals an 
important step forward, with a balanced approach 
that includes (in the accompanying Implementation 
Matrix) an explicit commitment to implement the 
UNODC/UNAIDS/WHO comprehensive package 
of harm reduction services, as well as providing 
alternatives to incarceration. At the 6th Conference 
in 2014 – under the bold heading ‘Drugs Kill, But Bad 
Policies Kill More’ – countries reviewed progress, 
recommitted to harm reduction, and held important 
discussions on drug policy reform in the region. (50) 
The Association of South East Asian Nations, 
in contrast to the other regional groups above, 
maintained a steadfast commitment to a ‘drug free 
ASEAN by 2015’.(51)
Human rights and harm reduction
Writing in the first edition of the Global State of 
Harm Reduction, Professor Paul Hunt, then Special 
Rapporteur on the right to health said: 
‘In seeking to reduce drug-related harm, without 
judgement, and with respect for the inherent 
dignity of every individual, regardless of lifestyle, 
harm reduction stands as a clear example of 
human rights in practice. What began as a health-
based intervention in response to HIV must today 
be recognised as an essential component of the 
right to the highest attainable standard of health for 
people who inject drugs’.(22) 
Since then support for harm reduction as a 
component of the right to health has strengthened 
considerably, as has its relationship with the right to 
benefit from scientific progress and its applications 
and the right to freedom from cruel, in human or 
degrading treatment or punishment.vi Since the last 
edition of the Global State in 2012, there have been a 
number of significant developments.
In 2013, the UN Committee on the Rights of the 
Child included harm reduction within its General 
Comment on the Child’s right to health (article 24 of 
the Convention on the Rights of the Child). General 
Comments are authoritative statements of the human 
rights treaty monitoring bodies providing normative 
guidance on the content of specific internationally 
protected rights. It is the clearest statement to date 
that appropriate harm reduction services must be 
considered a component of the right to health for 
children and young people under the age of eighteen 
who use drugs.(23)
Complementing this, the UN Committee on 
Economic, Social and Cultural rights continued to 
strengthen its positions on harm reduction, raising 
concerns with Ukraine in 2014 about “the punitive 
approach taken in the State party towards persons 
who use drugs, which results in high numbers of 
such persons being imprisoned”. The Committee 
also raised concerns about “existing regulations 
which restrict access to opioid substitution therapy 
(OST) and needle and syringe exchange (NSE)” 
and recommended, alongside efforts to address 
vi For an overview of developments in human rights and harm reduction to 2012 see: Barrett, D. and Gallahue, P. Harm Reduction and Human Rights. Interights 
Bulletin. 2012;16:188.
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discrimination against people who use drugs 
“Allocating financial resources for the proper 
operation of opioid substitution therapy (OST) and 
needle and syringe exchange (NSE) programmes 
and increasing their coverage, as well as ensuring 
better access to such programmes in prisons 
programmes”.(24)
Professor Paul Hunt was succeeded by Anand Grover 
as UN Special Rapporteur on the Right to Health. 
Mr Grover followed on from Prof Hunt’s work, raising 
harm reduction issues with governments during 
country visits and presenting a thematic report on 
drug control and the right to health to the General 
Assembly.(25) In 2014 Mr Grover was succeeded by Dr 
Dainius Puras, a strong supporter of harm reduction 
who was very influential in improving the drugs 
and harm reduction recommendations of the UN 
Committee on the Rights of the Child during his term 
from 2007-2011. As such, all three of the UN Special 
Rapporteurs on the right to health (Prof Hunt was the 
first) have been champions of harm reduction.
The former UN Special Rapporteur on Torture, Prof 
Manfred Nowak, was also a strong harm reduction 
advocate in the context of places of detention.(25) His 
successor, Juan Mendez, appointed in 2013, has 
followed suit making clear his ongoing support for 
harm reduction in places of detention in an important 
thematic report on torture in healthcare.(26)
A final important development was the progress on 
drug policy debates within the UN Human Rights 
Council. At the 27th session of the Council in 2014 a 
side event, co-sponsored by the Global Commission 
on Drug Policy, Switzerland, Colombia, Mexico and 
Guatemala was organised in which the outgoing UN 
High Commissioner for Human Rights made clear her 
office’s support for harm reduction: 
“Criminalization of drug use has considerable 
impact on drug users’ right to health…In many 
States, access to proven harm-reduction measures 
– including syringe exchange programmes and 
opiate substitution therapy – is extremely limited, 
non-existent or banned. Failure to provide 
healthcare and harm-reduction programmes…
facilitates transmission of diseases such as HIV and 
hepatitis C. In some States, laws prohibit carrying 
injecting paraphernalia, and this creates additional 
health risks for people who inject drugs.”(52) 
The side event was followed at the 28th session of 
the Council with a cross-regional statement endorsed 
by sixteen countries from Europe, Latin America and 
Africa; calling for human rights to be at the forefront of 
the UNGASS debates in 2016.vii
Research and data collection 
A well known refrain in HIV is to ‘know your epidemic’. 
An important question is therefore whether global, 
regional and national data collection and analysis 
is improving over time on global harm reduction 
developments. 
Since the disbanding of the UN Reference Group on 
HIV and Injecting Drug Use, the Global State of Harm 
Reduction has become the only independent and civil 
society led project collating global HIV and hepatitis 
C related harm reduction data. Central to this effort, 
however, is the UNODC’s World Drug Report, which 
took in-house the former epidemiological data 
gathering function of the reference group. In 2013 
the first data from this new data collection process 
emerged and were immediately problematic leading 
HRI to issue an advisory challenging the data and 
methodology.(27) The 2014 World Drug Report saw 
significant improvements and stronger sharing of 
information between UNODC and HRI.
In 2013, a new ‘Strategic Advisory Group’ to the 
United Nations on HIV and injecting drug use was 
established; including representatives from UN 
agencies, researchers as well as Harm Reduction 
International, the International Drug Policy 
Consortium, the International Network of People Who 
Use Drugs and the International HIV/AIDS Alliance. In 
April 2014, the group held its first meeting in Geneva. 
This and future meetings will play a key role in helping 
to motivate and coordinate joint working on harm 
reduction and related issues within the UN and its 
partners.
Technical guidance
In 2013 and 2014 new guidance has emerged with 
regard to key populations and specific groups of 
people who inject drugs, both from UN agencies and 
civil society. From UN agencies:
 » In July 2014 the World Health Organization 
(WHO) released new consolidated guidelines 
on HIV prevention, diagnosis, treatment and 
care for key populations. The guidelines bring 
together all existing guidance relevant for men 
who have sex with men, people who inject 
drugs, people in prisons and other closed 
settings, sex workers and transgender people. 
Importantly the guidance recommended revising 
laws and policies, such as decriminalising drug 
use to enable a supportive environment for key 
populations,(28) this is the first time the WHO has 
made such a recommendation.  
vii Full statement and list of co-sponsors at http://www.cndblog.org/2014/09/human-rights-council-cross-regional.html 
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 » This guidance has also led to a separate 
WHO guideline on the management of opioid 
overdose.(59)
 » In April 2014 the WHO also developed new 
guidance the screening, treatment and care of 
viral hepatitis.(29) The guidance includes strong 
recommendations for the treatment rollout 
for people who inject drugs. An important 
recommendation given the current low levels of 
treatment access for people who use drugs. 
 » In 2014 UNODC released a toolkit providing 
guidance on implemented needle and syringe 
programmes in prisons.(30) The toolkit aims to 
assist governments to set specific targets to 
achieve universal access for prisoners to access 
evidence based HIV treatment, prevention and 
care. 
Developments for specifically vulnerable groups:
 » In recent years children and young people who 
use drugs have been highlighted as a particular 
group requiring more concerted attention with 
harm reduction and HIV responses. In 2013, 
Harm Reduction International published a 
report on injecting drug use among under 18s 
highlighting the serious data gaps relating to this 
age group. The report was launched at a thematic 
session on young people at the UNAIDS PCB in 
December 2013. (31) 
 » Throughout the first half of 2014 the WHO led 
a process of developing guidelines on HIV and 
young key affected populations, including young 
people who inject drugs and young people 
who sell sex. The process involved widespread 
consultation with UN, civil society and academic 
partners. Youth RISE organised consultations 
with young people who inject drugs in fourteen 
countries whose recommendations fed into the 
briefing on this key population. At the time of 
going to print the briefs remain in draft form, a 
release date remains unclear.
 » A policy brief on women who inject drugs 
was produced jointly by UNODC, UN Women, 
WHO and INPUD(32) The brief provides 
recommendations, good practice and guidance 
tools for service providers and governments 
to ensure interventions that are designed and 
gender sensitive and meet the needs of women 
who inject drugs. 
 » Harm Reduction International worked with sex 
worker advocates and researchers to develop 
a new report on the overlap between sex work 
and drug use from a harm reduction perspective.
(33) The report was launched at the International 
Congress on AIDS and HIV in Asia and Pacific.
 » The WHO in partnership with UNFPA, 
UNAIDS and the Global Network of Sex Work 
Projects (NSWP) launched a new toolkit to 
guide the implementation of the WHO’s 2012 
recommendations on HIV and sex work. The 
guide recommends the implementation of peer 
led programmes and urges countries to work 
towards the decriminalisation of sex work.(34) A 
similar toolkit to support the implementation of 
the UNAIDS/UNODC/WHO technical guide for 
countries to set targets for universal access to 
HIV prevention, treatment and care for injecting 
drug users is currently being developed by WHO, 
UNAIDS, UNODC, UNFPA and INPUD, it is 
expected to be released in 2015. 
 » A toolkit to help care workers in HIV handle 
ethical dilemmas when working with key 
populations and their children i.e. people living 
with HIV, people who use drugs, sex workers, 
transgender people, gay men, and other men 
who have sex with men was launched at AIDS 
2014 in Melbourne.(60) This innovative publication 
was developed by the Coalition for Children 
Affected by AIDS in collaboration with global key 
population networks, ethicists and care workers.
Community Action on Harm Reduction
Community Action on Harm Reduction (CAHR) 
is a five year project led by the International HIV/
AIDS Alliance and funded by the Dutch Ministry 
of International Affairs (BUZA).  The project 
aimed to significantly improve the lives of people 
who inject drugs in China, India, Indonesia, 
Kenya and Malaysia. Over a five year period 
the project exceeded its targets reaching over 
250,000 people who inject drugs, their partners 
and children. An independent review concluded 
that access to HIV prevention and treatment and 
care had improved in all five countries as a result 
of this highly successful project. The project 
involved a strong focus on building the capacity 
of people who use drugs in the development, 
implementation and evaluation of services in 
country. Due to the success of the project CAHR 
will extend for one year through 2015 with a 
continued on the same five countries with the 
addition of Myanmar.
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Civil society action
Additional to the efforts already noted above, there 
have been a number of important initiatives from civil 
society groups.
Civil society played a leading role in securing 
important reductions in the cost of ground breaking 
new hepatitis C medications. At the AIDS 2014 
conference in Melbourne, activists stormed the stage 
to protest Gilead’s pricing of new HCV drug Sovaldi 
currently costing USD 84,000 per course.(35) Civil 
society led advocacy in Egypt, India(56) and Georgia(57) 
has seen the cost of new medications reduced. 
In February 2013, UNODC established a civil society 
group on HIV and people who use drugs. The group 
consists of regional and global harm reduction and 
drug user networks and aims to improve UNODC’s 
collaborative work with civil society on HIV and drug 
use. The group has developed a joint work plan and 
meets face to face once a year and is facilitated by a 
civil society secretariat. 
Civil society action around the world led to a 
successful replenishment for the Global Fund to Fight 
AIDS, TB and Malaria. In particular after concerted 
civil society efforts in the UK, a record UK £1 billion 
was pledged by the Government.(36) 
A new project to address the growing HIV epidemic 
in Asia started in 2012. Entitled “Asia Action,” it seeks 
to increase the evidence and build support for harm 
reduction approaches among key policy makers in 
six countries - China, Cambodia, Vietnam, Malaysia, 
Indonesia and India. The project is implemented by 
a consortium of partners, led by the International 
HIV/AIDS Alliance, which include Harm Reduction 
International (HRI), the International Drug Policy 
Consortium (IDPC) and six national civil society 
organisations: AIDS Care China (China), Rumah 
Cemara (Indonesia), KHANA (Cambodia), India 
HIV/AIDS Alliance (India), Malaysian AIDS Council 
(Malaysia) and Supporting Community Development 
Initiatives (Vietnam) An advocacy focused project, it 
seeks to focus on areas such as developing gender 
sensitive guidelines for harm reduction programmes, 
developing community based alternatives to 
compulsory drug detentions centres and advocating 
for the meaningful engagement of people who use 
drugs in advocacy and service delivery.
Harm reduction networks continue to operate in every 
region of the world and make important contributions 
at national, regional and international levels. 
Global Networks that include harm reduction as 
a key part of their focus continue to operate at 
the international level. These include YouthRISE, 
International Network of People who Use Drugs 
(INPUD), International Doctors for Healthy Drug 
Policies (IDHDP), International Centre for Science 
in Drug Policy (ICSDP), Law Enforcement and HIV 
Network (LEAHN), Women’s Harm Reduction Network 
(WHRN) and the International Drug Policy Consortium 
(IDPC). 
Regional networks include the Caribbean Harm 
Reduction Coalition (CHRC), Eurasian Harm 
Reduction Network (EHRN), European Harm 
Reduction Network (EuroHRN), Middle East and North 
African Harm Reduction Network (MENAHRA) and 
Intercambios Asociacion Civil (Latin America).
Since 2012, there are have been significant 
developments in the visibility of networks of people 
who use drugs. Regional networks have been 
established in Asia, Eurasia, Europe, MENA and most 
recently in the United States. National level networks 
have also developed with new networks being 
initiated in countries such as Greece, Tanzania and 
Lithuania. 
The International Network of People who Use 
Drugs has continued to strengthen since 2012 and 
has increased capacity and staff. This has allowed 
the network to actively engage in international 
forums such as the CND and UNAIDS Programme 
Coordinating Board (PCB).
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Table 2.1.1: Epidemiology of HIV and viral hepatitis, and harm reduction responses in Asia
Country/territory
with reported
injecting
drug use
People who
inject drugs
Hiv 
prevalence
among people
who inject 
drugs (%)
Hepatitis C (anti-
HCv) prevalence
among people
who inject 
drugs (%)
Hepatitis B
(anti-HBsag)
prevalence among
people who  
inject drugs (%)
Harm reduction response
nSPi oSTii
afghanistan
20,000 (18,000–
23,000)(1)
4.4(2)iii 31.2(2) 6.6(2) (31)(3) (1)(3)
bangladesh 21,800–23,800(4)iv 1.1(4) 39.6(5)v 9.4(6) (88)(4) (3)(4) (m)
bhutan nk nk nk nk x x
brunei darussalam nk nk nk nk x x
cambodia 1,300 (1,200–2,800)(7) 24.8(7) nk nk (2)  (1)
china 2,580,000(8)vi 6.3(9) 67(6) 10(6) (898) (763) (b, m)
Hong Kong nk nk nk nk x 
india 177,000–180,000(10)vii 7.14(11) 41(6) viii 10(6) (295) (145)
(12) (b, 
m, o)
indonesia
74,326 (61,901–
88,320)(13) 
36.4(14) 77.3(6) 2.9(6) (194) (85) (b, m)
Japan nk nk 64.8 (55–74.5)(6) 3.2 (2–4.3)(6) x x
Korea (republic of) nk nk 54(6) 4(6) x x
laos Pdr 1,700(15) nk nk nk (4)(15)ix  x
macau 238(16) 1.32(17) 80.4(18) 10.7(18) (4)(18) (4)(18) (b, m)
malaysia 170,000(19) 18.9(20) 67.1(6) ? (728)(20) (811)
(20) (b, 
m)
maldives 793 (690–896)(21) 0(21) 0.7(22) 0.8(22) x (1)(23) (m)
mongolia nk nk nk nk (1)(24) x
myanmar 75,000(25) 18.7(26) 79.2(6) 9.1(6) (40)(25) (18)(25)
nepal 52,174(27) 6.3(28) 87.3 (80.5 –94)(6) 5.8 (5.5–6)(6) (40) (12)(28)
Pakistan 91,000(29)–423,000(30)x  27.2(29) 85 (75-92.9)(6)xi 6.8 (6–7.5)(6) (34)(31) x
Philippines 12,304–16,607(32)xii  41.6(33) 70(6) nk xiii x
Singapore nk nk 42.5(6) 8.5(6) x x
Sri lanka nk nk nk nk x x
taiwan 60,000(34)xiv 17.7(34) 41(6)xv 16.7(6) (1,103)(22)xvi (90)(22) (b, m)
thailand 40,300(35) 25.2(36) 89.8(6)xvii nk (38)(36) (147) (m)
Vietnam
271,000 (100,000–
335,000)(37)
10.3(37) 74.1(6)xviii 19.5(6) (297)(37) (80)(37)
i	 This	includes	all	operational	NSP	sites,	including	fixed	sites,	vending	machines	and	mobile	NSPs	operating	from	a	vehicle	or	through	outreach	workers.
ii	 (M)	=	methadone,	(B)	=	buprenorphine,	(O)	=	any	other	form	(including	morphine	and	codeine).
iii	 Prevalence	varies	from	0.3%	in	Mazar	city	to	13.3%	in	Herat	city.
iv	 Data	from	2009,	and	only	for	men	who	inject	drugs.
v	 Based	on	data	from	Dhaka.
vi	 Figure	indicates	the	number	of	registered	people	who	use	drugs	that	have	been	recorded	by	the	police.	There	are	an	estimated	10	million	people	who	use	drugs	thought	to	exist	in	China.	
vii	 Data	from	2008,	with	civil	society	organisations	believing	the	actual	figure	to	be	much	higher.
viii	 HCV	prevalence	varies	greatly	across	the	region,	from	90%	in	Manipur	to	1%	in	Bihar,	but	no	national	data	is	collected.
ix	 These	are	pilot	NSPs	in	four	districts	of	Houaphanh	and	Phongsaly	province.
x	 91,000	figure	based	on	a	mapping	methodology	in	2009	in	hotspots	where	people	inject	drugs.	The	423,000	figure	was	derived	from	an	epidemiological	survey.	Civil	society	recommended	a	range	
between	both	figures.
xi	 Figure	from	2003.
xii	 Figure	relates	to	adult	males	only.
xiii	 Needles	and	syringes	are	distributed	regularly	to	people	who	inject	drugs	but	only	at	a	health	facility,	thus	limiting	coverage.
xiv	 Based	on	longitudinal	data	from	two	prison	cohorts.
xv	 Figure	from	2001.
xvi	 Figure	from	2005;	no	updated	information	on	NSPs	or	OST	in	Taiwan.
xvii	 Figure	from	2000.
xviii	 Figure	from	2003.
Asia
312.1 Asia
JAPAN
KOREA
(REPUBLIC OF)
DPR KOREA
MACAU
Both NSP and OST available
OST only
NSP only
Neither available
Not known
DCR available
Map 2.1.1: Availability of needle and syringe exchange programmes (NSP) and opioid substitution therapy (OST)
32 Global State of Harm reduction
An	estimated	3–5	million	people	who	inject	drugs	live	
in Asia,(38)	with	an	estimated	1.3	million	opioid	users	
residing	in	China.(39)	Since	2012,	new	population	size	
estimates	are	available	for	people	who	inject	drugs	
from	Cambodia,	China,	Indonesia,	Nepal,	Philippines	
and	Vietnam.	However,	data	quality	and	greater	
concentrations	of	people	who	use	drugs	in	certain	
geographical	areas	limit	the	scope	of	these	estimates,	
and	can	often	hinder	accurate	assessments	of	
required	harm	reduction	service	coverage.(40)
Unsafe	injecting	drug	use	is	a	major	driver	of	the	
HIV	epidemic	in	many	Asian	countries,	including	
Indonesia,	Pakistan	and	the	Philippines,	where	
HIV	prevalence	among	people	who	inject	drugs	
continues	to	grow	rather	than	stabilise.(38)	Overlaps	
between	people	who	inject	drugs	and	other	key	
population	groups,	including	sex	workers	and	men	
who	have	sex	with	men,	have	also	been	detected	in	
several	countries	in	the	region,	and	require	increased	
attention.(40)	In	2013,	UNAIDS	reported	that	in	11	
countries	across	Asia	less	than	half	of	sex	workers	
and	men	who	have	sex	with	men	surveyed	reported	
using	a	condom	with	their	last	sexual	partner.(38)
HIV	prevalence	among	people	who	use	drugs	ranges	
from	over	40%	in	Pakistan	and	the	Philippines	to	
under	10%	in	China,	India,	Macau,	Malaysia	Maldives	
and Nepal (see	Table	2.1.1).	However,	national	figures	
can	often	hide	significant	regional	and	sub-national	
variations.	For	example,	national	figures	in	Indonesia	
appear	to	be	declining,	with	36.4%	HIV	prevalence	
among	people	who	inject	drugs.(14)	However,	in	
urban	centres	such	as	Jakarta	and	Surabaya,	2013	
HIV	prevalence	estimates	were	56.4%	and	48.8%	
respectively.(41)	A	2011	study	of	16	cities	in	Pakistan	
found	an	overall	prevalence	of	HIV	among	people	
who	inject	drugs	of	27.2%,	but	this	ranged	from	
3.3–52.5%	depending	on	the	city.(42)	These	differences	
highlight	the	importance	of	multi-site	studies	in	
countries to ensure that targeted and appropriate 
harm	reduction	services	are	scaled	up.
Although	harm	reduction	is	becoming	increasingly	
accepted	across	the	region,	a	largely	punitive	policy	
and	legal	environment	remains	firmly	in	place,	
undermining	access	to	life-saving	harm	reduction	
programmes,	and	directly	blocking	progress	towards	
United	Nations	2011	Political	Declaration	on	HIV/
AIDS	targets	to	reduce	the	transmission	of	HIV	among	
people	inject	drugs	by	50%	by	2015.(43)	There	are	11	
countries	that	still	have	compulsory	centres	for	people	
who	use	drugs,	and	15	that	still	have	the	death	
penalty	for	drug-related	offences.(38) 
In	certain	countries,	the	early	implementation	of	
harm	reduction	services	in	the	form	of	needle	and	
syringe	programmes	(NSPs)	and	opioid	substitution	
therapy	(OST)	contributed	to	a	significant	drop	in	HIV	
prevalence	among	people	who	inject	drugs.	Nepal,	
for	example,	saw	rates	of	HIV	prevalence	decline	
drastically	from	68%	in	2002	to	6.3%	in	2011.(38) 
However,	because	coverage	of	services	fell	well	
below	the	recommended	levels	in	these	countries,	it	is	
possible	that	mortality	related	to	HIV,	tuberculosis	(TB)	
and	hepatitis	C	(HCV)	was	also	a	contributing	factor	
to	the	decline.	However,	examples	such	as	this	are	
few,	and	although	harm	reduction	coverage	has	been	
increased	in	Bangladesh,	China,	India,	Indonesia,	
Malaysia	Myanmar,	Taiwan	and	Vietnam,	the	pace	
and	scale	up	has	been	too	slow	to	have	a	significant	
impact	on	reducing	HIV	transmission	among	people	
who	unsafely	inject	drugs.(40)	In	Mongolia,	the	main	
non-governmental	organisation	(NGO)	working	on	
drug	issues,	the	Association	to	Protect	Citizens	from	
Drugs	and	Narcotic	Substances,	which	implements	
a	small-scale	NSP	mainly	for	morphine	users,	states	
that	people	who	inject	drugs	are	extremely	difficult	to	
reach	due	to	the	punitive	environment.(24)	
Stimulant	use	across	the	region	has	also	greatly	
expanded,(44)	and	several	countries	have	already	seen	
a	trend	for	amphetamine-type	stimulants	(ATS)	far	
exceed	use	of	opiates.(44)	Few	countries,	however,	
report	the	existence	of	harm	reduction	services	in	
response	to	the	growing	use	of	ATS.	There	is	an	
urgent	need	for	research	and	monitoring	of	ATS	
use	in	order	to	develop	targeted	harm	reduction	
services	–	a	gap	that	UNODC’s	Global	SMART	
(Synthetics	Monitoring:	Analyses,	Reporting	and	
Trends)	Programme	is	helping	to	fill.(45)	In	a	study	
undertaken	as	far	back	as	1999	of	32	survey	
respondents	in	a	treatment	centre	in	Japan,	53.8%	
used	methamphetamine	as	their	drug	of	choice,	of	
whom	82.1%	reported	needle	sharing.(46) 
Developments	in	harm	reduction	
implementation
Needle	and	syringe	exchange	programmes	(NSPs)
A	total	of	17	countries	in	Asia	have	NSP	provision	
to	varying	degrees	(see	Table	2.1.1),	a	number	
that	appears	to	have	remained	stable	rather	than	
increased since The Global State of Harm Reduction 
2012.(22)	NSPs	operate	to	differing	degrees	within	
the	region,	from	small-scale	projects	in	countries	
such	as	Laos	PDR,	Macau	and	Mongolia,	to	higher	
provision	in	India,	Indonesia	and	Malaysia.	Between	
2012	and	2014,	five	countries	reported	scaling	
up	NSP	provision	–	Afghanistan,	India,	Indonesia,	
Malaysia	and	Thailand	–	with	Malaysia	seeing	the	
steepest	increase,	from	297	sites	in	2012(22)	to	728	in	
2014.(20)	During	this	period,	four	countries	reported	a	
decline	in	NSP	services:	Bangladesh,	China,	Pakistan	
and	Vietnam.	In	Vietnam,	coverage	has	reduced	
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significantly,	and	the	average	number	of	needles	
and	syringes	provided	to	people	who	inject	drugs	
has	dropped	from	180	in	2012(22)	to	98	in	2014.(37)	In	
China,	the	number	of	NSP	sites	has	decreased	from	
941	sites	across	17	provinces(22)	to	898	sites	across	
15	provinces.(9)	In	Thailand,	NSP	coverage	remains	
low,	with	only	12	syringes	distributed	per	person	
who	injects	drugs	per	year.(36)	Afghanistan’s	NSP	
service	provision	is	also	limited,	reaching	only	eight	
provinces	in	the	country	and	providing	an	average	of	
92	syringes	per	person	who	injects	drugs	per	year.(1) 
For	countries	with	limited	geographical	coverage	or	
low	service	provision,	there	is	an	urgent	need	to	scale	
up	NSPs	to	reduce	the	transmission	of	HIV	and	viral	
hepatitis	through	unsafe	injecting.
Models	of	NSP	service	delivery	differs	from	country	
to	country	in	the	region.	In	Indonesia,	NSPs	are	
provided	through	government-run	community	
health	centres	(known	as	puskesmas)	and	civil	
society	organisations.(48)	NSPs	in	Malaysia	are	also	
provided	through	government-run	health	clinics	and	
civil	society	organisations,	with	the	majority	being	
delivered	by	civil	society	(79%),	and	the	remainder	
government	run	(21%).(48)	In	Lao	PDR	the	situation	is	
rather	different,	with	a	community-based	NSP	pilot	
project	initiated	on	the	border	with	Vietnam	being	the	
only	NSP	service	in	the	country.(15) 
Although	NSP	provision	exists	in	a	number	of	Asian	
countries,	there	are	many	barriers	to	accessing	these	
services	for	people	who	inject	drugs.	In	Indonesia,	
for	example,	although	NSP	provision	exists	for	
people	who	inject	drugs	who	are	using	OST,	they	
can	be	forbidden	to	access	NSP	services	by	certain	
OST	clinics.	Coupled	with	this	is	a	lack	of	human	
resources	to	run	the	services	and	inflexible	hours	
of	service	providers.	There	are	further	barriers	for	
women	and	young	people	who	inject	drugs,	who	
can	be	uncomfortable	about	accessing	existing	NSP	
services,	especially	where	these	are	provided	via	
government-run	puskesmas.(48)	In	Malaysia,	although	
there	has	been	a	large	increase	in	NSP	provision,	
partly	due	to	increased	funding	but	also	improved	
government	and	stakeholder	relations,	people	who	
use	drugs	still	face	structural	barriers	in	terms	of	law	
enforcement	agencies.(48)	A	recent	survey	of	Malaysian	
police	officers	found	that	the	majority	seized	needles	
and	syringes	even	if	no	arrest	was	made,(49)	serving	to	
increase	the	risk	of	unsafe	injecting	and	associated	
harms.
As	reported	in	2012,(22)	Bhutan,	Brunei-Darussalam,	
Hong-Kong,	Japan,	Republic	of	Korea,	Maldives,	
Singapore	and	Sri	Lanka	still	have	no	NSP	sites	in	
operation.	
Opioid	substitution	therapy	(OST)
OST	provision	has	continued	to	be	scaled	up	in	
several	Asian	countries,	with	an	estimated	297,000	
people	who	inject	drugs	accessing	these	services.(38) 
Between	2012	and	2014,	Bangladesh	increased	
from	1	site	to	3	sites,(4)	India	from	72	to	145	sites,(12) 
Malaysia	from	674	to	811	sites,(20)	Myanmar	from	
10	to	18	sites,(26)	Nepal	from	3	to	12	sites,(28)	China	
from	738	to	763	sites,(8)	Vietnam	from	41	to	80	
sites(37)	and	Indonesia	from	74	to	85	sites.	There	is	
low-level	coverage	(less	than	20%	of	people	who	
inject	drugs	using	services)	of	OST	in	Afghanistan,	
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A	successful	response	to	HIV	among	people	who	use	drugs	cannot	be	realised	in	a	punitive	policy	
environment,	where	evidence	and	rights-based	approaches	are	blocked,	service	access	is	restricted,	
and	the	meaningful	participation	of	people	who	use	drugs	in	decision-making	and	service	delivery	is	
undermined	or	simply	not	allowed.
Asia	Action	on	Harm	Reduction	(Community	alternatives	to	the	war	on	drugs:	community	advocacy	
for	harm	reduction)	is	a	European	Union-funded	project	running	between	2013	and	2016	that	seeks	
to	empower	civil	society	organisations,	and	increase	the	evidence	and	build	political	support	for	harm	
reduction	among	key	policymakers	in	Cambodia,	China,	India,	Indonesia,	Malaysia	and	Vietnam.	
The	project	is	implemented	by	a	consortium	of	partners,	led	by	the	International	HIV/AIDS	Alliance,	
which	include	Harm	Reduction	International	(HRI),	the	International	Drug	Policy	Consortium	(IDPC)	
and	six	national	civil	society	organisations:	AIDS	Care	China	(China),	Rumah	Cemara	(Indonesia),	
KHANA	(Cambodia),	India	HIV/AIDS	Alliance	(India),	Malaysian	AIDS	Council	(Malaysia)	and	Supporting	
Community	Development	Initiatives	(Vietnam).	The	project	works	on	advocacy	areas,	including	
enhancing	law	enforcement	engagement	with	rights-based	harm	reduction	approaches	in	Malaysia;	
assessing	the	harm	reduction	advocacy	capacity	of	state-level	drug	user	forum	members	and	mapping	
stakeholder	support	of	harm	reduction	policies	in	India;	advocating	for	access	to	treatment	in	pre-trial	
detention	and	other	closed	settings	in	Malaysia;	and	documenting	the	implementation	of	diversion	policy	
to	drug	treatment	as	opposed	to	prison	for	people	arrested	for	drug-related	offences	in	Indonesia.(47)
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India,	Myanmar,	Sri	Lanka	and	Vietnam,	and	it	is	
recommended	that	OST	provision	in	these	countries	
should	be	scaled	up	as	a	matter	of	urgency.(40)	In	
Cambodia,	OST	provision	remains	limited	to	only	one	
clinic,	which	provides	methadone	to	approximately	
200	people.	It	has	been	reported	that	the	drop-
out	rate	has	increased	to	48%	because	clients	are	
required	to	visit	the	clinic	on	a	daily	basis	due	to	a	
lack	of	takeaway	doses.(50) 
Since	2012,	OST	has	been	approved	and/or	newly	
piloted	in	both	Pakistan	and	Bhutan.(40)	In	Pakistan,	a	
pilot	feasibility	study	was	initiated	at	one	site	in	2013,	
implemented	by	the	Institute	of	Psychiatry	and	the	
Narcotics	Control	Division,	in	coordination	with	the	
National	AIDS	Control	Programme	(NACP),	UNODC,	
WHO	and	UNAIDS.(40)	While	the	pilot	was	a	positive	
development,	it	ended	in	2013	and	OST	remains	
unavailable	for	large	numbers	of	opioid-dependent	
individuals.	Introduction	and	scale	up	of	OST	in	
Pakistan	is	critical,	not	only	to	provide	evidence-
based	drug	dependence	treatment	for	all	who	need	
it,	but	also	to	halt	ongoing	transmission	of	HIV	among	
people	who	inject	and	their	sexual	partners,	as	well	as	
to	facilitate	adherence	to	antiretroviral	therapy	(ART)	
among	HIV-positive	people	who	inject	drugs.	
In	Bhutan,	the	ministry	of	health,	the	Narcotic	Control	
Agency	and	the	government	have	endorsed	OST,	
earmarking	three	centres	for	pilot	projects.(51) A pilot 
drop-in	centre	in	Thailand	has	also	been	initiated	by	
Population	Services	International,	to	ensure	OST	is	
available	for	people	who	inject	drugs	living	in	remote	
locations	with	difficulty	accessing	government	OST	
services.	Implementing	community-based	OST	
was	made	possible	through	staff	collaboration	
with	community	leaders,	peer	volunteers,	and	local	
public	health	staff,	with	results	in	the	first	six	months	
showing	a	relapse	rate	of	8%	compared	to	92%	in	
traditional	government	programmes.(36)
Methadone	is	the	main	medicine	used	for	OST	in	
the	region.(40)	However,	Indonesian	ministry	of	health	
plans	to	release	a	specific	decree	to	regulate	use	
of	buprenorphine	during	2014,	which	is	presently	
only	available	in	private	clinics.(48)	In	Lao	PDR,	where	
OST	is	not	provided,	tincture	of	opium	capsules	are	
used	for	detoxification	and	treatment	among	opium	
users.(15)	In	Sri	Lanka,	although	meetings	on	issues	
concerning	people	who	use	drugs	have	reportedly	
been	held,	no	consensus	has	been	reached	on	OST	
provision.	However,	a	literature	review	has	been	
conducted	to	decide	on	the	initiation	of	OST,	with	
plans	to	move	on	to	a	pilot	study	in	the	near	future.(52)
As	with	NSPs,	OST	provision	in	Asia	is	hindered	
by	legal	and	policy	barriers	that	restrict	or	prohibit	
its	implementation	and	scale	up.	For	example,	in	
Malaysia,	recent	punitive	enforcement	and	coercive	
action	means	that	people	who	inject	drugs	have	
reduced	trust	in	OST	programmes,	and	therefore	
underuse	them	because	of	fear	of	arrest.(49)	OST	
procedure and protocol across the region also 
appears	unclear;	for	example,	concerning	terms	and	
conditions	on	how	to	use	OST,	take-home	dosages,	
and	tapering	off	from	treatment.	There	is	also	often	
a	perspective	from	service	providers	that	OST	is	an	
exit	strategy	and	cannot	be	used	in	conjunction	with	
NSP	services.(48)	Additional	barriers,	including	limited	
hours	of	operation,	specific	requirements	for	women	
in	some	regions	(for	example,	in	Indonesia	written	
permission	is	required	from	husbands	to	access	OST),	
and	limited	financial	commitment	of	governments	and	
donors	for	maintaining	and	expanding	programmes,	
mean	there	is	still	much	work	to	be	done	to	ensure	an	
appropriate	and	enabling	environment	for	OST.	
Viral	hepatitis
A	systematic	review	in	2011	found	that	the	region	
contained	the	largest	number	of	people	with	viral	
hepatitis	who	inject	drugs,	with	an	estimated	300,000	
having	the	hepatitis	B	surface	antigen	(HbsAg)xix 
(range	100,000–700,000)	and	approximately	2.6	
million	having	HCV	(range	1.8–3.6	million).(6)	In	2014,	
HCV	infection	has	become	an	urgent	issue	among	
people	who	inject	drugs	across	Asia,	and	there	is	a	
critical	need	for	diagnostic	and	treatment	services	to	
be	scaled	up	across	the	region	and	integrated	into	
HIV	testing	and	treatment	services.(40)	The	limited	data	
that	is	available	suggest	that	60–90%	of	people	who	
use	drugs	who	live	with	HIV	in	Asia	and	the	Pacific	
also	have	HCV	co-infection.(38)	
In	Afghanistan,	it	is	estimated	that	1.5%	of	people	
who	inject	drugs	are	co-infected	with	HIV	and	HCV.(53) 
However,	there	is	still	no	policy	or	strategy	to	address	
the	problem	of	HCV	among	people	who	inject	drugs.(1) 
In	Vietnam,	guidance	for	treatment	of	HCV	has	been	
made	widely	available,	but	health	insurance	coverage	
excludes	antiviral	treatment.(37)	Bhutan	reports	having	
a	prevention	and	control	programme	that	includes	
people	who	inject	drugs	and	those	living	with	HIV.(54)	
Significant	efforts	have	been	made	by	civil	society	
organisations	and	people	who	use	drugs	in	Indonesia	
to	scale	up	the	government	response,	with	a	recently	
developed	set	of	guidelines	on	HCV	treatment	
becoming	available,	care	and	support	among	people	
who	inject	drugs	in	place,	and	plans	to	integrate	HCV	
xix	 HbsAg	indicates	active	(either	acute	or	chronic)	infection.	Approximately	95%	of	adults	with	acute	HBV	infection	clear	the	virus	and	develop	anti-HBv	and	
hepatitis	B	(HBV)	surface	antibodies	(anti-HBs).	People	who	inject	drugs	have	lower	clearance	rates	for	HBV	than	the	general	population	because	more	people	
who	inject	drugs	may	be	chronically	infected.	For	more	information,	see	Nelson	PK,	Mathers	BM,	Cowie	B,	Hagan	H,	Des	Jarlais	D,	Horyniak	D,	et	al.	Global	
epidemiology	of	hepatitis	B	and	hepatitis	C	in	people	who	inject	drugs:	results	of	systematic	reviews.	Lancet.	2011;378(9791):571-83.
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into	national	surveillance	among	people	who	inject	
drugs	as	of	2015.	(55) 
However,	treatment	of	HCV	still	remains	out	of	reach	
for	most	people	who	inject	drugs	in	the	region	due	to	
exorbitant	prices.	In	Indonesia,	the	test	to	diagnose	
HCV	costs	upwards	of	$650,	and	although	tests	are	
available	and	technically	covered	by	national	health	
insurance	schemes,	people	with	a	history	of	drug	use	
are	excluded	from	universal	health	insurance	via	the	
Presidential	Decree	2012/13.(48)	Urgent	measures	are	
needed in Asia to ensure that access to diagnosis and 
treatment	for	people	who	inject	drugs	improves.		
Tuberculosis
Similar	to	HIV	and	viral	hepatitis,	people	who	inject	
drugs	in	Asia	have	a	high	rate	of	TB	infection,	with	
southeast	Asia	accounting	for	nearly	15%	of	the	
global	burden	of	new	cases	of	HIV–TB	co-infection.(56) 
Data	on	TB	for	people	who	inject	drugs	in	the	region	
is	sparse,	but	individual	studies	indicate	that	there	
is	high	prevalence	of	TB	among	people	who	inject	
drugs.	Pakistan	ranks	fifth	among	TB	high-burden	
countries	worldwide,	accounting	for	61%	of	TB	cases	
in	the	WHO	Eastern	Mediterranean	region.(57) Although 
TB	treatment	in	Pakistan	is	free	for	people	living	with	
HIV,	Pakistan	is	estimated	to	have	the	fourth	highest	
prevalence	of	multi-drug	resistant	TB	(MDR-TB),(29) 
and	as	far	as	we	are	aware	there	is	no	TB	testing	and	
treatment	service	specifically	for	key	populations,	
including	people	who	inject	drugs.
In	Malaysia,	TB	remains	a	public	health	challenge,	
with	approximately	16,000–20,000	new	cases	
reported	annually.(41)	The	government	currently	
conducts	routine	TB–HIV	screening	for	all	new	
detainees in closed settings, such as prisons and 
drug	rehabilitation	centres,	and	findings	indicate	that	
TB–HIV	co-infection	reported	nationwide	increased	
from	6	to	1,477	cases	between	1990	and	2013.(20,58)	
However,	these	figures	do	not	relate	specifically	
to	people	who	inject	drugs.	In	China,	TB	testing	is	
often	provided	for	people	who	inject	drugs	who	are	
in	detention.(8)	Although	rates	of	TB	among	people	
who	inject	drugs	in	China	is	unknown,	an	estimated	
84.9%	of	people	received	TB	testing,	with	the	rate	
of	treatment	for	people	co-infected	with	TB–HIV	
increasing	from	35.6%	in	2011	to	57.2%	in	2013.(9) 
TB	treatment	is	integrated	into	HIV	programmes	in	
Bhutan,	Cambodia,	India,	Indonesia	and	Nepal,	but	
whether	services	are	designed	for	people	who	inject	
drugs	again	is	unknown. 
The	primary	barriers	to	TB	testing	and	treatment	in	
the	region	include	a	lack	of	integration	into	harm	
reduction	programmes,	stigma	and	discrimination	
against	people	who	use	drugs	among	service	
providers,	a	lack	of	awareness	of	TB	referral	systems	
between	criminal	justice	and	healthcare	(particularly	
in	China),	and	limited	testing	and	treatment	
opportunities	provided	at	NSP	and	OST	sites.(40)	It	is	
therefore	clear	from	the	limited	data	on	people	who	
use	drugs	and	TB	prevalence	that	further	research	
should	be	undertaken,	and	greater	integration	of	TB	
services	into	existing	harm	reduction	initiatives	is	
required.
Antiretroviral	therapy	(ART)
In	2013,	UNAIDS	reported	that	in	Asia	and	the	Pacific	
more	than	two-thirds	of	people	who	inject	drugs	do	
not	know	their	HIV	status,(38)	and	in	2013	only	18%	of	
the	total	number	of	people	living	with	HIV	who	were	
eligible	for	ART	accessed	treatment	in	the	region.(38)	
With	the	HIV	testing	indicator	among	people	who	
inject	drugs	now	included	in	routine	Global	AIDS	
Progress	reporting,	it	is	hoped	that	monitoring	of	HIV	
testing	access	among	people	who	inject	drugs	will	
improve.
In	Vietnam	in	2013,	WHO	supported	the	Vietnam	
Administration	of	HIV/AIDS	Control	(VAAC)	to	
provide	evidence	of	the	benefits	of	integrating	OST,	
HIV	testing	and	counselling,	and	ART.	The	study,	
conducted	in	Hanoi	and	Can	Tho,	showed	that	men	
living	with	HIV	who	were	receiving	OST	were	more	
likely	to	be	enrolled	in	care,	start	ART	and	have	
higher	retention	rates	than	men	not	receiving	OST.
(37)	The	findings	of	this	study	have	helped	support	
and	promote	the	integration	of	OST	and	ART	service	
delivery	in	Vietnam.	
Several	barriers	are	still	documented	to	HIV	testing	
and	access	to	ART	treatment	for	people	who	inject	
drugs	in	the	region.	In	India,	HIV	testing	among	
people	who	inject	drugs	is	limited,	with	some	states	
not providing any form of ART.(59)	In	Malaysia,	people	
who	use	drugs	often	feel	stigmatised	by	healthcare	
staff,	and	a	lack	of	confidentiality	discourages	
people	who	use	drugs	from	coming	forward	for	early	
diagnosis	and	treatment.(48)	In	Nepal,	HIV	testing	is	not	
initiated	at	NSP	sites,	and	there	is	a	recommendation	
for	drug	treatment	facilities	to	enable	capacity	for	
testing	and	treatment.(60) 
Reductions	in	HIV	prevalence	among	people	who	use	
drugs	in	certain	countries	in	the	region	have	been	
largely	attributed	to	the	early	implementation	and	
scale	up	of	key	harm	reduction	programmes	such	as	
NSPs	and	OST,(61)	although	HIV-related	mortality	may	
also	have	played	a	contributing	role	in	this	period.	
HIV	prevalence	rates	have	decreased	significantly	in	
Nepal,	where	prevalence	among	people	who	inject	
drugs	in	Pokhara	was	4.6%	in	2011	compared	to	
22%	in	2003.(28)	Although	early	implementers	of	NSPs	
and	OST	have	seen	a	decline	in	HIV	prevalence	
among	people	who	inject	drugs,	much	more	needs	
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to	be	done	in	the	region	to	integrate	testing	and	
treatment	services	for	HIV,	viral	hepatitis	and	TB.
Harm	reduction	in	prisons
Injecting	drug	use	is	common	in	prisons	and	other	
places	of	detention	across	Asia.	However,	there	is	
often	insufficient	surveillance	reporting	on	HIV	in	the	
prison	setting,	and	the	limited	information	indicates	a	
need	to	increase	greatly	the	scale	of	HIV	prevention	
and	treatment,	including	the	initiation	of	NSPs	and	
OST	services.(62)	In	a	study	undertaken	in	Indonesia	
on	prisoners	incarcerated	for	drug-related	crimes,	
almost	90%	had	consumed	an	illicit	drug,	and	more	
than	one-third	had	injected	heroin.(63)	In	another	study	
undertaken	in	Afghanistan,	92.9%	of	people	who	
inject	drugs	had	previously	spent	time	in	prison,	with	
17.2	reporting	injecting	in	prison.(64) As drug detention 
and	rehabilitation	centres	remain	widespread	across	
the	region,	and	punitive	approaches	to	drug	use	
remain	the	dominant	policy,	there	is	an	urgent	need	
for	harm	reduction	measures	to	be	made	more	readily	
accessible.	
At	present,	only	Malaysia	and	Indonesia	provide	OST	
in	prison,	with	no	NSP	available	in	prisons	in	any	
country	in	the	region.	However,	although	OST	has	
been	expanded	in	prisons	in	Malaysia,	increasing	
from	1	prison	in	2008	to	18	by	2013,(20)	methadone	
is	currently	unavailable	in	pre-trial	police	detention,	
which	can	cause	interruptions	in	service	access	
during	arrest.	In	Indonesia,	there	are	currently	10	
prisons	providing	OST,	which	is	made	available	for	
new	clients	without	prior	history	of	OST	use.	The 
Global State of Harm Reduction 2012(22) reported 
that	plans	were	underway	to	initiate	harm	reduction	
services	in	prisons	in	the	Maldives,	although	as	far	as	
we	are	aware	this	has	not	yet	begun.	
There	are	some	signs	of	increasing	political	
commitment,	and	certain	countries	in	the	region	have	
made	important	efforts	to	review	and	gradually	shift	
from	a	punitive	approach	to	a	voluntary,	rights-based	
approach	to	drug	treatment.(40)	For	example,	Malaysia	
has	transformed	eight	compulsory	detention	centres	
into	voluntary	Cure	and	Care	centres	or	clinics,	widely	
praised	as	examples	of	best	practice	for	the	region.(38) 
There	have	also	been	indications	of	increasing	
political	commitment	in	Vietnam,	with	the	approval	
of	the	Law	on	Handling	of	Administrative	Violations	
in	June	2012.	As	a	result	of	this	law,	80	of	the	107	
compulsory	detention	centres	will	be	reformed	to	
provide	voluntary	and	friendly	detoxification,	with	
possible	OST	provision	also	planned.(37) 
While	these	steps	are	a	positive	development,	it	is	
crucial	to	ensure	that	voluntary	treatment	is	also	
community	based,	and	includes	strong	referral	
systems	to	other	harm	reduction	interventions,	as	well	
as	to	HIV	treatment	and	support	services.(40)	In	2014,	
UNODC	produced	specific	guidance	for	community-
based	treatment	in	southeast	Asia.(65)	In	March	2012,	
a	group	of	12	United	Nations	agencies	–	including	
UNODC,	WHO,	UNAIDS	and	the	Office	of	the	High	
Commissioner	for	Human	Rights	–	released	a	joint	
statement	“call[ing]	on	States	to	close	compulsory	
drug	detention	and	rehabilitation	centres	and	
implement	voluntary,	evidence-informed	and	rights-
based	health	and	social	services	in	the	community”.(66) 
In	November	2014,	the	Global	Fund	called	for	the	
closure	of	compulsory	drug	detention	centres,	making	
a	public	commitment	not	to	provide	funding	for	
programmes	in	such	centres.(74)
A	further	area	of	concern	for	people	who	inject	drugs	
who	are	incarcerated	or	placed	in	detention	centres	is	
their	limited	access	to	ART	provision	in	some	prisons	
and	closed	setting	in	Asia.	While	ART	is	technically	
available	in	prisons	in	Indonesia,	provision	is	based	in	
the	hospital	with	an	assigned	healthcare	worker	who	
takes	care	of	the	procurement	and	dosing.	Detainees	
have	to	pay	the	prison	officer	for	accessing	ART	
medication	on	a	monthly	basis,	which	is	a	further	
barrier	to	access.(48)	In	Malaysia	and	Cambodia,	ART	
is	available	for	people	who	are	incarcerated,	and	
some	prisons	in	China	have	ART	provision	although	
the	exact	coverage	figures	are	unknown.	In	Pakistan,	
fewer	than	100	prisoners	were	accessing	ART	in	
2014.
Overdose
Data	on	the	extent	of	drug-related	overdose,	
prevention	and	management	is	limited	across	Asia.	
No	countries	in	the	region	collect	and	routinely	
monitor	drug-related	overdose	deaths.	The	response	
is	largely	small	scale	and	local,	with	activities	
implemented	by	civil	society	organisations	and	
networks	of	people	who	use	drugs.(40)	For	example,	
in	two	states	in	northeast	India	(Manipur	and	
Nagaland),	the	community	has	taken	substantive	
steps	towards	addressing	the	management	of	
overdose	by	forming	a	crisis	response	team	that	
provides	naloxone.(59)	In	Indonesia,	a	regulation	exists	
that	overdose	programmes	should	be	made	available	
in	OST	sites.	However,	in	practice	this	regulation	is	
not	implemented	consistently.	Instead,	overdose	
responses	consist	of	limited	awareness	activities	
among	activists,	and	there	is	no	comprehensive	
programme	including	naloxone	provision.	While	China	
has	no	national	programme	for	overdose	prevention,	
AIDS	Care	China,	with	support	from	the	European	
Commission-funded	Asia	Action	project,	has	
recently	started	to	operate	naloxone	peer	distribution	
programmes	in	Yunnan	and	Sichuan	provinces.(8)	By	
the	end	of	May	2014,	4,361	naloxone	kits	had	been	
distributed	by	AIDS	Care	China	to	1,900	people	who	
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inject	drugs,	and	119	people	had	been	saved	from	
fatal	overdose.(8)
Although	there	is	no	national	programme	for	overdose	
in	Nepal,	civil	society	organisations	providing	harm	
reduction	services	raise	awareness	about	overdose	
among	the	community.	The	lack	of	availability	of	
naloxone	in	countries	such	as	Nepal	remains	a	barrier	
to	effective	overdose	prevention,	and	implementation	
and	scale	up	of	naloxone	peer-led	services	should	be	
increased	to	ensure	effective	overdose	prevention	for	
people	who	inject	drugs	in	Asia.
Policy	development	for	harm	reduction
In	2014,	19	Asian	countries	or	territories	identified	
people	who	inject	drugs	as	a	target	population	for	the	
HIV	response,	and	explicitly	included	harm	reduction	
in their national plans and drug policies (see	Table	
1.1.1).	These	include	Afghanistan,	Bangladesh,	
Cambodia,	China,	Hong	Kong,	India,	Indonesia,	
Macau,	Malaysia,	Maldives,	Mongolia,	Myanmar,	
Nepal,	Pakistan,	Laos	PDR,	Philippines,	Taiwan,	
Thailand	and	Vietnam.	Since	2012,	no	new	countries	
in	the	region	have	explicitly	referenced	harm	reduction	
in	policy	documents.(22)
Despite	policies	that	have	facilitated	implementation	
and	scale	up	of	harm	reduction	services	in	the	
region,	the	existence	of	national	policy	on	harm	
reduction	does	not	inevitably	equate	to	provision	of	
an	adequate	response	in	either	scope	or	quality.	For	
example,	although	Cambodia’s	Drug	Control	Law	
2012	states	that	a	person	who	injects	drugs	and	is	
arrested	for	a	drug-related	offence	should	be	referred	
to	treatment	and	related	services,(50) in practice, 
efforts	to	reduce	HIV	transmission	among	people	who	
inject	drugs	have	been	hampered	by	the	current	legal	
and	policy	environment,	with	legal	provision	of	referral	
not	implemented.(7) 
In	Vietnam,	despite	the	introduction	of	a	new	law	in	
October	2012	that	enabled	people	who	use	drugs	to	
go	through	a	trial	process	via	court	hearings	and	have	
legal representation,(67)	there	are	still	many	examples	
of	people	who	use	drugs	being	placed	in	compulsory	
detention.	However,	a	decree	on	substitution	
treatment	for	opioid	dependence,	which	was	
approved	in	2012,	has	simplified	the	administrative	
procedures	needed	to	increase	accessibility	to	OST	
treatment	services.	Nevertheless,	inconsistencies	
remain	in	the	legal	framework	for	harm	reduction	
in	Vietnam,	and	its	heavy	dependence	on	external	
donors	requires	innovative	financing	strategies	if	
provision	is	to	expand.	
In	Singapore,	with	some	of	the	most	punitive	drug	
laws	in	the	region,	parliament	passed	legal	reforms	
that	took	effect	in	2013,	allowing	those	facing	the	
death	penalty	the	opportunity	to	ask	for	resentencing	
under	certain	circumstances.	Since	then,	nine	
prisoners	have	applied	for	resentencing	and	have	had	
their	sentences	reduced	to	life	imprisonment	rather	
than	death.(68)	
Civil	society	and	advocacy	
developments	for	harm	reduction
Over	the	last	two	years,	the	European	Commission-
funded	Asia	Action	on	Harm	Reduction	project	has	
played	an	important	role	in	supporting	civil	society	
advocacy	on	harm	reduction	and	drug	policy	in	six	
Asian	countries.	As	of	August	2014,	Asia	Action	has	
supported	AIDS	Care	China	to	scale	up	naloxone	
training	and	dissemination	among	people	who	inject	
drugs	in	two	provinces	through	24	project	sites,	
including	compulsory	detoxification	centres.(40)	In	
addition,	the	first	community-based	drug	treatment	
programme	was	piloted	in	China	in	2014,	which	aims	
to	provide	an	alternative	to	compulsory	detoxification	
centres	implemented	throughout	the	country.(8)
In	Cambodia,	KHANA,	supported	by	Asia	Action	
and	AusAID’s	HAARP	programme,	has	worked	with	
police	to	offer	a	more	enabling	environment	in	order	
to	increase	access	for	people	who	inject	drugs	to	
treatment	and	health	services,	and	reduce	human	
rights	violations.(50)	In	Indonesia,	Rumah	Cemara	
supported	by	Asia	Action	and	in	collaboration	with	
the	Indonesian	Drug	Users’	Network,	is	conducting	
research	documenting	the	implementation	of	
Indonesia’s	2011	diversion	policy,	which	stipulates	
that	people	arrested	on	drug-related	offences	with	
personal	possession	under	a	stated	weight	should	be	
referred	to	treatment	rather	than	imprisoned.(69)
In	July	2014,	issues	relating	to	women	who	inject	
drugs	were	highlighted	at	the	global	level	in	Nepal	
when	the	Red	Ribbon	Award	2014	went	to	Dristi	
Nepal.	This	is	an	organisation	run	by	women	with	
a	history	of	drug	use	that	is	dedicated	to	reducing	
drug-related	harms	through	advocacy,	treatment	
and	support	to	women	currently	using	drugs.(70) 
Dristi	Nepal	is	one	of	two	drug-user	led	civil	society	
organisations	in	Asia	–	both	organisations	run	by	
people	who	use	drugs,	with	a	focus	on	promoting	
better	access	to	harm	reduction	and	evidence-based	
drug	policies	–	to	win	the	prestigious	Red	Ribbon	
Award	for	2014–2015.(71) The other organisation is 
Perssaudaraan	Korban	Napza	Indonesia,	a	leading	
national	network	representing	the	joint	priorities	of	25	
self-organised	drug	user	groups	across	19	provinces	
in	Indonesia.	The	network,	which	was	established	in	
2006	to	address	the	stigma,	violence,	discrimination	
and	human	rights	violations	experienced	by	people	
who	use	drugs,	has	grown	significantly	in	the	last	
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two	years.(71)	The	Red	Ribbon	Award,	a	joint	global	
effort	by	United	Nations	agencies,	is	presented	every	
two	years	to	ten	organisations	around	the	world	at	the	
International	AIDS	Conference.	The	award	honours	
community-based	organisations	for	outstanding	
initiatives	that	show	leadership	in	reducing	the	spread	
of	HIV.
India	HIV/AIDS	Alliance	also	continues	to	showcase	
best	practice,	reaching	out	to	women	who	use	drugs	
and	the	sexual	partners	of	men	who	inject	drugs,(72)	
including	through	the	involvement	of	female	outreach	
workers	in	the	programme.	Based	on	evidence	
produced	by	civil	society	organisations,	NACP	Phase	
IV:	2014–2017	has	gone	on	to	include	this	staff	position	
in	their	strategy	document.(59)	Under	the	NACP	Phase	IV	
initiative,	a	national	consultation	took	place	in	December	
2014	on	the	HIV	response	to	women	who	inject	drugs	
and	the	sexual	partners	of	men	who	inject	drugs,	in	
order	to	inform	the	national	programme.(12)
The	Support.	Don’t	Punish(73)	campaign	represents	
the	largest	national-level	and	regional	campaign	to	
be	implemented	simultaneously	across	a	number	
of	countries	in	Asia,	including	activities	in	Thailand,	
Malaysia	and	Vietnam.	In	2014,	the	campaign	included	
press	conferences,	concerts,	street	protests,	meetings	
with	policymakers	and	other	stakeholders,	and	the	
distribution	of	harm	reduction	materials	in	10	countries	
in	the	region.(40,	73)	Other	civil	society	developments	
have	been	the	Indian	Drug	Users’	Forum	meeting	on	
including	HCV	in	the	national	HIV/AIDS	programme,(59)	
the	Indonesian	Drug	User	Network’s	engagement	
with	HCV	price	reduction,	drug	policy	reform,	and	
the	renewal	of	national	harm	reduction	guidelines.(48)	
In	Cambodia,	the	Support!	Reduce	harm	of	drug	use	
campaign,	run	by	KHANA	and	the	local	drug	user	
network,	targeted	police,	local	authorities	and	service	
providers	to	change	their	attitudes	towards	people	who	
use	drugs,	portraying	them	as	victims	of	drugs	who	they	
should	support	rather	than	criminals.(50)
Mobilisation of people who use drugs in 
asia
The	Asian	Network	of	People	who	Use	Drugs	
(ANPUD),	established	in	2008	and	registered	
in	2010,	remains	the	only	regional	network	in	
Asia	that	unifies	and	represents	the	voices	of	
communities	of	people	who	use	and	inject	drugs.	
Since	2012,	the	network	has	grown	to	include	
the	voices	of	Thai	and	Malaysian	people	who	use	
drugs,	in	addition	to	community	representatives	
from	Cambodia,	India,	Indonesia,	Nepal	and	
Vietnam.	
ANPUD	advocates	for	evidence-based	changes	
in	punitive	drug	laws	and	policies	that	negatively	
affect	the	lives	of	people	who	use	drugs.	It	focuses	
on	key	areas,	such	as	HCV	testing	and	treatment	
access,	alternatives	to	compulsory	detention	and	
rehabilitation	centres,	decriminalisation	of	drug	
possession	for	personal	use,	and	improving	the	
coverage	and	quality	of	harm	reduction	services	in	
the	region.	To	broaden	the	reach	of	its	advocacy,	
ANPUD’s	2014–2016	strategic	plan	prioritises	
partnerships	with	law	enforcement	agencies,	
research	institutions	and	national	networks	of	key	
affected	populations.			
Efforts	are	now	underway	to	support	and	
strengthen	national	networks	of	people	who	use	
drugs	in	Cambodia,	Malaysia	and	Myanmar.	
During	the	11th	International	Congress	on	AIDS	
in	Asia	and	the	Pacific	(ICAAP)	in	2013,	ANPUD	
launched	a	module	for	network	strengthening	
and	development.	The	module,	now	available	
in	English,	Vietnamese	and	Khmer	languages,	
is	aimed	at	building	organisational	capacity	in	
the	areas	of	governance,	networking,	resource	
mobilisation,	leadership	and	monitoring	and	
evaluation.
The	participation	of	women	ANPUD	members	in	
regional	and	International	forums	and	the	network’s	
decision-making	process	has	also	increased	over	
the	years,	with	two	of	the	current	executive	board	
members	now	being	women.
392.1 Asia
Funding:	developments	for	harm	
reduction
Although	the	need	for	harm	reduction	funding	is	a	key	
priority	in	a	number	of	countries	in	the	region,	several	
international	donors	are	gradually	withdrawing.(40)	
Information	on	most	countries	is	limited,	and	HIV	
prevention,	treatment	and	care	budgets	are	not	
disaggregated	to	provide	information	on	funding	for	
harm	reduction	interventions,	meaning	assessments	
are	largely	based	on	anecdotal	information	from	civil	
society.	
In	Indonesia,	the	National	Drug	User	Network	has	
tried	to	build	evidence	around	the	need	to	improve	
the	quality	of	harm	reduction	programming	and	use	
this	as	a	tool	to	advocate	for	continued	support.	
In	2013,	Perssaudaraan	Korban	Napza	Indonesia,	
in	collaboration	with	UNAIDS,	held	a	training	for	
members	on	budgeting	advocacy	to	raise	awareness	
and	enable	the	drug-using	community	to	better	
understand	funding	and	budgeting	mechanisms	
in	the	country.(48)	In	Cambodia,	funding	challenges	
include	the	HAARP	programme	finishing	in	December	
2015,	and	the	Global	Fund	decreasing	its	financial	
support	towards	harm	reduction,	in	particular	OST	
programmes.(50)	In	Pakistan,	reports	have	indicated	
that	after	the	closure	of	the	Enhanced	HIV/AIDS	
Control	Programme	in	2010,	availability	and	coverage	
of	services	for	people	who	inject	drugs	declined	
significantly.(29)
Multilaterals	such	as	UNODC,	UNAIDS	and	the	World	
Bank	support	several	civil	society	organisations	in	the	
region.	In	Indonesia,	the	Community	Action	on	Harm	
Reduction	project	(CAHR),	run	by	the	International	
HIV/AIDS	Alliance	through	Rumah	Cemara,	and	
Bridging	the	Gap	programme,	run	by	Mainline	
Foundation/Dutch	government	have	supported	civil	
society	organisations	in	some	areas	of	Indonesia	to	
fill	harm	reduction	intervention	gaps.(48)	Although these 
projects	have	contributed	to	an	increasing	focus	
on	harm	reduction	in	Indonesia,	CAHR	is	ending	in	
December	2015	and	no	new	funding	has	yet	been	
established.	
In	India,	the	new	national	programme	funds	harm	
reduction	activities,	including	NSPs,	OST,	voluntary	
counselling	and	testing,	and	ART,	but	no	funding	is	
available	for	advocacy	activities.	Only	the	European	
Commission-funded	Asia	Action	project	supports	
this,	although	it	is	limited	to	three	states.(59)	In	both	
China	and	Indonesia,	anecdotal	evidence	from	civil	
society	indicates	that	funding	for	harm	reduction	has	
actually	decreased,(8,48)	but	no	figures	are	available	
to	confirm	this.	In	2014	in	Malaysia,	the	government	
announced	more	funding	for	drug	control,	but	this	is	
likely	to	be	devoted	to	abstinence-based	programmes	
and	primary	prevention	rather	than	harm	reduction.(49) 
Although	few	countries	in	the	region	receive	national	
government	funding	support	for	harm	reduction,	
Malaysia	and	India	are	examples	of	where	the	
government	supports	an	almost	fully	fledged	harm	
reduction	programme.	Similarly,	national	government	
investment	in	China	has	supported	harm	reduction	for	
several	years,	including	OST	and	NSPs,	although	that	
investment	continues	to	reduce.(8)	
Since	few	Asian	countries	have	accurate	and	up-to-
date	estimates	for	key	affected	populations	such	as	
people	who	inject	drugs,	it	is	difficult	to	ascertain	
whether	current	figures	on	spend	accurately	represent	
epidemiological	need,	as	data	limitations	seriously	
hamper	any	rigorous	assessment	of	whether	national	
government	investment	is	adequate.	Further	work	on	
the	cost	and	scope	of	harm	reduction	in	this	region	is	
greatly	needed.
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Table 2.2.1: Epidemiology of HIV and viral hepatitis, and harm reduction responses in Eurasia
Country/territory
with reported
injecting
drug use
People who
inject drugs(1)
HIV 
prevalence
among 
people
who inject 
drugs (%)(1)
Hepatitis C (anti-
HCV) prevalence
among people
who inject 
drugs (%)(1)
Hepatitis B
(anti-HBsAg)
prevalence 
among
people who  
inject drugs(%) (1)
Harm reduction response(1)
NSPi OSTii
albania 4,000–6,000 0.5 28.8 11.5  2 6 (m)
armenia 12,700(2) 6.3 nk nk  12 4 (m)
azerbaijan 71,283(2) 9.5 62.8 10.9   17 2 (m)
belarus 75,000(2) 17.1(2) 13.3 39  33 14(m)
bosnia and Herzegovina 9,500–15,500 (12,500)(92) 0.3 12–43.4iii 2–3  28 8 (b,m)
bulgaria 19,000(93) 10.6(3) 67.8 5.7  102  31 (b,m)
croatia 6,251 0.48 39.30 6.5  (102)   (b,m)
czech republic 38,700 (38,450–38,900) 0.0–0.7 18.6 15.1  (106) (P) (372)
(4) (b,m, 
bn)
estonia 13,801 (8,178–34,732) 50–60(5)iv 75 21.3 (36) (7) (b,m)
Georgia 45,000(4) 3.0 53 7.2  (14)  18 (bn,m)
Hungary 5,699 0.0 24.1 0.5  (29)  12 (bn,m)
Kazakhstan 11,6840(6) 4–4.8 60.3 7.9  (155 – 168) (10)(4) (m)
Kosovo 3,000–5,000 0 36.5 1   (3) (m) 
Kyrgyzstan 25,500(7) 12.4–14.6 50 nk  (53)  (17 – 20) (m) 
latvia 18,000(4, 8) 20.3(4, 8) 74.2 1.6 (18) (4)(b,m)
lithuania 6,056(8) 4.6(8)   70.3–89.7  3.3–8.9 (11) (19) (b,m)
macedonia 15,000–20,000v 0 70 nk (16) (12)(m, b)
moldova 31,562(9) 7.9(4) 70.2–72.8(4) 3.4–14.2 (23)vi (11) (m)
montenegro nk 0.3 53.6 nk  (13) (3) (m)
Poland 15,119 (10,444–19,794) 5 70 2.5–3.8 (12) (25)(bn,m)
romania 19,265(2) 24.90vii 79(10) 5 (7) (13)(10)(b,bn,m)
russia 1,815,000viii 18–31(11)  72.5(12)  9 (4)(13) x
Serbia
30,383 (12,682–
48,083)(14)
<5(15) 61(15) 68.95 (60.5–77.4)(16)ix (13)(15) (29) (b,bn,m)(15)
Slovakia 18,841 (13,732–34,343)x 0.3(17)  37.8 28.1 (28) (7)(bn, b,m)
Slovenia 6,100 (5,580–6,750) 1.9 28.5 2 (17)(4)(P) (20)
(4) 
(bn,b,m,o)
tajikistan 25,000 (20,000–30,000) 13.5(18) 36.2 nk (9) (34)(m)
turkmenistan nk nk nk nk (2)(19) x
ukraine 310,000 19.70(20) 27.1xi   4.5 (1667)  (169)(b,m)
uzbekistan 80,000xii 7.3(21) 20.9  nk (235) x
i	 This	includes	all	operational	NSP	sites,	including	fixed	sites,	vending	machines	and	mobile	NSPs	operating	from	a	vehicle	or	through	outreach	workers.	(P)	=	needles	and	syringes	reported	to	be	
available	for	purchase	from	pharmacies	or	other	outlets.
ii	 (M)	=	methadone,	(B)	=	buprenorphine,	(O)	=	any	other	form	(including	morphine	and	codeine).
iii	 Based	on	a	study	conducted	in	five	cities.
iv	 Based	on	a	study	conducted	in	two	cities.	
v	 Data	from	EMCDDA	2010	based	on	people	who	inject	drugs	in	Skopje.
vi	 Figure	relates	to	regions	rather	than	cites.
vii	 Civil	society	believe	this	figure	to	be	higher.
viii	 Figure	from	2007.
ix	 Based	on	findings	from	two	cities.
x	 Figure	includes	high-risk	drug	users.
xi	 Year	of	reporting:	2012	for	both	HCV	and	HBV,	Global	Fund	Round	6	Programme	monitoring,	Alliance	Ukraine.
xii	 Year	of	estimate:	2006.	EMCDDA	Country	Profile:	http://www.emcdda.europa.eu/publications/country-overviews/uz#pdu
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Map 2.2.1: Availability of needle and syringe exchange programmes (NSP) and opioid substitution therapy (OST)
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The	large	and	diverse	Eurasian	region	is	home	to	
an	estimated	3.1	million	people	who	inject	drugs,	
with	two	of	the	largest	populations	living	in	Russia	
(1.8	million)(22)	and	Ukraine	(310,000).(23) Eastern 
Europe	and	Central	Asia	is	one	of	two	regions	
globally	where	rates	of	HIV	infection	are	continuing	
to	rise.	Approximately	1.3	million	adults	and	children	
are	living	with	HIV	in	the	region	(range	1,000,000–
1,700,000).(2)	However,	it	should	be	noted	that	this	
figure	has	been	strongly	disputed	by	civil	society,	and	
population	size	estimates	for	people	living	with	HIV	
in	the	region	should	be	treated	with	caution.[4]	One	in	
three	new	cases	of	HIV	were	reported	to	be	attributed	
to	a	lack	of	access	to	sterile	injecting	equipment	
between	2006	and	2010.(24)	A	recent	systematic	
review	suggested	that	one	in	two	people	who	inject	
drugs	are	living	with	HIV	in	parts	of	Estonia,	Russia	
and	Ukraine.(25)
Prevalence	of	hepatitis	C	(HCV)	is	extremely	high	
across	the	region	for	people	who	inject	drugs,	
although	it	should	be	noted	that	robust	data	is	lacking	
for	many	countries.	Where	data	is	available,	high	
rates	are	reported	in	Russia	(up	to	90%),	Romania	
(82.4)	and	Lithuania	(70.3–89.7%).(1)	Rates	of	HCV	
are	exacerbated	in	prison	settings,	with	around	
91%	of	prisoners	in	Kazakhstan	living	with	HCV–HIV	
co-infection(26)	and	38%	of	prisoners	in	Kyrgyzstan	
having	been	exposed	to	HCV.(27)	Given	that	90%	of	
people	who	inject	drugs	in	the	region	will	experience	
incarceration	at	some	point	in	their	lives,(28)	it	is	likely	
that	rates	of	HCV	prevalence	in	prisons	among	people	
who	inject	drugs	will	be	extremely	high.	Tuberculosis	
(TB)	prevalence	in	the	region	varies	but	is	also	
generally	high,	with	some	of	the	highest	rates	of	multi-
drug	resistant	TB	(MDR-TB)	in	the	world	reported	in	
Kazakhstan,	Uzbekistan,	Tajikistan	and	Kyrgyzstan.(29) 
Overdose	continues	to	be	a	major	cause	of	morbidity	
and	mortality	for	people	who	inject	drugs	across	
Eurasia.	A	recent	review	found	that	overdose	remains	
the	leading	cause	of	death	for	people	who	inject	
drugs	globally.(30)	While	comparable	data	across	the	
region	is	lacking,	where	evidence	is	available	rates	
of	overdose	have	been	described	as	“alarming”,	
with	between	21–24%	of	people	who	inject	drugs	in	
Central	Asia	reporting	having	experienced	a	non-fatal	
overdose	in	the	past	year.(31)
Although	service	provision	across	the	region	has	
expanded	since	2012,	coverage	levels	continue	to	
remain	lower	than	internationally	recommended	
targets.1	Needle	and	syringe	programmes	(NSPs)	exist	
in	all	29	countries	of	the	region,	but	coverage	varies	
widely,	ranging	from	two	sites	in	Albania	to	1,667	in	
Ukraine	(see	Table	2.2.1).	Regionally,	only	10%	of	
people	who	inject	drugs	in	Eastern	Europe	and	36%	
in	Central	Asia	access	NSPs.(13)	The	coverage	of	harm	
reduction	programmes	in	Eastern	Europe	and	Central	
Asia	is	less	than	1%	of	the	estimated	number	of	
people	who	inject	drugs.(11)
Opioid	substitution	therapy	(OST)	is	available	in	26	
countries	of	the	region,	with	only	three	countries	
reporting	evidence	of	injecting	drug	use	not	providing	
OST:	Russia,	Turkmenistan	and	Uzbekistan.(25) 
However,	it	should	be	noted	that	coverage	levels	
are	low	across	the	region,	with	the	Czech	Republic	
having	the	highest	coverage,	with	372	sites.	The	
European	Union	part	of	the	region	represents	only	
5%	of	the	total	number	of	people	accessing	OST	in	
the	European	Union,	while	20%	of	people	who	use	
opiates	live	in	these	countries.(32) 
Civil	society	continues	to	play	an	important	role	in	
advocating	for	the	scale	up	of	harm	reduction	in	the	
region.	The	appointment	of	Michel	Kazatchkine	as	
United	Nations	Secretary-General’s	Special	Envoy	for	
AIDS	in	Eastern	Europe	and	Central	Asia	has	brought	
much-needed	attention	to	harm	reduction	and	HIV	in	
the	region.	The	Eurasian	Network	of	People	who	Use	
Drugs	(ENPUD)	has	continued	to	strengthen,	and	now	
includes	members	from	Armenia,	Azerbaijan,	Belarus,	
Georgia,	Latvia,	Lithuania,	Moldova,	Kazakhstan	
and	Kyrgyzstan,	Russia,	Tajikistan,	Ukraine	and	
Uzbekistan.	Several	important	events	have	also	
taken	place	in	the	region	recently,	including	the	23rd	
International	Harm	Reduction	Conference	in	Vilnius	
in	2013,	and	regional	conferences	in	Ukraine	and	
Moldova	organised	by	the	Eurasian	Harm	Reduction	
Network	(EHRN).	
However,	the	most	significant	development	affecting	
the	state	of	harm	reduction	in	the	region	is	that	of	the	
changing	donor	landscape.	The	region	is	overly	reliant	
on	international	donors,	with	approximately	15%	of	
financial	resources	coming	from	domestic	budgets.(33) 
In	particular,	the	Global	Fund’s	New	Funding	Model,	
with	its	new	focus	on	disease	burden	and	income	
level,	is	likely	to	further	threaten	investments	in	harm	
reduction,	as	many	countries	in	the	region	are	now	
either	ineligible	or	will	not	receive	“new”	resources	
until	2017.(34) 
In	response	to	this	growing	crisis,	EHRN	became	the	
recipient	of	the	region’s	first	regional	grant	from	the	
Global	Fund.	This	project	seeks	to	build	an	enabling	
environment	for	harm	reduction	funding	in	the	region	
and	to	develop	the	capacity	of	people	who	use	drugs	
to	advocate	for	the	availability	and	sustainability	of	
harm	reduction	services	to	meet	their	needs.	The	
regional	programme	is	implemented	in	five	countries:	
Belarus,	Georgia,	Kazakhstan,	Moldova	and	Tajikistan.
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Developments	in	harm	reduction	
implementation
Needle	and	syringe	exchange	programmes	(NSPs)
In	the	past	few	years,	the	number	of	programmes	
providing	needles	and	syringes	increased	(an	
increase	documented	from	13	countries,	compared	
to	a	decrease	in	6	countries	for	which	updated	data	
is	available;	see	Table	2.2.1).	Since	we	reported	in	
The Global State of Harm Reduction 2012,(19) the 
most	significant	increases	have	been	observed	in	
Bosnia	and	Herzegovina,	Croatia	and	Ukraine,	while	
the	most	significant	decrease	occurred	in	Poland. 
However,	overall	coverage	of	services	remains	low	in	
all	countries.	
In	2012,	the	Eastern	Europe	and	Central	Asia	part	
of	the	region	had	the	lowest	number	of	syringes	
distributed	per	person	–	a	rate	of	around	50	syringes	
per	person	who	injects	drugs	–	which	represents	a	
further	decrease	from	2011.(2)	According	to	global	
AIDS	progress	reporting	in	2012,	the	Czech	Republic	
and	Kyrgyzstan	reached	a	rate	of	more	than	200	
syringes	per	person,	with	Tajikistan	significantly	
expanding	coverage	from	88	to	199	per	person	in	a	
year.(2)	The	most	significant	decrease	was	in	Hungary	
(from	74	to	14	syringes	per	person),	with	Azerbaijan,	
Belarus,	Moldova,	Poland,	Romania,	Serbia	and	
Macedonia	delivering		fewer	than	50	syringes	per	
person.(2) 
Coverage	estimates	vary	significantly	between	
countries	(for	example,	50%	in	Kazakhstan,(1)	22%	
in	Tajikistan,(1)	21%	in	Slovakia,(1)	10%	in	Poland(1)).	
In	Romania,	services	are	limited	mainly	to	the	capital	
Bucharest,	and	in	Lithuania	rates	dropped	below	the	
2008	rate.(1)	Hungary	documented	a	decline	of	over	
30%	in	syringes	distributed,	despite	availability	across	
the	country	using	diverse	distribution	systems.(1)	
Changing	patterns	of	drug	use	are	documented	in	the	
eastern	part	of	Europe,	including	Ukraine,(35)	Russia	
and	Georgia	in	the	Caucasus.(36)	In	Budapest,	a	rise	in	
injecting	of	legal	highs	(mephedrone-like	substances)	
has	been	documented.(37)	This	not	only	suggests	the	
need	to	scale	up	existing	services,	but	also	points	
to	the	challenges	in	adapting	them	to	address	the	
changing	needs	of	people	who	inject	drugs.	For	
example,	in	the	Czech	Republic,	NSPs	have	begun	
providing	gelatine	capsules	to	stimulant	users	to	
encourage	transitioning	from	injecting	to	oral	use.(38,39)
Inadequate	funding	remains	the	key	constraint	to	
accessible	and	high-quality	services,	particularly	in	
the	non-European	Union	part	of	the	region	that	has	
been	affected	by	changing	donor	priorities.	Other	
barriers	include	unequal	coverage	between	urban	
and	rural	settings,	a	lack	of	legislative	regulation	
of	services,	the	criminalisation	of	people	who	use	
drugs,	restricted	opening	hours	and	poor-quality	
equipment.(4)	Additional	barriers	to	accessing	NSPs	
for	specific	groups	include	age	restrictions	for	those	
under	18	years	and	a	lack	of	gender-sensitive	services	
for	women	who	use	drugs.(4)	Political	hostility	towards	
harm	reduction	is	also	a	growing	concern,	and	has	
led	to	the	closure	of	the	biggest	NSP	programme	
in	Hungary,	providing	around	40%	of	the	country’s	
clean needles(40)	–	a	decision	criticised	by	Hungary’s	
Commissioner	on	Fundamental	Rights.(41)
Opioid	substitution	therapy	(OST)
OST	is	provided	in	various	forms	and	on	different	
scales	in	26	countries	of	the	region.	It	remains	illegal	
in	Russia	and	Turkmenistan,	and	Uzbekistan	did	
not	renew	its	programme	that	closed	in	2009.	With	
support	from	the	Global	Fund,	Kosovo	initiated	a	pilot	
OST	programme	in	mid-2012,	and	by	the	end	of	the	
year,	55	people	were	receiving	methadone.(4)
Since	2012,	a	number	of	countries	have	removed	
barriers,	facilitating	access	and	improving	the	quality	
of	OST	programmes.	In	Latvia,	new	regulations	to	
legalise	OST	provision	resulted	in	a	28%	increase	
in	patients	in	2012.(37)	In	Bulgaria,	buprenorphine	
was	approved	for	the	treatment	of	HIV-positive	or	
high-risk	people	under	18	years,	enabling	OST	to	
become	accessible	to	this	age	group.(37)	Ukraine	also	
removed	a	number	of	barriers,	including	a	weakening	
of	age	restrictions	for	legal	minors,	which	resulted	in	
expanded	access.(42)
Countries	that	have	scaled	up	OST	include	Armenia,	
Belarus,	Georgia,	Kazakhstan,	Kyrgyzstan,	Latvia,	
Macedonia,(19)	Tajikistan	and	Ukraine.(11)	However,	the	
most	significant	progress	is	being	made	in	the	Czech	
Republic,	which	has	the	highest	coverage	rates	in	
the	region,	of	approximately	40–45%	of	people	who	
inject	drugs.(43)	A	steady	increase	in	coverage	is	also	
reported	from	Ukraine,	where	the	number	of	OST	
patients	at	the	beginning	of	2014	reached	7,784.(44)	
Elsewhere,	progress	is	slow	and	OST	coverage	
remains	limited.	Despite	the	increased	access	
mentioned	above,	Latvia	remains	the	country	with	
the	lowest	OST	coverage	in	the	European	Union,(37)	
with	only	2.3%	of	all	opiate	users	receiving	OST.(1) 
In	Estonia,	coverage	remains	below	15%.(1)	Belarus	
reported	a	steady	increase	in	OST	patients,	from	79,2	
to	107,7 between	January	2012	and	2014,	although	
this	is	only	a	small	proportion	of	the	estimated	75,000	
people	who	inject	drugs	in	the	country.	
A	30%	decrease	in	OST	access	has	been	
documented	in	Romania,(45)	the	limited	geographical	
reach	of	programmes	in	Estonia,	Hungary	and	
Lithuania	has	been	recorded,	and	a	significant	
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reduction	in	the	number	of	treatment	slots	available	
in	Bulgaria	noted.(32)	Although	11	countries	in	the	
European	Union	part	of	the	region	have	legalised	
buprenorphine,xiii	three	of	these	(Bulgaria,	Estonia,	
Lithuania)	are	reported	not	to	provide	it	in	practice,xiv 
and	Slovakia	enrolled	only	two	people	by	the	end	of	
2012.(46)	
Gender-based	discrimination	in	access	persists,	and	
women	are	often	excluded	from	OST	treatment.	For	
example,	in	Georgia	less	than	1%	of	women	who	
inject	drugs	have	access	to	OST.(47)	Other	barriers	
affecting	the	scale	and	quality	of	OST	in	countries	
across	the	region	include	centralisation	of	access,(32)	
stigma,(48)	lack	of	a	legal	framework(49)	and	cost	of	
treatment.	
Viral	hepatitis
Prevalence	rates	for	viral	hepatitis	are	generally	far	
higher	than	HIV	rates	for	people	who	inject	drugs	
across	the	region,	although	limitations	on	the	data	for	
both	hepatitis	B	(HBV)	and	HCV	make	it	difficult	to	
assess	changes	in	the	epidemic	accurately.	Despite	
this,	prevalence	rates	of	HCV	infection	among	people	
who	inject	drugs	appear	to	be	extremely	high	in	many	
countries,	with	rates	of	50%	or	higher	in	at	least	
17	countries	(Azerbaijan,	Bosnia	and	Herzegovina,	
Bulgaria,	Estonia,	Georgia,	Kazakhstan,	Kyrgyzstan,	
Latvia,	Lithuania,	Moldova,	Montenegro,	Poland,	
Romania,	Russia,	Serbia,	Tajikistan,	Ukraine).	In	
Russia,	Lithuania	and	Romania,	HCV	rates	have	been	
observed	of	70–90%	of	people	who	inject	drugs.
Access	to	hepatitis	treatment	remains	generally	
low.	For	example,	although	Ukraine	has	the	highest	
prevalence	of	HCV	among	adults	in	Europe	(1.2	
million),	only	80	courses	for	treating	adults	infected	
with	HCV	were	procured	between	2011	and	2013.(54) 
The	high	cost	of	hepatitis	treatment	remains	a	key	
obstacle	to	access	in	most	countries.	While	some	
countries	provide	partial	public	funding	for	treatment	
(Armenia,	Belarus,	Bulgaria,	Croatia,	Czech	Republic,	
Estonia,	Hungary,	Latvia,	Lithuania,	Macedonia,	
Moldova,	Montenegro,	Poland,	Russia,	Serbia	and	
Slovenia),(55)	access	remains	low.	However,	some	
significant	progress	in	reducing	treatment	costs	
has	been	achieved	since	2012	through	civil	society	
advocacy.	In	Ukraine,	a	substantial	reduction	in	price	
announced	in	2013	has	provided	HCV	treatment	for	
100	patients	with	HIV–HCV	co-infection	who	inject	
drugs.(54)  
xiii	 Bulgaria,	Czech	Republic,	Croatia,	Estonia,	Hungary,	Latvia,	Lithuania,	Poland,	Romania,	Slovakia,	Slovenia.
xiv	 EMCDDA.	Table	HSR-3.	Estimated	number	of	clients	in	methadone	treatment	and	of	all	clients	receiving	any	opioid	substitution	treatment	(OST).	[Online].	2012.	
Available	from:	http://www.emcdda.europa.eu/stats12/hsrtab3b	[Accessed	28	November	2014].
The Hiv epidemic and the battle for harm reduction in Ukraine
The	scale	up	and	investment	in	HIV	and	harm	reduction	programming	in	Ukraine	has	made	it	one	of	the	
largest	harm	reduction	programmes	in	the	world.	It	is	also	one	of	the	most	significant	successes,	with	
rates	of	HIV	decreasing	among	people	who	inject	drugs	in	the	country.(50)	
It	is	estimated	that	around	50%	of	people	who	inject	drugs	(200,000	people)	are	reached	by	these	
services	annually,	including	large-scale,	peer-driven	interventions;	pharmacy-based	NSPs;	new	
programming	for	people	who	use	stimulants;	and	services	for	women	who	use	drugs.	
However,	the	Global	Fund’s	New	Funding	Model	has	resulted	in	changes	in	allocations	for	Ukraine,	
leading	to	a	projected	53%	reduction	in	support	for	harm	reduction	programmes	between	2014	and	
2015.	Programme	managers	predict	that	plans	to	scale	up	access	to	OST	will	cease,	along	with	funding	
for	legal	services	and	sexually	transmitted	infection	(STI)	testing	and	treatment,	and	that	outreach	
programmes	will	have	a	reduced	reach.	While	it	is	hoped	that	a	small	increase	in	funding	will	be	
allocated	through	the	next	round	of	Global	Fund	support	in	2016,	if	further	reductions	are	experienced	
there	is	likely	to	be	an	overall	cut	of	72%	in	harm	reduction	programmes	by	2017.(51)
In	2014,	after	the	annexation	of	Crimea	by	Russia,	all	substitution	programmes	operating	there	were	
discontinued,	resulting	in	around	800	patients	no	longer	receiving	OST	since	Crimea	was	now	subject	to	
Russian	law,	under	which	OST	is	illegal.	While	the	health	and	welfare	of	these	former	patients	is	largely	
unknown,	it	was	reported	that	10	people	died	between	March	and	May	2014(52)	and	approximately	
200	people	were	displaced	because	of	the	discontinuation	of	OST.	Since	the	unrest,	OST	provision	is	
also	under	threat	in	eastern	regions.	Donetsk	and	Luhansk	in	particular	are	at	risk	of	being	cut	off	from	
essential	medical	supplies,	including	methadone	and	buprenorphine.(53)
According	to	the	UNAIDS	representative	in	Ukraine,	Crimea’s	OST	provision	was	considered	an	example	
of	best	practice.	Among	the	800	people	formerly	enrolled	in	OST	in	Crimea,	38%	were	living	with	HIV	
and	50%	of	them	were	receiving	antiretroviral	therapy	(ART).(52)
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In	2014,	the	Georgian	government	negotiated	
a	significant	60%	price	reduction	in	treatment	
courses,(56)	leading	the	government	to	announced	that	
10,000	people,	including	those	in	prison,	will	receive	
treatment.
Political	commitment	on	these	issues	is	generally	
low,	with	only	five	countries	reporting	national	
HCV	strategies	(Bosnia	and	Herzegovina,	Latvia,	
Lithuania,	Slovenia	and	Ukraine).(57)	Stigma	and	
discrimination	related	to	drug	use,	as	well	as	
widespread	misconceptions	among	treatment	
specialists	about	a	lack	of	adherence	to	treatment	
by	people	who	use	drugs,	create	further	barriers	to	
treatment.	Many	countries	have	restrictive	admission	
criteria	for	people	who	use	drugs,	which	range	from	
abstinence	requirements	in	some	countries	(Hungary	
and	Macedonia)	to	systematic	exclusion	in	others	
(Bulgaria	and	Romania).(4)	A	recent	report	covering	
six	countries	(Georgia,	Kazakhstan,	Kyrgyzstan,	
Lithuania,	Russia	and	Ukraine)	found	that	treatment	
is	unavailable	due	to	a	lack	of	guidelines	prioritising	
modern,	internationally	agreed	HCV	diagnostic	and	
treatment	protocols,	with	some	existing	guidelines	
recommending	medications	of	questionable	value	
whose	effectiveness	has	been	insufficiently	proven.(58) 
Overdose	
Overdose	remains	a	major	cause	of	avoidable	
death	in	the	region.	Although	data	is	sparse,	where	
available	it	is	clear	that	overdose-related	mortality	is	
increasing	in	many	parts	of	the	region.	For	example,	
it	has	been	estimated	that	around	100,000	people	
die	from	overdose	every	year	in	Russia.(59)	Rates	in	
Estonia	are	also	particularly	high;	a	trend	associated	
with	changing	drug	patterns,	particularly	the	use	
of	fentanyls	(a	family	of	highly	potent	synthetic	
opioids).(45)	However,	it	is	difficult	to	assess	the	
true	scale	of	overdose	morbidity	and	mortality,	as	
inconsistent	reporting	and	differences	in surveillance	
systems	has	led	to	systematic	undercounting	of	
overdose events.	Accordingly,	there	is	a	lack	of	
data	to	effectively	inform overdose prevention	
programmes.(60)
The	overdose	epidemic	among	people	who	inject	
drugs	remains	unacknowledged	as	an	urgent	political	
issue	at	a	regional	level.	However,	some	progress	
has	been	made	since	2012,	with	both	Estonia(60) and 
Kyrgyzstan	specifically	referencing	overdose	in	their	
national	anti-drug	strategies.(4)
The	Global	Fund	has	played	an	important	role	in	
supporting	the	scale	up	of	peer	workers	in	overdose	
prevention	programmes	in	Kyrgyzstan.(4) Further scale 
up	of	services	is	expected	in	Georgia	and	Moldova	
following	inclusion	of	overdose	in	recent	Global	Fund	
proposals.(4)
Naloxone,	a	highly	effective	opioid	antagonist	used	to	
reverse	the	effects	of	opioid	overdose,	is	registered	
in	the	essential	medicines	list	in	all	countries	
in	the	region	with	the	exception	of	Albania.(61) 
However,	harm	reduction	programmes	providing	
naloxone	are	extremely	limited,	with	only	Georgia,	
Kyrgyzstan,	Russia,	Tajikistan	and	Ukraine	reporting	
implementation.(60)	Of	the	11	European	Union	member	
states	within	Eurasia,	only	Estonia	provides	takeaway	
intranasal	naloxone.(62) 
The	most	significant	progress	has	been	made	in	
Central	Asia,	where	a	regional	project	has	been	
initiated	to	make	naloxone	available	through	
pharmacies	using	a	voucher	system.	In	Tajikistan,	
home	to	some	of	region’s	first	overdose	projects,	local	
and	international	non-governmental	organisations	
(NGOs)	were	successful	in	advocacy	to	the	ministry	
of	health	to	allow	harm	reduction	programmes	to	
store	naloxone	legally	on	site,	enabling	a	significant	
increase	in	the	distribution	of	naloxone.(60)	In	2014,	
the	Georgian	government	amended	legislation	that	
required	medical	services	to	report	drug	overdose	
cases	to	the	police,	removing	a	large	barrier	to	
overdose	prevention.(63)	
Barriers	to	accessing	naloxone	in	the	region	
include	extensive	regulations	for	management	of	
naloxone	by	non-medical	staff,	while	simultaneously	
provision	though	medical	personnel	is	restricted	
by	overregulation.(64)	Moreover,	intense	stigma	and	
discrimination	create	additional	barriers	for	people	
who	inject	drugs,	coupled	with	structural	and	legal	
barriers	such	as	harsh	penalties	for	drug	use	and	
possession,	and	high	threshold	criteria	for	acquiring	
naloxone	–	often	only	available	through	medical	
personnel.	Furthermore,	those	limited	services	that	
are	able	to	provide	naloxone	are	usually	inadequately	
funded,	meaning	that	programmes	are	frequently	
limited	to	small-scale	pilot	projects.	This	financial	
instability	has	led	to	interruptions	in	naloxone	supply	
in	some	countries.(60)	
Tuberculosis	
Throughout	the	region,	TB	testing	and	treatment	
services	are	not	generally	tailored	to	the	needs	of	
people	who	inject	drugs,	being	rarely	linked	to	HIV	
or	drug	treatment	services.	However,	some	countries	
have	taken	positive	steps	forward,	including	Belarus	
and	Ukraine,	where	TB	testing	is	offered	at	some	
harm	reduction	sites.	Despite	this,	take	up	is	low	
as	concerns	around	lengthy	hospital	stays	without	
access	to	OST	and	other	drug	treatment	interventions	
deter	testing.(4)	 
Prisons	and	other	correction	facilities,	such	as	pre-
trial	detention	centres,	have	some	of	the	highest	rates	
of	MDR-TB	in	the	region.	In	Russia,	MDR-TB	rates	
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among prison populations have ranged from 12–55% 
in previously treated patients.(65) 
Key barriers in TB diagnostics, treatment and care 
include a lack of political will and sustainable funding. 
A large proportion of TB services in communities 
and prisons are supported by the Global Fund. 
However, due to the changing nature of eligibility 
criteria, a number of countries, including Azerbaijan, 
Belarus and Romania, will no longer be eligible 
for Global Fund support for TB programmes. 
Although Azerbaijan has the third-highest MDR-TB 
rate in the world,(66) the current Global Fund grant 
supporting TB programmes is due to end in 2015. 
Following cancellation of Round 11, Belarus became 
ineligible to apply for continued support through 
the Transitional Funding Mechanism.(67) Equally, in 
Romania, where 27% of all TB cases in the European 
Union occur and 19% of previously treated cases are 
now multi-drug resistant,(68) the government has yet 
to allocate sufficient funding to address the issue. 
Although the government demonstrated willingness 
in 2012 to fund the TB response, pledging €5.75 
million, parliament has failed to allocate the funds so 
far.(67) Service provision for prisoners is particularly 
dependent on international sources of funding, with 
an estimated 90% of countries in Eastern Europe and 
Central Asia funding TB services with grants from the 
Global Fund.(69)
Antiretroviral therapy (ART)
Across the region ART coverage remains extremely 
low, with around 20% of people who inject drugs 
who are living with HIV able to access treatment.(25) 
In Russia, 35% of people who are living with HIV 
inject drugs,(70) but just 1 in 10 access ART.(2) Such 
disproportionately poor access to ART is likely to be 
even more pronounced among subgroups such as 
people living with HIV who inject drugs and women 
who are pregnant. For example, a prospective cohort 
study in Ukraine among pregnant women with HIV 
showed that the mother-to-child transmission rates 
of HIV were almost twice as high among women who 
injected drugs as among women who did not.(71)
Despite these reported low coverage levels, some 
progress can be seen. For example, between 2010 
and 2012, the number of people receiving ART 
increased by 50% in Azerbaijan and Tajikistan.(72) 
Since 2008, the Ukraine government has significantly 
increased investments in providing ART. Resources 
allocated for HIV treatment in the central state budget 
covered 43,790 people living with HIV at the end of 
2013; an impressive increase from 12,751 people 
receiving treatment on 1 January 2010.(73) Romania 
and Georgia have also achieved ART rates of over 
60%.(74)
Key barriers include stigma and discrimination, 
unavailability of low-threshold testing and counselling 
services, and a lack of comprehensive care and 
treatment, including evidence-based drug treatment. 
Currently, ART is financed through a combination 
of domestic budget allocations and out-of-pocket 
spending. However, in cases where treatment is 
covered by the state, people who inject drugs face 
heightened barriers to access. For example, around 
30–50% of people who inject drugs in Estonia do 
not have healthcare insurance and are therefore 
unable to access ART.(75) Other barriers include limited 
geographical reach of service provision (for example, 
in Belarus under 20 medical professionals can 
prescribe ART), poor case management, and a lack of 
joined-up service provision between drug treatment 
services and HIV clinics, as well as TB and hepatitis 
issues.(4)
HIV diagnosis and AIDS-related mortality remain high, 
particularly for people who inject drugs. Between 
2006 and 2011 there has been a reported 58% rise 
in AIDS-related deaths in the region.(70,74) There is 
a critical need to scale up integrated HIV and drug 
treatment services, in particular OST, which has 
been shown to improve adherence to ART among 
people who inject drugs. The implementation of OST 
provision has been projected to reduce new HIV 
infections by 54%.(76)
Harm reduction in prisons
The region has a high prison population, with Russia 
alone incarcerating 850,000–1 million people each 
year – the second highest prison population in the 
world.(77) A repressive legal environment and an 
over-reliance on punitive drug laws in many countries 
ensure that a large proportion of the prison population 
are likely to be people who use drugs.(78) In Central 
Asia it has been estimated that 90% of people who 
inject drugs have been imprisoned at some point in 
their lives.(27)
NSPs in prisons are available in three countries 
(Kyrgyzstan, Moldova, Tajikistan). Prison NSP 
programmes that previously had been established 
in Armenia, Belarus and Romania have now ceased 
to operate. Although the programme in Tajikistan is 
a pilot, the response in Kyrgyzstan and Moldova is 
more robust, with NSPs available in 16 and 9 prisons 
respectively.(79) 
Civil society reports that OST in prison or detention 
settings exists to some extent in 19 countries in 
the region (see Table 1.1.1). However, regulation, 
coverage and quality differs substantially, with 
some countries allowing people to maintain OST 
in prisons if they were accessing it before arrest 
(Albania, Bulgaria, Croatia, Czech Republic, Estonia, 
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Kyrgyzstan,	Macedonia,	Moldova,	Montenegro,	
Poland,	Romania,	Serbia,	Slovenia),	while	others	use	
methadone	for	detoxification	only	(Georgia),	allow	
it	in	policy	but	have	not	implemented	it	in	practice	
(Hungary),	or	have	made	it	available	in	some	cases	in	
police	lock-up	only	(Ukraine).	Slovenia	has	scaled	up	
OST	in	prison	settings	and	is	now	reaching	over	10%	
of	the	prison	population.(75)	
Civil	society	confirms	the	availability	of	ART	in	
prisons	in	at	least	13	countries	(Albania,	Azerbaijan,	
Belarus,	Bulgaria,	Czech	Republic,	Georgia,	Hungary,	
Kyrgyzstan,	Macedonia,	Poland,	Romania	Slovakia	
and	Ukraine).	A	number	of	countries	(for	example,	
Bulgaria, Latvia	and	Romania)	reportedly	practice	
mandatory	HIV	testing	within	prisons.(75)
Policy	developments	
Within	the	region,	26	countries	or	territories	have	
national	HIV	or	drug	policies	explicitly	supporting	
harm	reduction.(19)	 
Positive	policy	developments	have	been	observed	in	
Albania,	where	the	newly	adopted	National	Strategy	
Against	Drugs	2012–16	consists	of	a	balanced	
approach,	including	harm	reduction.	In	Kyrgyzstan,	
the	anti-drug	programme	that	was	adopted	at	the	
beginning	of	2014	acknowledges	harm	reduction,	
including	OST	and	naloxone.	Furthermore,	it	
specifically	identifies	the	importance	of	creating	
a	conductive	legal	environment	for	implementing	
a	comprehensive	package	of	services	that	meet	
international	standards.	
However,	drug	policy	across	the	region	is	marked	
by	an	overreliance	on	criminalisation,	and	political	
hostility	towards	harm	reduction	is	common.	For	
example,	in	Uzbekistan	and	Ukraine,	possession	of	
very	small	amounts	of	drugs,	equal	to	the	residue	
found	in	a	used	syringe,	can	lead	to	imprisonment.(80) 
This	zero	tolerance	policy	shift	is	also	supported	
by	the	national	anti-drug	strategy	called	“Clear	
Consciousness,	Sobriety	and	the	Fight	Against	
Drug	Crime”,	with	aims	for	a	drug	free	Hungary	by	
2020.	In	January	2014,	a	new	Criminal	Code	bill	was	
introduced	in	Bulgaria	that	is	looking	to	recriminalise	
drug	use.	If	approved,	fines	for	minor	possession	will	
be	replaced	with	imprisonment.(81) 
The	Russian	Federation	continues	to	implement	a	
zero	tolerance	approach	to	drug	use.(82)	In	recent	
years,	the	Russian	government	has	used	anti-
propaganda	laws	to	suppress	harm	reduction	
services	and	advocacy,(83)	as	well	as	considering	the	
recriminalisation	of	drug	use.	In	2013,	the	United	
Nations	Special	Rapporteur	on	torture	and	other	
forms	of	cruel,	inhuman,	degrading	treatment	or	
punishment,	Juan	E	Méndez,	released	a	report	
equating	the	denial	of	OST	to	cruel,	inhuman	or	
degrading	treatment	and,	in	some	cases,	torture,	
and	advised	“similar	reasoning	should	apply	to	the	
non-custodial	context,	particularly	in	instances	where	
Governments	impose	a	complete	ban	on	substitution	
treatment	and	harm	reduction	measures.”(84) 
Civil	society	and	advocacy	
developments	for	harm	reduction	
Civil	society	has	continued	to	play	a	strong	and	
important	role	in	the	region	in	advocating	for	harm	
reduction	in	Eurasia	and	internationally.	
Regional	initiatives	have	included	a	clear	focus	on	
the	lack	of	sustainable	funding	for	harm	reduction	in	
the	region.	EHRN	became	the	principle	recipient	for	
the	first	regional	HIV/AIDS	grant	in	Eastern	Europe	
and	Central	Asia.	The	programme	Harm	Reduction	
Works:	Fund	it!	is	now	set	to	focus	on	strengthening	
civil	society	in	the	region	to	advocate	for	sustainable	
funding	for	national	harm	reduction	programmes,	
covering	Belarus	Georgia,	Kazakhstan,	Moldova	and	
Tajikistan.	
Since	2012	a	number	of	online	interactive	campaigns	
have	been	launched.	In	2012,	over	6,000	people	
signed	the	EHRN	Hepatitis	C	Treatment	Waiting	List,	
which	highlighted	the	lack	of	access	to	treatment	
for	people	who	use	drugs.	In	the	same	year,	in	
partnership	with	ENPUD,	EHRN	launched	the	‘I	
am	the	Evidence’	campaign,	recording	personal	
testimonies	advocating	for	naloxone	provision.	In	
2014,	the	Women	against	Violence	campaign	was	
launched,	aiming	to	document	cases	of	violence	
against	women	who	use	drugs	and	raise	awareness	
of	the	heightened	vulnerability	to	violence	many	
women	experience.(85)	
Several	international	meetings	held	in	the	region	
between	2012	and	2013	helped	to	facilitate	debate	on	
harm	reduction	and	dialogue	between	policymakers,	
international	organisations,	and	harm	reduction	and	
drug	user	activist	groups.	In	July	2012,	EHRN	and	the	
International	HIV/	AIDS	Alliance	in	Ukraine	organised	
the	AIDS	forum	‘Ensuring	That	Our	Voice	is	Heard’	
in	Ukraine.	Over	100	participants	attended	from	11	
Eastern	European	and	Central	Asian	countries,	more	
than	half	representing	communities	of	people	who	
use	drugs.	The	2012	International	AIDS	conference	
was	held	in	the	USA,	where	visa	restrictions	meant	
that	many	representatives	of	people	who	use	drugs	
could	not	attend.	EHRN	organized	the	AIDS	Hub	as	a	
pre-conference	for	community	members	from	Eastern	
Europe	and	Central	Asia.	In	June	2013,	the	23rd	
International	Harm	Reduction	Conference	was	held	
in	Vilnius,	Lithuania,	ensuring	wide	regional	focus	and	
dialogue	between	government	representatives,	harm	
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reduction	organisations,	and	people	who	use	drugs.	
ENPUD	has	also	continued	to	grow,	and	currently	has	
approximately	100	members	representing	the	majority	
of	Eastern	European	and	Central	Asian	countries.
A	number	of	successful	harm	reduction	advocacy	
campaigns	have	been	carried	out	at	a	national	
level,	including	securing	the	development	of	take-
home	naloxone	by	the	drug	user-led	Association	of	
the	Substitution	Treatment	Advocates	of	Ukraine	
(ASTAU);	the	opening	of	a	new	OST	site	in	Tajikistan	
by	the	OST	patients’	group	Choice;	and	removing	
barriers	to	OST	access	in	Armenia.	Here,	the	drug	
user	activist	group	Awakening	Power	successfully	
advocated	for	removal	of	police	representatives	
from	medical	commissions	evaluating	a	individual’s	
readiness	to	undergo	OST.	In	Hungary	and	Romania,	
civil	society	groups	are	working	towards	establishing	
drug	consumption	rooms.	In	Kyrgyzstan	and	Ukraine,	
groups	of	people	living	with	HIV	and	people	who	
inject	drugs	have	joined	forces	to	advocate	for	
reduction	of	HIV	and	HCV	treatment	prices.	
Funding:	developments	for	harm	
reduction 
Funding	for	the	majority	of	harm	reduction	
programmes	in	Eastern	Europe	and	Central	Asia	
is	mainly	reliant	on	international	sources,	primarily	
the	Global	Fund.	The	Global	Fund	has	allocated	
$688.5	millionxv	for	financing	programmes	for	2014	
and	beyond.	Currently	the	largest	funding	allocation	
within	the	region	is	to	Ukraine	(28%),	followed	by	
Uzbekistan	(10%)	and	Georgia	(9%).(88)	
A	period	of	instability	from	2011	to	2012,	during	
which	the	Global	Fund	cancelled	Round	11(19) and 
offered	only	limited	funds	for	“essential	services”,	
was	followed	by	a	Transitional	Funding	Mechanism(89) 
in	2013,	and	finally	the	New	Funding	Model	was	
adopted.	According	to	new	eligibility	criteria,	more	
than	half	of	countries	(16	out	of	29)	within	this	region	
will	become	ineligible	for	funding	from	2014.(90)
The	New	Funding	Model	may	threaten	investments	
in	harm	reduction,	as	many	of	the	countries	with	the	
greatest	need	are	now	either	ineligible	for	further	
funding	or	are	not	receiving	any	“new”	resources	
for	harm	reduction,	and	national	sources	are	
expected	the	fill	the	gap.	However,	across	the	region	
governments	have	shown	little	“willingness	to	pay”	for	
harm	reduction	programmes.(91) 
All	countries	except	Armenia,	Bulgaria,	Moldova	and	
Montenegro	provide	some	domestic	funding	for	harm	
reduction.	However,	the	degree	of	domestic	financing	
varies	substantially.	Available	data	for	2009–2012	
indicate	that	out	of	21	countries	in	the	region,	the	
largest	proportion	of	funding	(over	90%)	for	harm	
reduction	in	Croatia,	Czech	Republic,	Estonia,	
Hungary,	Latvia,	Lithuania	and	Poland	comes	from	
domestic	sources.(2)	However,	as	harm	reduction	
coverage	estimates	show,	adequate	scale	is	achieved	
only	in	the	Czech	Republic.	In	Armenia,	Azerbaijan,	
Belarus,	Bulgaria,	Moldova,	Montenegro,	Romania,	
Russia,	Tajikistan,	Ukraine	and	Uzbekistan	domestic	
funding	varies	from	0%	(Armenia,	Bulgaria,	Moldova,	
Montenegro)	to	12		(Belarus).(2)  
Successful campaign to reduce prices for hepatitis C treatment in Georgia
According	to	available	data,	6.7%	of	Georgia’s	adult	population	(around	200	000	people)	live	with	the	
HCV.	The	prevalence	level	is	twice	as	high	as	the	global	average.(86)	It	has	been	estimated	that	around	
20,000	people,(56)	or	around	one	in	ten,	in	need	of	treatment	have	undergone	a	course	in	Georgia.	One	
course	of	treatment	can	cost	up	to	US$15,000.	This	exorbitant	price	ensures	it	is	almost	inaccessible	for	
most	people	in	the	country,	where	the	average	monthly	wage	is	around	US$400.	
A	campaign	to	improve	access	to	HCV	treatment	was	initiated	by	the	Georgian	Harm	Reduction	Network	
(GHRN)	in	partnership	with	patients’	groups.	The	cornerstone	of	the	campaign	was	to	make	people	living	
with	HCV	visible	in	order	to	create	a	demand	for	treatment.	In	2012,	a	campaign	‘We	Need	Treatment	
NOW’	was	organised,	targeting	policymakers	at	national	and	local	levels,	followed	by	an	innovative	
campaign	telling	pharmaceutical	companies	it	was	‘Time	for	Sale’.	In	parallel,	GHRN	and	patient	
groups	led	a	number	of	meetings	with	the	health	and	justice	ministries	in	order	to	develop	national	
hepatitis	strategy.	The	partnership	between	the	harm	reduction	groups	and	patient	groups	was	crucial	
to	presenting	treatment	access	as	an	urgent	public	health	issue	and	to	ensuring	a	non-discriminatory	
approach.	
As	a	result	of	three	years	of	advocacy,	a	significant	price	reduction	was	achieved,	from	US$246	to	
US$93	per	vial	for	Pegintron,	allowing	10,000	people	to	undergo	treatment	at	a	reduced	price.	The	price	
reduction	has	also	enabled	the	government	to	expand	treatment	to	prisoners	living	with	HCV.(87)
xv	 This	figure	includes	US$658	million	under	the	New	Funding	Model,	plus	US$30.5	million	available	to	countries	no	longer	eligible	as	of	January	2014.	
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In	Kazakhstan	and	Kyrgyzstan,	the	gap	between	
domestic	and	external	source	is	lowest	in	the	region	
(see	Table	1).	
In	Kyrgyzstan,	public	spending	for	HIV	between	2010	
and	2012	more	than	doubled,	indicating	the	progress	
made	by	the	country	in	taking	over	the	financial	
burden	of	HIV,	and	the	total	share	of	harm	reduction	
funding	in	HIV	support	from	international	sources	is	
now	below	6%	(see	Table	1).	In	all	other	countries	for	
which	data	is	available	(Albania,	Georgia,	Lithuania,	
Moldova,	Romania),	domestic	spending	on	HIV	
decreased	between	2011	and	2012xvi.	According	to	
UNAIDS,	the	influx	of	domestic	resources	into	the	HIV	
response	directly	correlates	with	country	income	level,	
with	higher	investments	in	higher-income	countries.(2)  
xvi	 UNAIDS.	AIDSinfo.	[Online].	2013.	Available	from:	http://www.unaids.org/en/dataanalysis/datatools/aidsinfo/	[Accessed	28	November	2014].
Country Year Harm 
reduction 
spending 
for iDUs 
from 
domestic 
sources 
(%)
Harm 
reduction 
spending for 
iDUs from 
international 
sources (%)
Share 
of harm 
reduction 
spending 
in the total 
Hiv / aiDS 
spending (%)
Share of harm 
reduction 
spending in Hiv/
aiDS spending 
from domestic 
sources (%)
Share of harm 
reduction 
spending in 
total Hiv/aiDS 
spending from 
international 
sources (%)
armenia 2012 0 100 20.5 0.0 26.7
azerbaijan 2011 6 94 10.2 0.9 31.8
belarus 2011 12 88 16.8 3.2 40.8
bulgaria 2011 0 100 10.2 0.0 15.3
croatia 2009 100 0 32.1 32.1 0.0
czech republic 2009 96 3 22.3 22.3 25.3
estonia 2010 100 0 46.9 46.9 0.0
Georgia 2012 39 42 59.7 64.1 48.2
Hungary 2009 100 0 2.1 2.1 0.0
Kazakhstan 2012 36 64 35.3 28.6 40.6
Kyrgyzstan 2012 40 60 5.4 4.9 5.8
latvia 2010 100 0 3.7 4.1 0.0
lithuania 2012 100 0 43.5 43.5 0.0
moldova 2012 0 100 35.5 0.0 56.6
montenegro 2009 0 100 22.0 0.0 22.0
Poland 2009 99 0 4.2 5.5 0.0
romania 2011 7 93 23.1 6.0 29.3
russia 2008 2 98 2.9 0.1 29.2
tajikistan 2011 5 95 25.8 7.2 30.8
ukraine 2010 4 96 23.3 1.7 50.1
uzbekistan 2012 6 94 7.9 0.8 17.6
The	table	is	based	on	UNAIDS.	AIDSinfo.	[Online].	2013.	Available	from:	http://www.unaids.org/en/dataanalysis/datatools/aidsinfo/	[Accessed	
28	November	2014].
The	table	summarising	information	for	countries	of	the	region,	and	an	interactive	maps,	is	available	at:	Eurasian	Harm	Reduction	Network.	
Harm reduction funding in EECA.	[Online].	http://www.harm-reduction.org/issues/funding-harm-reduction/map	[Accessed	28	November	2014].
Table 1: The proportion of domestic versus external spending for harm reduction and share of harm reduction 
in domestic and external HIV spending*
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Table 2.3.1: : Epidemiology of HIV and viral hepatitis, and harm reduction responses in Western Europe
Country/
territory
with 
reported
injecting
drug use
People who
inject drugs(1)
HIV 
prevalence
among 
people
who inject 
drugs (%)(2)
Hepatitis C (anti-
HCV) prevalence
among people
who inject 
drugs (%)(3)
Hepatitis B
(anti-HBsAg)
prevalence 
among people 
who inject 
drugs (%)(28)
Harm reduction response
NSP(4)i OST(5)ii DCR(57)
andorra nk nk nk nk x x x
austria 17,500 (12,000-23,000)iii 0.7–5.3 44.3–59.9 nk (40) (b,m,o) x
belgium 24,810 (18,286–36,896) 0.0–8.3 17.1–75.1iv 3·0v (102) (b,H,m) x
cyprus 231 (192–3,010) 0–1.3 55.4 2.4 (1)  (1) b,o x
denmark 12,754 (10,066–16,821) 5(6) 52.5 1.3vi  (b,H,m) 5
finland 15,650 (12,200–19,700)(7)vii 0.9 60.5 nk (42) (b,m,o) x
france 122,000(8)viii 7.2 41.7ix 4.8(9)x (583)  (19,484) 
(b,m,o)
x
Germany 94,250 (78,000–110,500)(8) 3.9–5.6xi 56.0–71.6xii 7.2xiii (391) (2,786-6,626) 
(b,H,m)
24
Greece 7,651(10) 5–8(10)xiv 59.6–73.4 1.3–3.3 (14)  (17)(b,m,o) x
iceland nk nk 63(9)xv nk x  (b,m) x
ireland 6,289 (4,694–7,884)(8)xvi nk 74.6 (72.3–76.9)(9)xvii nk (91) (332)(b,m,o) x
italy 326,000(8)xviii 11.5 61.0–64.8xix nk   (b,m,o) x
luxemburg 1907 2.4 70.3–89.7xx 5.1xxi (10) (b,m,o) 1
malta (1,524–2,301) 0 40.8 nk (7)  (≥2) (b,m) x
monaco nk nk nk nk x x x
netherlands 2,390 (2,336–2,444) 0.0–3.7xxii 86.2(9)xxiii 3.0xxiv (175)  (b,H,m) 30
norway 9730 (8,299-11,757) 2.32 65.8 1.2xxv (44) (b,m) 1
Portugal nk 4.9– 6.5 83.8 4.9 (1,270) (b,m) x
Spain 7,393 (7,098–7,886) 33.6 79.6 (73.3–85.9)(9)xxvi 3.6xxvii (2,386)  (497-2,229)
(b,H,m)
13
Sweden nk 4.4 75·1 (62·0–88·2) (9)xxviii  2.3 (4) (b,m) x
Switzerland 31,653 (24,907–38,399)(8)xxix 7.3 78.3(9)xxx 4.0xxxi   (b,H,m,o) 13
turkey nk 0.3 50.1 8.6 x (b) x
uK 133,112 (126,852–143,278) 1.2 43 8.9 (1,523)(59)xxxiii  (b,H,m,o) x
Western Europe
i. Figure is based on total number of fixed sites (including specialist agency sites, 
vending machines, pharmacy-based services and prison-based services) combined 
with total number of mobile sites (outreach workers and services carried out by a 
van). Data is from 2012 unless otherwise stated.
ii. Year of estimate: 2011.
iii. Year of estimate: 2000.
iv. Estimate is based on sub-national data.
v. Year of estimate: 2008. See reference 9.
vi. Year of estimate: 2007. See reference 9.
vii. Civil society argues that figures are greater than stated by UNODC.
viii. Year of estimate: 1999.
ix. Estimate is based on sub-national data.
x. Year of estimate: 1992–1995.
xi. Figure is based on sub-national data.
xii. Estimate is based on sub-national data.
xiii. Year of estimate: 1992–94. See reference 9.
xiv. Figure is based on sub-national data.
xv. Year of estimate: 1990–1993.
xvi. Year of estimate: 1996.
xvii. Year of estimate: 2001–3.
xviii. Year of estimate: 1996.
xix. Figure is based on sub-national data.
xx. Figure is based on sub-national data.
xxi. Year of estimate: 1990–93. See reference 9.
xxii. Figure is based on sub-national data.
xxiii. Year of estimate: 2008.
xxiv. Year of estimate: 2000. See reference 9.
xxv. Year of estimate: 2008. See reference 9.
xxvi. Year of estimate: 2003.
xxvii. Year of estimate: 2003. See reference 9.
xxviii. Year of estimate: 2007.
xxix. Year of estimate: 1997.
xxx. Year of estimate: 2002.
xxxi. Year of estimate: 1996. See reference 9.
xxxii. Year of estimate: 1996–2000. See reference 9.
xxxiii. Year of estimate: 2010.
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Map 2.3.1: Availability of needle and syringe exchange programmes (NSP) and opioid substitution therapy (OST)
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In most of Europe, HIV rates among people who 
inject drugs appear to be stable or declining(11) as a 
result of early scale up of harm reduction measures. 
However, recent severe outbreaks of HIV among 
people who inject drugs in Greece and Romania 
prompted the European Centre for Disease Prevention 
and Control (ECDC) and the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) to 
undertake a risk assessment in 2013. They concluded 
that five countries in Western Europe are of concern 
for HIV risk: Estonia, Greece, Latvia, Lithuania and 
Romania.(11)  
There have been few notable changes in the 
dynamics of drug use in Europe since 2012. The rate 
of opioid use in Europe, including in new European 
Union member states, is estimated to be around 
0.4% among people aged 15–64 (approximately 1.3 
million users).(11) While heroin use is slightly declining, 
use of other opioids, including fentanyl, methadone 
and buprenorphine, is growing. Injecting drug use 
has also been declining since 2006, including among 
people who use opioids,(12) and the number of new 
users of opioids also appears to be declining.(12) At 
the same time, Europe’s drug-using population is 
ageing, particularly in the countries of Western Europe 
that experienced heroin epidemics in the 1980s and 
1990s.(60)
Amphetamine use has remained relatively low and 
stable, with less than 2.5% of the population using in 
most countries.(12) Although amphetamines are often 
taken orally or snorted, injection is also common 
in some communities.(12) Stimulant injecting poses 
challenges for needle and syringe programme (NSP) 
coverage, since more frequent injection requires 
more syringes, and adapted outreach is needed 
to reach stimulant users.(11) Use of amphetamine-
type stimulants (ATS) in conjunction with risky 
sexual behaviour (described as “chem sex” in a 
2013 study on amphetamine use among men who 
have sex with men in London(13)) is believed to 
be contributing to rising rates of HIV among men 
who have sex with men in many countries. New 
psychoactive substances and ‘legal highs’ are also 
getting increasing attention, but the discourse is often 
focused on supply reduction and law enforcement 
issues rather than understanding and managing the 
impact on health and rights. 
A myriad of factors, including criminalisation, 
stigma and inadequate medical and social services, 
contribute to disproportionately high mortality and 
morbidity among people who use drugs in Europe, 
with overdose remaining the main cause of mortality. 
People who inject drugs in Europe face a mortality 
rate of 1–2% per year and are 10 times more likely 
to die than their non-using peers of the same gender 
and age,(12) with women who use opioids facing a risk 
that is 30 times greater.(12) Although the majority of 
the mostly high-income countries of Western Europe 
remain among those countries in the world with the 
best-controlled HIV epidemics among people who 
inject drugs, HIV prevalence within this population 
is still high (greater than 5%) in France, Greece, 
Italy and Spain.(14) In Austria, Belgium, Cyprus, 
Denmark, Finland, Germany, Luxemburg, Malta, the 
Netherlands, Norway, Sweden and the UK(14) it is 
moderate (1–5%), low (less than 1%) or stable, and 
in Finland, Germany and Sweden, HIV prevalence 
among people who use drugs is declining.(14) The 
relatively low and/or declining prevalence reported 
in most of these countries is generally attributed 
to the scope and quality of their harm reduction 
programmes.  
The World Health Organization (WHO) estimates 
that there may be as many as 1.2 million people 
who inject drugs living with hepatitis C (HCV) in the 
European Union/Free Trade Agreement region,(3) with 
an estimated HCV prevalence of approximately 44% 
among people who inject drugs.(3) Increases in HCV 
prevalence among people who inject drugs have 
been seen in Belgium, Cyprus, Greece and Turkey.
(11) Problematically, access to HCV treatment and 
prevention for people who inject drugs remains low. 
Data on tuberculosis (TB) prevalence in Western 
Europe is still very limited. In European countries, the 
disease is predominantly concentrated among high-
risk groups, such as migrant populations, homeless 
people, people who use drugs and people in prison.(15) 
People who are living with HIV and who inject drugs 
are two to six times more likely to develop TB than 
non-injectors, and commonly have co-morbidities 
with hepatitis B (HBV) and HCV infection. Among 
people who inject drugs who develop TB, at least one 
in three will also have HIV, and two out of three will 
have HCV antibodies. They are also at increased risk 
of criminalisation and incarceration.(16)
Although the availability of health data on people 
who use drugs and harm reduction programming 
in West European Union countries is better than 
in other regions, there are some important gaps. 
For example, although previous ECDC reports on 
implementation of the Dublin Declaration on HIV/AIDS 
in Europe and Central Asia have noted that data was 
needed on access to antiretroviral treatment (ART) 
for people who inject drugs, this is still very limited. 
However, in 2012 the ECDC did report that availability 
of population size estimates for people who inject 
drugs has improved,(14) and that more countries are 
now reporting on availability of needles/syringes per 
person.(14) There has also been an improvement in 
data on HIV prevalence among people who inject 
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drugs.(14) In 2013, a major report on HIV in the European 
region was also launched, synthesising evidence on 
the HIV epidemic among key populations and the 
effectiveness of responses to it.(17) 
Developments in harm reduction 
implementation
Needle and syringe exchange programmes (NSPs)
In most Western European countries, the annual 
number of syringes distributed per person who injects 
drugs approaches WHO’s recommendation of 200.(18) 
However, the number of syringes distributed (the key 
indicator for NSP coverage) has been in flux. Between 
2007 and 2012, increases were seen in Austria, 
France, Finland, Greece, Malta and the UK (Northern 
Ireland),(12) while there were decreases in Belgium, 
Ireland, Luxembourg, Norway, Portugal, Spain, Sweden 
and the UK (Scotland).(12) Belgium, France and Turkey 
have particularly low NSP coverage (less than 100 
syringes per person who injects drugs per year),(11) 
while moderate to high coverage (distribution of more 
than 100 syringes per person per year) is reported in 
Austria, Finland, Hungary, Luxembourg, Malta, Norway, 
Portugal, Spain and Sweden.(14) For some countries, 
data on the number of syringes distributed are lacking or 
do not reflect the situation fully. Germany, for example, 
is not on the list of countries with high or moderate 
coverage, and this is most likely due to nationwide 
data being unavailable. There are nearly 1,000 NSP 
services in Germany but there is no central processing 
of information.
In many cases where decreases were seen, this has 
been attributed to financial strains. In Greece, where 
a new initiative to scale up NSP access was launched 
in 2011, implementation was slowed due to funding 
constraints.(10,14) Restrictions such as these, together 
with changing financing mechanisms, may jeopardise 
quality as well as coverage. In Finland, for example, 
there are fears that new tendering procedures for NSP 
service provision could lead to compromised quality, as 
providers undercut each other in order to win the tender.
Even in countries with relatively good levels of coverage, 
important gaps exist. In many countries, provision of 
services to young people aged under 18 is a challenge. 
Reaching out to migrants, especially undocumented 
migrants, is also difficult, and NSP provision in rural 
communities is often underdeveloped. In many Western 
European countries, rates of sharing injecting equipment 
have also been documented as high,(14) increasing the 
risk of transmission of HIV and viral hepatitis.
Various approaches to NSP are employed in Europe, 
including through fixed sites and outreach and mobile 
units, as well as pharmacies and vending machines. 
Vending machines are used in Austria, France, Germany, 
Luxemburg and the UK, and there is significant 
distribution of sterile syringes through pharmacies in 
Belgium, France, Ireland, the Netherlands, Portugal, 
Spain and the UK.(4) Among other interesting innovations 
in NSP service provision, Luxemburg introduced low 
dead space syringes in 2014, responding to evidence 
that these may reduce transmission of HIV and 
viral hepatitis. Also, in Finland in 2012, the A-Clinic 
Foundation’s drop-in needle exchange started to offer 
home visits from peer workers and health and social 
services professionals. During its first two years, the 
service reached 700 clients, more than half of them 
female.(19) 
Opioid substitution therapy (OST)
Over half of opioid users in Europe access opioid 
substitution therapy (OST),(20) with an estimated 734,000 
receiving OST in 2012(12) – a slight rise compared to 
2011. The most significant increase in OST between 
2011 and 2012 was in Turkey, which saw an increase of 
250% from 8,000 to 28,656, followed by Greece, which 
saw an increase of 45% to 9,878.(12) One country, Italy, 
saw a substantial decrease in access, with the total 
number of people accessing OST falling from almost 
110,000 in 2011 to 98,460 in 2012.(61)
In some countries, national rates of access to 
OST may be adequate, in accordance with WHO 
recommendations, while in sub-national regions or for 
some populations in those countries, levels of access 
may remain inadequate. In Germany, 77,300 people 
(30–50% of the entire population who inject drugs) 
receive OST,(21) but advocacy for expanded access in 
some areas, especially in rural settings, is ongoing.  
While access to OST in Europe has been expanding 
slowly and steadily, there are areas of concern. In 
England and Wales, growing focus on abstinence-based 
treatment models is jeopardising programme quality by 
making programmes higher threshold, limiting dosing 
and requiring programmes to progressively lower doses 
to push clients towards drug-free outcomes.
Approximately two-thirds of OST clients in Europe 
receive methadone, while around 20% receive 
buprenorphine.(20) Approximately 6% of OST 
programmes use slow-release morphine. Heroin-
assisted treatment (HAT) programmes are in place in 
Belgium, Denmark, Germany, the Netherlands, Spain 
and the UK, and low-release morphine programmes in 
Austria, Luxemburg and the UK.(20) HAT programmes in 
Germany are funded by health insurance,(22) the result 
of advocacy by Junkies Ehemalige Substituierte (JES), 
an organisation of people who use drugs, in partnership 
with Deutsche AIDS-Hilfe. 
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Viral hepatitis
There are approximately 1.2 million people who inject 
drugs living with HCV in the European Union/Free 
Trade Agreement region, representing approximately 
44% of people who inject drugs in the region.(3) As 
with HIV, there is a significant gap in data related to 
access to HCV treatment for people who inject drugs, 
but available data suggests that access is “alarmingly 
low”.(23) Of 16 Western European countries submitting 
data to a study, eight had national strategies that 
included people who inject drugs and nine had 
treatment guidelines that included people who inject 
drugs.(24) The treatment gap for people who inject 
drugs is in part related to a legacy of treatment 
recommendations that excluded people who are 
currently using drugs. The European Association for 
the Study of the Liver (EASL) published a revision 
of its guidelines in 2013 that recommends providing 
treatment to people who inject drugs providing that 
they want it and are able to regularly attend follow-
up visits to a multidisciplinary medical service.(23) 
However, many doctors remain unwilling to treat 
people who inject drugs, and many people who inject 
drugs do not come forward for treatment.(23) 
The advent of direct acting antivirals (DAAs) – new 
medicines approved by the European Commission 
in January 2014, with cure rates of up to 98% – is 
potentially a revolution in HCV treatment. However, 
the pharmaceutical industry has priced the drugs 
beyond the reach even of the relatively well-resourced 
healthcare systems of Europe, with Gilead’s DAA, 
Sofosbuvir, vending at $84,000 for each 12-
week course. Significant progress will probably 
be impossible until pharmaceutical companies 
are pushed to reduce the price. There is growing 
momentum in Europe and globally to fight for access 
to HCV treatment and services, including for people 
who inject drugs (see box Hepatitis C: momentum for 
change).  
Some countries in Europe demonstrate good HCV 
practice. For example, Scotland has a well-funded 
HCV action plan that is credited with reducing 
HCV prevalence.(25) The programme makes testing 
available in low-threshold settings and provides 
treatment to people who inject drugs using a 
multidisciplinary approach. The action plan was 
implemented locally by managed care networks that 
involved governmental as well as voluntary sector 
representatives.(26) The experience of the German 
non-governmental NSP service Fixpunkt suggests 
that NSPs can have an important role in providing 
information, support and materials to prevent 
HCV transmission, and to encourage testing and 
treatment.(27)
 
Hepatitis C: momentum for change
Demand for access to HCV prevention and 
treatment is growing. There is broad consensus 
among global, regional and national civil society 
that the HCV epidemic is a health emergency. 
In response, civil society actors, including 
people who use drugs, are working hard to force 
their governments to implement the historic 
HCV resolution they signed in May 2014 at the 
World Health Assembly, and to pressure the 
pharmaceutical industry to lower the exorbitant 
price they have set for lifesaving DAAs.  
The Correlation Network’s European Initiative 
on Hepatitis C and Drug Use(28) brings together 
more than 30 organisations to share information 
and engage in advocacy. In September 2014, it 
released a supplemental edition of the journal 
BMC Infectious Diseases devoted to ‘Viral 
Hepatitis and Drug Use in Europe’, containing a 
series of 18 articles by leading European thinkers 
on HCV service access, including by people 
who use drugs.(29) In October 2014, it hosted the 
European Conference on HCV and Drug Use and 
launched a petition to the European parliament 
calling for urgent action on HCV. The initiative is 
also supporting sharing practical information on 
clinical aspects of HCV treatment and related low-
threshold services.
Regional momentum on HCV in Europe is 
matched at national level. Current good practice 
in Scotland, where there is a national hepatitis 
strategy and relatively good access to testing 
and treatment for people who inject drugs, came 
about in part due to calls from civil society.(26) In 
Helsinki, an awareness symposium entitled ‘HCV 
is Preventable and Curable: Act Now on this Public 
Health Emergency!’ was held in May 2014, and 
the Finish government is now developing a policy 
on HCV.(19) In Ireland, a HCV strategy was adopted 
in September 2012 following pressure from civil 
society groups,(30) and action is being taken not 
only to advocate for national change but to provide 
direct help to individuals as well.
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Tuberculosis
Data on TB prevalence in Western Europe is still 
very limited. In European countries, the disease is 
predominantly concentrated among high-risk groups, 
such as migrant populations, homeless people, 
people who use drugs and people in prison.(15) People 
who are living with HIV and who inject drugs are two 
to six times more likely to develop TB than non-
injectors, and commonly have co-morbidities with 
HBV and HCV infection. Among people who inject 
drugs who develop TB, at least one in three will also 
have HIV, and two in three will have HCV antibodies. 
They are also at increased risk of criminalisation and 
incarceration.(16)
Antiretroviral therapy (ART)
Rates of HIV testing among people who inject 
drugs are generally high in Western Europe, except 
in Malta and Greece, where the ECDC reports 
that they are inadequate.(14) The ECDC notes that 
countries with higher levels of access to NSPs 
and OST tend to have higher levels of access to 
testing.(14) Countries with particularly good access 
to HIV testing for people who inject drugs include 
Finland, Luxembourg, the Netherlands, Portugal, 
Spain and the UK.1 Low access to testing (less than 
30%) was reported in Malta and Turkey.(14) Although 
ART is available in principle in all countries, the 2013 
ECDC Thematic Report identified inadequate ART 
coverage among people who inject drugs in several 
countries, including Greece, Italy, Portugal, Spain 
and Sweden.(14) Late presentation (where people 
learn their HIV status at the point when their immune 
system is already significantly compromised) is often 
more common among people who inject drugs, and 
was specifically reported in Belgium, France, Italy 
and the Netherlands.(14) In Italy, for example, 61% of 
people who inject drugs and test positive are late 
presenters.(31) In Ireland, the proportion of people who 
inject drugs who were diagnosed late was 63%.(32) 
The European AIDS Treatment Group (EATG) began to 
prioritise the demedicalisation of HIV testing in 2013 
in order to promote testing in low-threshold settings. 
In Germany, programmes offering HIV testing in low-
threshold services are being piloted.(33)
There is little information available about levels of 
access to ART among people who inject drugs in 
Western Europe, although the region is considered 
to have largely achieved universal access to HIV 
prevention, treatment and care. Data also suggests 
that improvements may be needed in social and 
adherence support for people who inject drugs. A 
Swiss study of over 6,500 people living with HIV 
conducted between 2007 and 2013 found that people 
who use drugs had poorer treatment outcomes and 
lower rates of survival than study participants who 
did not use drugs.(34) This finding, however, was not 
true for people in OST programmes who did not use 
street drugs, but did apply to people who were in OST 
programmes and also used street drugs. Treatment 
interruptions, missed appointments and drug-related 
deaths contributed to these outcomes.(34) 
Harm reduction in prisons
With the exception of Portugal, where possession of 
amounts of drugs for personal use is decriminalised, 
drug use in Europe remains a criminal offence. It is 
estimated that around half of the prison population 
in Europe have used drugs,(35) while a survey of 15 
European countries found that 15–30% of prisoners 
reported ever having injected drugs.(36) 
In 1990, the United Nations General Assembly called 
for equivalence between health services, including 
harm reduction, inside and outside of prison, and this 
was reiterated in the 2013 WHO policy brief Good 
Governance for Prison Health in the 21st Century.(37) 
The 2009–12 EU drugs action plan also called for the 
development and implementation of prevention, harm 
reduction and treatment services in prison that are 
equivalent to services outside of prison,(38) but levels 
of access to harm reduction interventions in prisons 
continue to lag behind those outside.(37) France, Italy, 
Norway, the United Kingdom, some Swiss cantons 
and two autonomous regions of Spain have taken 
steps toward addressing health inequities in prison 
by transferring the responsibility for the healthcare 
of prisoners from ministries of justice or the prison 
administration to health ministries, and Finland is 
currently considering doing the same.(37)  
NSPs are only available in prisons in Spain (38 
prisons), Switzerland (seven prisons, dependent on 
political decisions in some cantons) and in Germany 
(one female prison in Berlin). A pilot programme in 
Portugal was stopped in 2013 as prisoners did not 
participate due to lack of confidentiality, and an NSP 
programme in Luxembourg (one prison) is currently 
under review.(39) 
Almost all European countries have now introduced 
OST in prison.(40) Greece and Cyprus are the only 
countries where prison doctors are not allowed 
to prescribe long-term substitution treatment.(40)  
Access to OST is generally high in Denmark, Ireland, 
Luxembourg, Slovenia, Spain and the United 
Kingdom. Coverage is lower in countries with less 
experience of OST delivery and countries that limit 
OST provision to prisoners who had started it prior 
to imprisonment.(41) The rate of overdose-related 
deaths following release from prison is also high,(42) 
with approximately six out of ten deaths occurring in 
the first 12 weeks after release being drug related.(40) 
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In Scotland, evidence suggests that giving naloxone 
kits to prisoners on release from prison reduces 
opioid-related deaths within the first four weeks after 
release.(43)
Rates of HIV, viral hepatitis and TB in many countries 
are significantly higher among prison populations 
than the general population.(37) HIV prevalence in 
prisons ranges from 0.2% in Finland to up to 39.7% 
in Spain.(2) HCV prevalence is also extremely high 
in prisons,(44) with the highest reported HCV level 
among people who inject drugs in prisons recorded 
in Luxembourg at 90.7%.(45) Data on TB among 
prisoners who inject drugs is scarce, but WHO 
suggests that TB rates in prison are up to 84 times 
higher than among the general population.(46) 
Overdose
Overdose continues to be a major cause of death 
among young people in Europe, accounting for 3.5% 
of all deaths in adult males under 40 years of age.(47) 
Overdose is the leading cause of death for people 
who use drugs,(47) who face mortality rates of 1–2% 
per year.(12) In 75% of overdose deaths, opioids were 
present.(12) In its 2014 Consolidated Guidelines on 
HIV Prevention, Diagnosis, Treatment and Care for 
Key Populations, WHO recommends that people 
likely to witness a drug overdose (including peers 
of people who inject drugs) should have access 
to naloxone and training in how to use it. Europe 
is home to an example of excellent practice in this 
respect. Scotland’s nationwide take-home naloxone 
programme is estimated to have saved at least 500 
lives since it began in late 2011, according to a 2014 
evaluation(48) (see box Saving Lives with take-home 
naloxone in Scotland). 
However, most countries in Europe still do not 
practice this highly effective,2 and cost-effective,(49) 
means of saving lives. In many countries, there are 
still administrative barriers to implementation of 
peer-modulated naloxone programmes, as naloxone 
is only available either by prescription or when it 
can be administered by medical personnel. Civil 
society representatives often cite “medical power” 
(medical personnel do not believe that laypeople 
can administer naloxone effectively) as a barrier. 
For many harm reduction advocates, the historical 
focus of harm reduction services on preventing 
transmission of infectious diseases leaves the issue 
of overdose neglected. However, since 2012 there 
have been important national and regional advocacy 
efforts. Overdose prevention was a key issue in the 
European Harm Reduction Network (EuroHRN)’s 2014 
conference. The ‘I am the Evidence!’ campaign, led 
by the Eurasian Harm Reduction Network (EHRN) 
in partnership with EuroHRN, aims to map good 
practice in countries implementing peer-led naloxone 
distribution, including Denmark, France, Italy and 
Scotland, and to document the experiences of 
people who use drugs through a video campaign that 
collects their life-saving stories.(50)
Other approaches proven to reduce drug-related 
deaths, such as OST(51) and drug consumption 
rooms (DCRs),(52) are available to varying degrees 
in Europe. As noted above, OST programmes are 
relatively accessible in most of Western Europe but 
are insufficient, even at good levels of access, to 
prevent overdose from being the leading cause of 
death for people who inject drugs. DCRs are still 
not widely available. In 2013, EuroHRN conducted 
an organisational review of DCRs in Europe, finding 
that of the 33 that responded to the study, all 
provided spaces for injection and two-thirds allowed 
smoking.(57) Thirteen DCRs stated that they were 
Saving lives with take-home naloxone in Scotland(48)
Scotland is the first country in the world to implement a national take-home naloxone programme.   
Following pilots in 2007 and 2009 that showed the feasibility of take-home naloxone, the Scottish gov-
ernment decided that the approach should be rolled out nationwide. An extensive training, a naloxone 
distribution system was set up targeting people who were in contact with drug services, including NSP 
and OST programmes, along with voluntary and statutory sector personnel and pharmacy staff. Since 
the programme’s launch in April 2011, a total of 5,830 naloxone kits have been distributed, reaching ap-
proximately 8% of Scotland’s 59,510 people who inject drugs, with 1,461 kits also distributed in prisons. 
Between the programme launch in November 2010 and an assessment in March 2013, 365 overdose 
reversals using the naloxone kits were reported, with conservative estimates suggesting that at least 500 
lives have been saved.  
In 2014, an extensive evaluation of the programme was carried out. It offers a wealth of practical guid-
ance that will be valuable not only for improvement and scale up of Scotland’s programme, but for other 
countries as they modernise their approach, bringing it into line with WHO recommendations by imple-
menting full-scale take-home naloxone programmes.(48)
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challenged to reach certain groups, including young 
people who use drugs, people using alternative 
drug administration methods, people using different 
substances, and migrants/non-locals. 
Currently, there are 86 DCRs across seven countries 
in Europe, including Denmark, Germany, Luxembourg, 
Norway, Spain and Switzerland, while in France, 
Portugal and the UK work is underway to open 
pilot DCRs. However, there is political resistance. 
In Greece, a DCR opened and was closed within a 
year due to political pressures. However, the EHRN 
study showed a clear increase in acceptance of 
DCRs among treatment, shelter and police staff, as 
well as neighbours, over the time that the DCRs had 
been functioning. In addition, while the review did not 
measure improvement in health status, it did show 
that the facilities improved access to other services. 
For example, 100% of DCRs surveyed reported 
that they facilitated improved access to primary 
healthcare. 
Policy development for harm reduction
On the whole, Western European HIV policy 
frameworks address harm reduction. For example, 
harm reduction is specifically addressed in the 
European Union Action Plan on HIV/AIDS in the EU 
and Neighbouring Countries: 2014–2016,(53) which 
is itself harmonised with the WHO-led European 
Action Plan for HIV/AIDS 2012–2015,(53) in which harm 
reduction is also covered.
Attention to harm reduction in European drug policy 
frameworks is also improving. The EU Drugs Strategy 
(2013–2020)(54) and EU Drugs Action Plan (2013-
2016)(38) address harm reduction, human rights, civil 
society engagement and transparency more than 
in previous European Union policy documents, and 
compare positively with policy frameworks in other 
regions. Advocacy and policy work by civil society 
had a positive impact on support for harm reduction 
in these processes.
In 2014, the European Commission announced that 
by 2015 the Drugs Unit will have moved from the 
Directorate-General for Justice to the Directorate-
General for Home Affairs. This is expected to be a 
positive change, given that the Directorate-General 
for Home Affairs has a role in promoting human rights. 
At the same time, the Drug Prevention and 
Information programme, which previously funded 
some harm reduction initiatives, is shifting its 
focus away from health. This is expected to impact 
negatively on financing for civil society initiatives 
that exchange and transfer best practice across the 
European Union, including EuroHRN.  
Legal and regulatory barriers can inhibit the 
implementation of some essential harm reduction 
services. In most countries, there are still regulatory 
obstacles to low-threshold HIV and HCV testing 
and to community naloxone programming. 
Most significantly, people who use drugs remain 
criminalised in nearly every country in Europe, with 
the exception of Portugal. Punitive law enforcement in 
Europe has the same unfortunate consequences for 
health and rights as it does globally, exacerbating the 
HIV(55) and HCV(56) epidemics, increasing stigma, and 
resulting in human rights violations, fear of accessing 
health services and all of the added risks associated 
with incarceration, among others.
Many European countries champion harm reduction 
internationally, with the Netherlands, Norway and 
Switzerland boldly supporting harm reduction during 
the Commission on Narcotic Drugs (CND). Sweden 
and Italy continue to oppose harm reduction, but 
through the Civil Society Forum on Drugs, civil society 
organisations are working together to advocate for a 
European Union position supportive of harm reduction 
in the 2016 United Nations General Assembly Special 
Session (UNGASS) on drugs.  
Civil society and advocacy 
developments for harm reduction
There have been significant developments in civil 
society mobilisation and advocacy around harm 
reduction in recent years, both at regional and 
national levels. 
While HIV policy has benefited from transparent 
and constructive interaction between governmental 
structures and civil society, the same has not been 
true historically for drug policy. The positive changes 
described above in the way civil society engagement 
and harm reduction were addressed in Europe’s drug 
policy were brought about only through active and 
coordinated wielding of influence by civil society. The 
European Civil Society Forum on Drugs, modelled 
after Europe’s Civil Society Forum on HIV, is a 
diverse group representing civil society organisations 
engaged in service provision and advocacy relating to 
prevention of drug use, drug-related treatment, social 
support services and harm reduction. The Forum 
put forward 20 recommendations as the EU Drugs 
Strategy (2013–2020) was being developed, many of 
which were taken into consideration.  
As discussed above, there has also been growing 
momentum to call for access to HCV treatment and 
prevention, including for people who use drugs. 
The ‘I am the Evidence!’ campaign for community 
naloxone programming has raised awareness of 
the gap between the evidence base related to 
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preventing overdose deaths and practice in most 
countries. There have also been efforts to increase 
understanding of and support for harm reduction for 
people who inject drugs through the ‘Support don’t 
Punish’ campaign.  
Until now, EuroHRN has brought together people who 
use drugs and those involved in harm reduction to 
promote harm reduction approaches. However, with 
the European Union Drug Prevention and Information 
programme now focusing less on health and rights 
issues, the network secretariat has lost its funding. 
EuroHRN intends to continue to function on a 
voluntary basis. 
The meaningful involvement of people who use 
drugs in policy development and service delivery in 
Europe continues to improve. Following a meeting 
of 30 representatives from 13 countries in 2011, 
the European Network of People who Use Drugs 
(EuroNPUD) was formally established, including a 
steering committee consisting of one representative 
from each country. The committee is the decision-
making forum for the network and is actively 
fundraising for work on priority issues, in particular 
access to HCV services.(33)   
In 2014, the German organisation JES will celebrate 
its 25th anniversary – it is one of the oldest networks 
of people who use drugs in the world. JES, in 
partnership with Deutsche AIDS-Hilfe, was successful 
in advocating for the non-voting representation of 
people who use drugs in the Federal Joint Committee, 
the highest decision-making body for Germany’s 
associations of physicians, dentists, hospitals and 
insurance funds, linking them with the ministry of 
health. In France, people who use drugs have been 
represented since 2012 on the National Narcotic 
Commission (Commission Nationale des Stupéfiants). 
Throughout Europe, there are increasing examples 
of representation of civil society and people who use 
drugs in decision-making bodies and processes at 
organisational, sub-national and national levels.
Several important regional events took place in 
recent years including the 2nd European Harm 
Reduction Conference which took place in Basel, 
Switzerland. The Conference was supported by the 
Swiss Government and co-organised by the European 
Harm Reduction Network. It attracted over 700 
delegates with a focus on innovative harm reduction, 
cooperation with stakeholders and a day dedicated to 
drug policy reform.
Funding: developments for harm 
reduction
Stigmatisation and criminalisation continue to drive 
health and rights inequities for people who inject 
drugs in Western Europe. While the EU Drugs 
Strategy (2013–2020) recommends harm reduction 
services, continued vigilance is necessary in order to 
ensure national implementation and to bring about 
the policy reforms needed to end criminalisation of 
people who use drugs and related health and rights 
inequities. 
The impact of the global financial crisis is also 
hindering the implementation of effective strategies 
in Western Europe. A survey by the European Union 
Civil Society Forum on Drugs in late 2013 revealed 
that over 60% of civil society organisations engaged 
in harm reduction and other drug-related service and 
policy work had experienced a significant decrease in 
funding, and 24% had reduced the drug services they 
provided within the four years preceding the survey. 
At the same time, several European governments 
do provide essential funds for harm reduction in 
low- and middle-income countries. These include 
the UK Department for International Development 
(DFID), the Netherlands Ministry of Foreign Affairs, 
the Norwegian Agency for Development Cooperation 
(Norad), GTZ (Germany) and the Swedish International 
Development Cooperation Agency (Sida). However, in 
this sector, too, budgets are becoming tighter. 
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Table 2.4.1: Epidemiology of HIV and viral hepatitis, and harm reduction responses in the Caribbean
Country/
territory
with reported
injecting
drug use
People who
inject drugsi
Hiv prevalence
among people
who inject drugs
(%)
Hepatitis C (anti-
HCv) prevalence
among people
who inject drugs
(%)
Hepatitis B
(anti-HBsag)
prevalence among
people who  
inject drugs 
(%)
Harm reduction 
response
nSPii oSTiii
bahamas nk nk nk nk x x
bermuda nk nk nk nk x x
dominican 
republic
200,000–350,000(1)iv 11v 3.4(1) 3.1(1) (1) x
Haiti nk nk nk nk x x
Jamaica nk nk nk nk x x
Puerto rico 30,000 22.9(2) 89%vi nk (6)vii (8)viii(m, b, o)
Suriname nk nk nk nk x x
 
i In 2008, the United Nations Reference Group found no reports of injecting drug use for Antigua and Barbuda, Barbados, Belize, Dominica, Grenada, St Kitts and Nevis, St Lucia or St Vincent and 
the Grenadines. However, civil society suggests this information is no longer up to date.
ii	 This	includes	all	operational	NSP	sites,	including	fixed	sites,	vending	machines	and	mobile	NSPs	operating	from	a	vehicle	or	through	outreach	workers.
iii (M) = methadone, (B) = buprenorphine, (O) = any other form (including morphine and codeine).
iv Figure is not representative of people who inject drugs, rather the total number of people who use drugs in the Dominican Republic.
v	 Figures	taken	from	http://www.housingworks.org/community/detail/housing-works-expands-hiv-aids-prevention-services-to-the-dominican-republi
vi	 Figure	is	sub-national	and	relates	to	San	Juan	only.
vii	 Each	of	these	has	multiple	sites;	for	example,	one	syringe	programme	has	15	sites.
viii	 This	includes	six	fixed	sites	and	two	mobile	units.
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The Caribbean has the second highest HIV 
prevalence	after	sub-Saharan	Africa,(3) although the 
region has seen the most pronounced decline in rates 
of	infection	globally	since	2001,	with	a	49%	drop.
(4) HIV in the Caribbean is predominantly transmitted 
through	unprotected	sex,(5) and injecting drug use 
is thought to be rare.(6)	The	exceptions	are	Puerto	
Rico, where an estimated 30,000 people inject drugs, 
and the Dominican Republic, where an estimated 
200,000–350,000	people	use	drugs	(including	
injecting	and	non-injecting).(7) Currently, only 7 out of 
18	countries	in	the	region	have	reported	injecting	drug	
use.(8) However, it is important to note that data on the 
Caribbean is sparse, and some of the data regarding 
drug use has been produced through research 
criticised as theoretically and methodologically 
weak.(9)	
In	2013,	three	islands	in	the	region	had	an	adult	HIV	
prevalence	rate	of	greater	than	1%.(4) HIV prevalence 
in	the	Bahamas	for	2012	was	3.1%.(10)	In	Jamaica,	HIV	
prevalence among homeless people and people who 
use	drugs	went	down	from	12%	in	2010	to	4.02%	
in	2013.(11) A recent report has noted the high rate of 
HIV	in	Haiti,	accounting	for	approximately	55%	of	all	
people living with HIV in the Caribbean.(12)	
Reliable data for HIV prevalence among people who 
inject drugs is only available for Puerto Rico and, 
to	some	extent,	the	Dominican	Republic,	where	a	
lack	of	access	to	sterile	injecting	equipment	has	
been	identified	as	a	significant	contributor	to	the	
HIV epidemic. In the Dominican Republic, unsafe 
injecting	drug	use	is	thought	to	account	for	1%	of	
HIV transmission,(13)	although	civil	society	queries	the	
accuracy	of	this	figure.(14) 
The most recent estimate indicates that there are 
approximately	30,000	people	who	inject	drugs	in	
Puerto	Rico,	22.9%	of	whom	are	living	with	HIV.	
This appears to be an increase on earlier estimates 
(The Global State of Harm Reduction 2012 reported 
HIV prevalence among people who inject drugs 
as	12.9%(10)) but, as noted in the introduction to 
this report, much of the data should be viewed 
critically.	The	2012	estimate	for	Puerto	Rico	refers	to	
information	gathered	between	1998	and	2001,	so	is	
now over a decade old. The most recent estimate is 
therefore deemed more reliable. 
In	2012,	the	Dominican	Republic	opened	its	first	
needle and syringe programme (NSP), while Puerto 
Rico introduced a harm reduction response in the 
form of NSPs and opioid substitution therapy (OST) 
in 2007. The positive effects of this harm reduction 
programme in Puerto Rico are already apparent. In 
2011,	22.9%	of	new	HIV	infections	were	transmitted	
through unsafe injecting,(2)	a	decrease	of	17.1%	from	
2007.(15) 
The Caribbean is one of two regions (the other 
being Latin America) in which the use of cocaine 
remains disproportionately high,(16)	with a reported 
link	between	the	sexual	transmission	of	HIV	and	the	
use	of	crack	cocaine	on	many	of	the	islands.(17)	Nearly 
2%	of	the	Jamaican	population	have	experienced	
a	period	of	crack	cocaine	use,(18)	and	non-injecting	
use	of	crack	cocaine	has	been	associated	with	
HIV transmission in the Bahamas.(19) Reported HIV 
prevalence	among	people	who	use	crack	cocaine	
is	7.5%	in	St	Lucia	and	5%	in	Jamaica,(20) although 
these	figures	date	from	2008.	At	the	time	of	writing,	
no	recent	data	relating	to	the	use	of	cocaine	and/
or	crack	cocaine	have	been	released,	even	after	
the	Joint	United	Nations	Programme	on	HIV/AIDS	
(UNAIDS) recommendation in 2006 to document HIV 
prevention	programmes	for	people	who	use	crack	
cocaine.(20)   
The harm reduction response in the Caribbean 
remains	extremely	limited.	NSPs	and	OST	exist	
predominantly in Puerto Rico, together with one NSP 
in the Dominican Republic. Drug treatment services 
for people who use drugs in the rest of the region 
are primarily abstinence focused, and outreach 
programmes providing hot meals and shelter for 
people who use drugs may often be faith based.(18) 
In	Jamaica,	the	Tek	it	to	Dem	initiative	takes	services	
to	homeless	crack	cocaine	users,	providing	a	mobile	
delivery	of	care	packages,	hot	food,	peer	education	
and transportation of people who use drugs to 
healthcare services and treatment centres.(18)	Trinidad 
has	a	government-supported	drop-in	centre	offering	
assessment, referral and rehabilitation for homeless 
people who use drugs,(21)	and St Lucia has a small 
number	of	drop-in	centres.(17)	Although injecting 
drug use is considered low overall in the region, the 
delivery of services where HIV and drug use have 
been associated, such as in Puerto Rico, is often 
restricted to urban areas and is underused due to 
police intolerance. In other areas of the Caribbean, 
services focused on homelessness and drug use are 
often combined illogically.
Developments in harm reduction 
implementation
Needle	and	syringe	exchange	programmes	(NSPs)
Only two countries in the Caribbean provide NSPs. 
A	study	in	2012	of	people	who	inject	drugs	in	the	
Dominican	Republic	found	that	more	than	40%	
shared	syringes	and	more	than	40%	used	discarded	
syringes found on the ground.(22) In	2012,	the	
Dominican	Republic	opened	its	first	NSP	supported	
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by Centro de Orientación e Investigación Integral 
(COIN).(14)	Since	its	inception,	over	1,000	people	
have accessed its Open Doors programme, and 
between	June	and	December	2012,	4,000	syringes	
were	distributed,	20%	of	them	to	females	who	inject	
drugs.(22) 
Puerto Rico has the largest NSP service in the region, 
with	six	active	NSP	sites	based	in	communities	
around	the	capital	city	of	San	Juan.	However,	police	
interference is currently one of the main obstacles 
to successful implementation. In the absence of a 
national policy on NSPs, the Puerto Rican police 
department’s	campaign	Golpe	al	Usuario	(Striking	
the Drug User)(23) is leading to NSP programmes 
being underused. There are also anecdotal reports 
of law enforcement authorities entering hospitalillos 
(shooting galleries) and destroying the available sterile 
injecting	equipment.(10) Coupled with this, the poor 
transportation infrastructure on the island means that 
people who inject drugs are often unable to travel 
and access the limited number of harm reduction 
services.(24)	Despite these obstacles, sterile injecting 
equipment	can	be	purchased	in	pharmacies,	and	it	
has been reported that many people who inject drugs 
obtain needles and syringes in this way.(10)	
In	the	Dominican	Republic,	the	legal	framework	is	
also presenting barriers to the implementation of an 
NSP service, as any amount of substances found 
are	considered	as	drug	trafficking,	including	small	
quantities	left	over	in	used	syringes.(25)
Opioid substitution therapy (OST)
Puerto Rico remains the only territory in the 
Caribbean	providing	OST.	However,	the	first	OST	pilot	
has now been approved in the Dominican Republic 
and	should	be	in	place	towards	the	end	of	2014.(25)	
At	present,	there	are	six	fixed	sites,	two	mobile	units	
and	one	prison-based	programme	in	Puerto	Rico.	In	
2007,	there	were	an	estimated	5,570	people	receiving	
methadone,	representing	19%	of	people	dependent	
on opiates.(8) Buprenorphine provision had also 
begun	to	be	scaled	up	in	collaboration	with	non-
governmental organisations (NGOs) in Puerto Rico, 
but since changes in government leadership this has 
now stopped.(24)	Although OST is available in Puerto 
Rico,	high	levels	of	bureaucracy	are	required	to	
secure and retain a place on the programme, meaning 
that	people	with	a	lower	socio-economic	status	
or without health insurance can struggle to gain 
access.(24) However, in contrast to many countries 
outside of the Caribbean, there are currently no legal 
age restrictions preventing access to NSP and OST 
services.(10)
Harm	reduction	for	people	who	use	crack	cocaine
Crack	cocaine	is	the	main	stimulant	used	in	the	
region.(14)	Despite this, there are only a small number 
of	drop-in	centres	in	the	Dominican	Republic,	
Trinidad,	Jamaica	and	St	Lucia	that	provide	
specific	services	for	this	group.(17)	The Castries 
facility in St Lucia offers shelter and other services 
for	homeless	crack	cocaine	users	living	with	HIV,	
providing adherence support for residents receiving 
antiretroviral therapy (ART). Although it does not 
distribute cannabis, the centre advocates the use 
of the drug for residents as a method of combating 
crack	cocaine	addiction	and	the	nausea	that	is	often	a	
side effect of ART.(17)	
In	Jamaica,	Tek	it	to	Dem	2	takes	services	to	
homeless	crack	cocaine	users	who	are	reluctant	
to access zero tolerance or total abstinence 
programmes. The initiative provides peer education 
on	HIV	and	sexually	transmitted	infection	prevention	
and	risk,	alongside	hot	food,	accompaniment	and	
transportation.(18)
Although	several	UNAIDS	reports	in	2012	included	
people	who	use	crack	cocaine	as	a	vulnerable	
population,	the	2014	UNAIDS	reports	do	not	discuss	
either	crack	use	or	cocaine	in	the	region.	
emerging trends:
Xylazine and steroid use in the 
Caribbean
The	use	of	xylazine,	an	injectable	veterinary	
anaesthetic	often	mixed	with	heroin,	has	
become an emerging trend in Puerto Rico, 
predominantly among males.(26) The associated 
harms	related	to	this	new	drug	are	still	under-
researched. However, studies have shown that 
chronic	xylazine	use	can	lead	to	open	skin	
ulcers.(27) These ulcers, which omit a strong 
odour	and	are	painful,	often	mean	that	xylazine	
users are denied access to NSP services(27) due 
to	the	stigmatising	nature	of	the	abscesses/
ulcers.(27) With its increasing popularity among 
people who inject drugs in Puerto Rico, 
more	research	into	tracking	xylazine	use	and	
associated harms, alongside advocacy and 
education, are needed to ensure the provision 
of appropriate responses within harm reduction 
services	for	xylazine	users.
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Viral hepatitis
There is very little information on hepatitis C (HCV) 
among people who inject drugs in the region. 
Similarly, data relating to hepatitis B (HBV) infection, 
including among those who do not inject, is limited to 
anecdotal reports.(28) National HCV prevalence among 
people who use drugs in the Dominican Republic 
is	3.4%.(1) However, this does not disaggregate for 
people who inject drugs, and there are no testing 
programmes and no access to treatment for those 
who use drugs.(25) National HCV prevalence data 
for people who inject drugs in Puerto Rico is not 
available,	although	sub-national	data	for	San	Juan	in	
2005	indicated	that	HCV	prevalence	among	people	
who	inject	was	89%.(29)	Although	this	2005	figure	is	
extremely	high,	no	recent	studies,	so	far	as	we	are	
aware,	have	been	undertaken	to	track	HCV	or	HBV	
prevalence. 
HCV testing and treatment is rarely offered to people 
who use drugs in the Caribbean,(14,	24)	with most 
diagnosis of HCV in Puerto Rico occurring in prisons, 
where testing and treatment is provided.(24) Treatment 
for those outside of the prison system and in the other 
islands remains in the hands of private healthcare 
providers, with prohibitive costs restricting access for 
most people. 
Tuberculosis
There	is	a	dearth	of	information	on	the	extent	of	
tuberculosis (TB) infection rates among people who 
inject	drugs	in	the	Caribbean.	In	1999,	one	study	in	
Puerto Rico found that TB incidence was highest 
among people living with HIV who inject drugs.(30) 
Whether in response to this data or for reasons of 
best practice, all drug treatment centres in Puerto 
Rico	now	require	TB	testing	prior	to	admission,	with	
treatment then available at health centres.(24) It is 
estimated	that	17.4%	of	TB	patients	in	the	Caribbean	
are living with HIV, but how many of them also inject 
drugs	is	unknown.(4)	
Antiretroviral therapy (ART)
There	are	80,190	adults	reported	to	be	receiving	ART	
in the Caribbean.(4) ART coverage is estimated to be 
72%,	the	second	highest	coverage	globally	among	
low-	and	middle-income	countries.(4) However, this 
rate	is	based	on	a	baseline	CD4ix	count	of	350,	and	
in	June	2013	the	World	Health	Organization	(WHO)	
raised	the	rate	to	a	CD4	count	of	500,(31) meaning 
coverage	in	the	Caribbean	fell	to	approximately	
40%.(14) While there are programmes in place on 
some islands to provide ART adherence support for 
people who use drugs, there are no estimates on 
the	number	of	either	injecting	or	non-injecting	drug	
users receiving ART in the Caribbean.(8) Out of nine 
Caribbean	islands,	four	have	adequate	healthcare	
facilities providing integrated HIV and TB treatment 
services (Antigua and Barbuda, Dominican Republic, 
Haiti,	St	Lucia)	while	five	are	seen	to	have	inadequate	
treatment services (Barbados, Dominica, Grenada, 
Jamaica	and	Trinidad	and	Tobago).(4) Although all 
national	programmes	acknowledge	the	need	to	focus	
on	ARVs	for	key	population	groups,	only	a	limited	
number actually report on these, and it is thought that 
there	is	a	low	utilisation	of	existing	services	by	key	
population groups.(14)
Barriers to ART include ease of testing and hours of 
operation in the clinics.(14)	In Puerto Rico, people who 
use	drugs	are	often	inadequately	targeted	by	HIV	
testing and ART. Overall, there is little information on 
coverage testing and ART for people who inject drugs 
in the region,(24)	even though a regional synthesis of 
UNAIDS progress reports from 2008 emphasised 
the	need	for	the	Caribbean	to	quickly	increase	
the meaningful involvement of its most vulnerable 
populations in its HIV response.(20)
Harm reduction in prisons
Drug use is highly criminalised across the region 
and incurs severe sentences. Due to these stringent 
criminal laws, large numbers of people who use 
drugs	are	incarcerated.	The	risk	of	HIV	transmission	
in prisons is further heightened by the criminalisation 
of	sex	between	men,	the	lack	of	condom	availability	
in prisons,(14,	24)	and	the	absence	of	prison-based	
harm reduction services. Puerto Rico is still the only 
country in the region that has OST operating in prison, 
and although promising, this service is limited to one 
prison and so far has not been scaled up.(24) 
At present, there is no systematic data on access 
to HIV prevention, treatment, care and support in 
prisons in the region, but indications are that service 
provision	remains	limited.	In	one	recent	study	looking	
at healthcare practices and associated needs among 
incarcerated men in Puerto Rico, it was found that 
73.8%	had	a	history	of	drug	use,	83.8%	received	their	
first	HIV	screening	in	prison,	55.6%	were	undertaking	
ART	and	83.8%	had	been	co-diagnosed	with	
HCV.(32)	It	is	estimated	that	approximately	6.9%	of	the	
incarcerated population in Puerto Rico present with 
HIV infection.(33) In	Jamaica,	it	is	standard	practice	to	
provide	opt-out	screening	for	HIV	and	syphilis,	with	
anyone	testing	positive	offered	follow-up	care.(11)	
ix	 A	CD4	count	is	a	measurement	of	HIV	infection	in	the	body	to	which	initiation	of	antiretrovirals	can	be	determined.	See:	www.aidsmap.com/CD4-cell-counts	
page/1254931	
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Overdose
The Caribbean currently has a limited overdose 
response,	with	no	naloxone	peer	distribution	and	
no overdose programmes operating in the region. In 
Puerto Rico, opiate overdose prevention education 
is	offered	by	only	1	service	across	15	sites,	and	
naloxone	can	only	be	prescribed	by	the	medical	
director.(24)	Anyone who calls the emergency services 
to respond to an overdose is liable to arrest or 
intimidation by the police. (34)
One	cross-sectional	survey	in	Puerto	Rican	prisons	
found that almost half of the incarcerated population 
had	witnessed	an	overdose	in	prison,	and	one-third	
had	known	someone	to	have	died	of	an	overdose	
while incarcerated.(35)	Of those reporting injecting 
drug	use	prior	to	incarceration,	60.6%	had	witnessed	
an	overdose	incident	and	44.9%	had	known	of	an	
overdose death.(35)
The only territory in the region to have reliable 
information on overdose is Puerto Rico. Further 
investigation into overdose prevention and reversal, 
including law and policy reform, is recommended 
across the region.
Policy development for harm reduction
Since the publication of The Global State of Harm 
Reduction 2012,(10) there have been few developments 
in harm reduction policy at either national or regional 
levels. New legislation to decriminalise cannabis 
appears to be the primary step forward.(14,	24)	Moves 
towards decriminalising the use of cannabis for 
medicinal purposes are in process in Puerto Rico, and 
a debate on the decriminalisation of cannabis has 
been	initiated	in	Jamaica.(14) There has been a small 
increase in awareness of harm reduction observed 
in	the	press	in	Puerto	Rico,	in	part	influenced	by	
the discourse around cannabis consumption and 
decriminalisation.(24)	
Harm reduction was included in Trinidad and 
Tobago’s	National	Anti-Drug	Plan	for	2008–2012	as	a	
key	component	of	the	national	response	to	drugs,(36) 
although this appears to be the sole national policy 
relating to HIV and drug use that includes harm 
reduction. A report from the Dominican Republic 
has	noted	that	the	legislative	framework	needs	to	be	
amended to be more harm reduction friendly, as it is 
discouraging people from accessing health services 
and	therefore	increasing	the	risks	they	face.(22) Among 
recommendations for the new National Strategic Plan 
on HIV and AIDS in the Dominican Republic is the 
introduction of harm reduction for people who use 
drugs.(25)
UNAIDS has set new targets for 2020 for reducing HIV 
in	the	Caribbean,	named	90-90-90:	increasing	to	90%	
the	proportion	of	people	living	with	HIV	who	known	
their	diagnosis;	increasing	to	90%	the	proportion	of	
people living with HIV receiving ART; and increasing to 
90%	the	proportion	of	people	on	HIV	treatment	who	
have an undetectable viral load.(37) There is no mention 
of	people	who	inject	drugs	as	a	key	population	within	
these overall goals.
Civil society and advocacy 
developments for harm reduction
The	majority	of	drop-in	centres	that	operate	drug	
treatment services, although primarily abstinence 
based, are implemented by civil society organisations 
(CSOs). A harm reduction coalition, the Coalicion 
Puuertorriqueña	de	Ruduccion	de	Daños	
(CoPuReDa), is being established in Puerto Rico, 
comprising all the NSPs operating in the country,(24)	 
and the Dominican Republic’s NSP was established 
by people who use drugs.(22)
Civil society advocacy is predominantly led by a 
Jamaican	coalition	of	civil	society	actors,	named	
the Caribbean Vulnerable Communities Coalition 
(CVC),	the	Dominican	Republic-based	COIN,	and	
the Dominican Republic Foundation for Harm 
Reduction	(FUNDOREDA).	These	organisations	work	
to challenge the structural drivers of the epidemic, 
focusing on socially marginalised populations affected 
by HIV. 
Although harm reduction in the Caribbean remains 
embryonic and fragile, it is an approach that is 
slowly gaining recognition.(14,	24)	The Caribbean Harm 
Reduction	Coalition	(CHRC),	founded	in	2001,	
implemented harm reduction and drug policy training 
in	Guyana,	Trinidad	and	Tobago	and	Jamaica	in	2014,	
and is currently leading advocacy for the revision of 
all national drug and HIV strategies to include issues 
related	to	the	sexual	transmission	of	HIV	among	
people	who	use	drugs	and	their	sexual	partners.(14) 
In	2011,	a	Caribbean	HIV	conference	was	held	in	
the Bahamas to discuss a sustainable response to 
the regional epidemic. The conference attracted 
more than 2,000 participants from across the 
region,	including	individuals	from	key	population	
groups, members of community organisations 
and representatives of regional and international 
governments.(38)
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Funding:	developments	for	harm	
reduction
The	Caribbean,	like	other	regions,	is	heavily	
affected by the global funding crisis for harm 
reduction.(39)	Although	the	Global	Fund	Round	9	
signified	an	important	advance	for	harm	reduction	
in the Caribbean, with a substantial grant of 
US$29,812,507,(40) this funding is now coming to 
an	end.	In	Jamaica,	it	is	estimated	that	the	cost	of	
implementing the national HIV and AIDS programme 
between	2013	and	2016	will	be	US$116.8	million.	In	
response to the withdrawal of funding by the Global 
Fund,	the	Jamaican	government	must	take	greater	
responsibility(11)	although the feasibility of this is 
questionable.	USAID	funding	of	the	National	Council	
on	Drug	Abuse	in	Jamaica	ended	in	2012,	and	Global	
Fund	monies	were	secured	only	until	March	2013.(18)
Round	9	of	the	Global	Fund	has	supported	a	regional	
project, with Pan Caribbean Partnership Against 
HIV and AIDS (PANCAP) as principal recipient. As a 
sub-recipients	of	that	grant,	CVC	and	COIN	plan	to	
undertake	an	assessment	of	harm	reduction	in	six	
countries	(Jamaica,	Dominican	Republic,	Trinidad	
and Tobago, Surinam, Guyana and Haiti), which will 
provide a clearer indication of the future needs.(14)	
However, funding for people who use drugs in the 
Dominican Republic, donated by the Centres for 
Disease Control and Prevention (CDC), came to an 
end	in	September	2014,	and	as	yet	no	alternative	
funding for prevention and harm reduction strategies 
has been sourced.(25) 
In	Trinidad	and	Tobago	and	Jamaica,	governments	
have	taken	over	funding	certain	programmes	as	
donors begin to retreat. However, assuming the 
financial	responsibility	of	private	funders	is	too	great	
a burden for Caribbean countries. In Puerto Rico, 
funding cuts to the health sector have affected 
NGOs providing services to people who inject drugs, 
leaving	organisations	to	seek	assistance	from	private	
foundations	to	keep	their	services	running.	(24)
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Table 2.5.1: Epidemiology of HIV and viral hepatitis, and harm reduction responses in Latin America
Country/
territory
with reported
injecting
drug use
People who
inject drugs
Hiv prevalence
among people
who inject 
drugs(%)
Hepatitis C (anti-
HCv) prevalence
among people
who inject 
drugs(%)(1)
Hepatitis B
(anti-HBsag)
prevalence among
people who  
inject drugs 
(%) (1)
Harm reduction 
responsei
nSP oST
argentina
65,829 (64,500–
67,158)(2)ii 
nkiii 4.8(3)iv 1.6(3) (25) (P)v x
bolivia nk nk nk nk x x
brazil 540,500vi 5.92(4) 63.9vii 2.3 (150-450)viii x
chile 21,783(3)ix nk nk nk x x
colombia nk 1.35-2.72(5) nk nk  (7)x 
costa rica nk nk nk nk x x
ecuador nk nk nk nk x x
el Salvador nk nk nk nk x x
Guatemala nk nk nk nk x x
Honduras nk nk nk nk x x
mexico 141,690(6)xi  2.5(6) 96 nk (19) (18) (m)xii 
nicaragua nk nk nk nk x x
Panama nk nk nk nk x x
Paraguay nk 9.35 (3.7–15)(2) 9.8xiii nk (3) x
Peru nk 1(7) nk nk x x
uruguay nk 0.2(8) 21.5(9) 19.5(9)  x
Venezuela nk nk nk nk x x
 
i Unless otherwise stated, data has been sourced from Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, et al. HIV prevention, treatment and care services for people who 
inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375(9719):1014-28. 
ii 	 This	estimate	was	taken	from	1999	and	injecting	drug	use	is	thought	to	have	reduced	significantly	since	this	date.
iii	 Although	estimates	exist,	they	range	from	11.9%	to	49.7%,	and	there	is	no	agreed	figure.
iv Local studies undertaken in Buenos Aires indicate higher prevalence, although civil society argues that these are not representative of countrywide HCV prevalence.
v Figure is taken from 2012, but we do not have data on how many NGOs are presently providing NSP services. (P) indicates needles and syringes being available for purchase in pharmacies. 
vi Figure is taken from 2003, and as far as we are aware no recent estimate of people who inject drugs in Brazil has been published.
vii Figure is taken from 2000/2001 and no recent estimate is available.
viii  Figure is taken from 2012, but we do not have data on how many NGOs are presently providing NSP services.
ix	 Civil	society	organisations	believe	this	figure	to	be	an	overestimate.
x In Columbia, OST is being developed in Armenia, Bogota, Bucaramanga, Cali, Cucuta, Medellin and Pereira, but exact numbers of sites are unknown.
xi	 This	figure	includes	all	opiate	users	and	does	not	differentiate	between	people	who	inject	opiates.
xii Of the 18 OST sites, 17 are private clinics and 1 is government run.
xiii  Figure is taken from 2006.
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Map 2.5.1: Availability of needle and syringe exchange programmes (NSP) and opioid substitution therapy (OST)
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Although prevalence of injecting drug use in Latin 
America remains low, unsafe injecting is thought to 
be	a	significant	route	for	both	HIV	and	viral	hepatitis	
transmission, particularly in the region’s southern 
cone.(10) In 2008, the Reference Group to the United 
Nations on HIV and Injecting Drug Use (which has 
now ceased to operate) estimated that over two 
million people inject drugs in the region, with the 
largest proportion (540,000) in Brazil.(2) However, 
civil society sources note that drug use in the region 
primarily centres on cocaine and its derivatives 
(especially smoking crack cocaine and pasta basexiv), 
so	the	figures	included	in	Table	2.5.1	may	not	
reflect	the	overall	prevalence	of	drug	use	across	the	
region.(11-13) 
Where data on HIV prevalence among people who 
inject drugs are available, the rates vary greatly 
between countries. In Peru, according to data 
collected in 2010, HIV incidence among people who 
inject drugs was reportedly 1%,(7) with Brazil reporting 
the highest incidence in the region at 5.92%.(4) 
However,	reliable	figures	on	incidence	of	HIV,	viral	
hepatitis and tuberculosis among people who inject 
drugs are limited.  In addition, the injecting of opiates 
is thought to be diminishing in the region(11,14) and 
where data are available these tend to place greater 
emphasis on people who use predominantly cocaine-
based substances. 
In Colombia, although the key population most at 
risk of HIV infection is the transgender community,(5) 
people who inject drugs have been highlighted as 
a priority group at-risk of HIV transmission, and 
recommendations have been developed to increase 
services for this population.(15) Opioid substitution 
therapy (OST) sites are in existence in Colombia 
and are being scaled up,(14) and needle and syringe 
programmes (NSPs) are also now operating in the 
country. A pilot NSP programme, supported by 
the Pan American Health Organization (PAHO) and 
involving 100 people who inject drugs in the city of 
Pereira, has led to the development of three mobile 
centres called Centros de Atención Móvil para 
Drogodependientes (CAMAD). Several CAMAD 
initiatives were launched in Bogotá in 2012,(16) and it is 
hoped that 20 further sites will be established.(14)
In Argentina, 90% of HIV infections are sexually 
transmitted, and approximately 50% of these 
are attributed to men who have sex with men.(17) 
Injecting drug use exists in the country, mostly 
involving injection of cocaine. The majority of studies 
have been undertaken in Buenos Aires,(11) where 
HIV prevalence among people who inject drugs 
is reported to be 1.9% among men, 0.7% among 
women(17) and 6.3% among intranasal cocaine users 
and smokers.(18)	Although	the	figures	indicate	that	
unsafe injecting does occur, since 2012 NSP service 
provision has diminished in Argentina and there is 
currently no OST service provision.(11) Brazil also has 
no OST provision, but NSP services are available. In 
a study undertaken in 10 Brazilian cities, there was 
thought to be a low number of people who inject 
drugs.(19) While a study in Bolivia found drug use 
among the lesbian, gay, bisexual and transgender 
community, there are presently no harm reduction 
services for people who use drugs in the country.(20) 
Although Latin America is at the forefront of a 
growing global movement to decriminalise drug 
use, harm reduction initiatives remain limited, and 
epidemiological research on people who inject 
drugs is sparse. Civil society advocacy has been 
instrumental in bringing about preliminary changes in 
national drug policy, and civil society is the primary 
provider of harm reduction initiatives, but there 
continues to be a lack of support for harm reduction 
services from governments.(11)
Developments in harm reduction 
implementation
Needle and syringe exchange programmes (NSPs)
NSP services for people who inject drugs in Latin 
America continue to be extremely limited, and 
up-to-date information on provision is unavailable. 
The Global State of Harm Reduction 2012 reported 
extremely low coverage, with only 2% of people 
who inject drugs accessing NSP services across the 
region, and only 0.3 syringes distributed per person 
per year.(21) Of the 12 counties in the region that 
report	injecting	drug	use,	only	five	currently	operate	
NSP services (see Table 2.5.1). Brazil offers the most 
extensive coverage, with between 150 and 450 sites. 
However, this estimate is from 2012, and it is thought 
that due to a decreasing number of people injecting 
drugs in the country, services have been scaled 
back.(11) NSP provision in the four remaining countries 
(Argentina, Mexico, Paraguay and Uruguay) is limited 
relative to the numbers of people who inject drugs, 
with Argentina believed to have scaled back its NSP 
services, similar to Brazil, in response to declining 
injecting drug use.(11) 
In Mexico coverage is improving, thanks to Global 
Fund programmes which currently provide 77.6% of 
all syringes supplied to people who inject drugs.(6) 
State funding is also available for NSP provision in the 
form of subsidies and there has been an increase of 
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8.1% in the number of syringes distributed per person 
per year. However, NSP provision remains under-
resourced	and	insufficient	relative	to	the	numbers	
of people who are unsafely injecting drugs in the 
country. Although drug use has been decriminalised 
in Mexico,(22) the threshold quantities are believed to 
be so low that drug laws continue to serve as a barrier 
to people accessing NSP services.
In Colombia, NSP services for people who inject 
drugs have been initiated recently, following a pilot 
study with 100 people who inject drugs in the city 
of Pereira, supported by PAHO.(14) Three mobile 
assistance centres were developed in 2014 in Pereira, 
with	the	first	launched	in	Bogotá	in	2012,	and	a	
further 20 planned for the city. These serve a wide-
range	of	people	who	use	drugs	rather	than	specifically	
those who inject since, as mentioned previously, 
injecting drug use has become less prevalent than 
inhalation of cocaine-based substances.
In the countries that do offer NSP provision, many 
people who inject drugs are deterred from accessing 
services because of restricted opening hours, long 
waiting	times,	insufficient	resources,	criminalisation	
of drug use and inadequately trained service 
providers.(11,13) Further research, advocacy and service 
provision is necessary in the region to ensure that 
people who use drugs have appropriate access to 
safe injecting equipment. 
Opioid substitution therapy (OST)
Opioid use is thought be rare in Latin America. At 
present, Mexico and Colombia are the only countries 
in the region that provide OST to people who inject 
drugs and/or use opiates (see Table 2.5.1), with 
approximately 18.6% of opiate users receiving OST 
in Mexico.(6) According	to	figures	deriving	from	a	
press report in June 2013, there were thought to be 
17 private OST facilities and one government facility 
providing methadone to people who use drugs in 
Mexico.(23)
In Colombia, there are currently OST sites operating in 
seven cities: Bogotá, Medellín, Cali, Pereira, Armenia, 
Cúcuta and Bucaramanga.(24) However, the number 
of sites in these cities is unknown. In Argentina, 
although opiate use is reportedly rare, some services 
in public hospitals, such as the toxicology service 
of the Fernández Hospital in Buenos Aires City, can 
prescribe methadone.(25) It is unclear however whether 
people who inject drugs are accessing this service. 
Cocaine and transmission of Hiv and viral hepatitis in latin america:
an increased harm reduction response
Research is increasing into harms related to non-injecting drug use in Latin America, as it is now widely ac-
knowledged that drug use in the region is predominantly non-injecting of cocaine and its derivatives.(10,11) In 
a systematic review of key populations in Brazil, HIV prevalence among people who use drugs was found 
to be 23.1%,(26) while in an earlier study looking at pooled data over a ten-year period in Brazil, people 
who inject drugs and people who smoke crack illustrated similar levels of risk for HIV infection.(27) Although 
much of the research is emerging from Brazil, a study in Montevideo, Uruguay published in 2013 also 
found an increased risk of HIV among cocaine smokers, with an estimated 6.3% HIV prevalence rate.(28) 
Growing recognition of HIV prevalence and hepatitis C (HCV)(29) among people who use cocaine and its 
derivatives has increased the harm reduction response for people who use drugs in parts of Latin America. 
For example, in Brazil, the non-governmental organisation É de Lei of São Paulo has successfully distrib-
uted new crack pipes(30) in an attempt to reduce viral hepatitis transmission through sharing pipes. In Sao 
Paulo, the Bracos Abertos (Open Arms) programme offers people in the favelas who use crack cocaine 
healthcare, information on treatment, paid work and three meals a day. The programme has already made 
a	significant	impact	on	health	outcomes,	as	well	as	on	lowering	the	levels	of	stigma	and	discrimination	as-
sociated with drug use in the area.(31) 
A study in Bahia, Brazil, also observed the use of ‘pitilho’ (the co-smoking of crack and marijuana in a 
cigarette-like	form)	and	identified	several	key	reasons	why	crack	users	have	adopted	the	pitilho	as	a	harm	
reduction tool, including a reduction in the negative behavioural and physical effects of crack cocaine, and 
greater control over a potential vulnerability to violence.(32) Oral HIV tests are also being offered in Brazil in 
areas where there is believed to be intense use of crack cocaine, both as a harm reduction measure and to 
help increase awareness of HIV and viral hepatitis transmission though sharing drug paraphernalia such as 
straws and pipes.(33) Although recognition, implementation and research into harm reduction initiatives for 
people who use cocaine is a positive step towards reducing transmission of HIV and viral hepatitis in Latin 
America, further initiatives for people who use drugs are needed.
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Viral hepatitis
Data on viral hepatitis among people who inject drugs 
in Latin America is sparse and often out of date. 
Argentina is believed to have the lowest prevalence 
of HCV among people who inject drugs in the region, 
at 4.8%(3) and Mexico the highest, at 96%.(1) However, 
these	figures	stem	from	data	published	in	2009	
and 2005 respectively, and as far as we are aware, 
there are few updated estimates available for most 
countries in Latin America. In Brazil, transmission 
rates for HCV were recorded as 28.9% among people 
who inject drugs in 2011.(34)
In a 2002 study in Buenos Aires and Montevideo, HCV 
and HIV prevalence among non-injecting cocaine 
users were 8.8% and 7.9% respectively.(35) This work 
highlighted the vulnerability to infection among people 
who use drugs but do not inject through practices 
such as sharing straws, and emphasised the need 
for harm reduction services tailored to them as 
key populations at risk in Latin America. Although 
injecting drug use has been reported, we have been 
unable to source information on HCV or hepatitis B 
(HCB) prevalence rates. In 2011, the Buenos Aires 
provincial ministry of health launched the Programme 
for Prevention and Detection of Viral Hepatitis to 
work in conjunction with the HIV/AIDS and Sexually 
Transmitted Infections (STIs) Programme. However, 
civil society organisations contest the levels of access 
to HCV testing and treatment said to be available 
across the country.(36) In 2012 we reported that the 
ministries of health and social security in Costa Rica 
and Panama pledged to guarantee access to testing 
and treatment services for HIV and viral hepatitis for 
all.(37) However, it has not been possible to corroborate 
whether	these	promises	have	been	fulfilled.
Tuberculosis
Previous evidence has suggested that tuberculosis 
(TB) rates in countries such as Brazil are extremely 
high, with 48 cases per 100,000 people in 2010.(38) 
However, the WHO reported in 2012 that Brazil has 
shown a sustained decline in TB over the past 20 
years.(39) Although research on TB prevalence among 
people who use drugs in Latin American is lacking, 
there is evidence to suggest that they are associated 
with elevated TB infection rates.(38) 
Where TB rates are reported in the region, they often 
appear with HIV co-infection. In Peru, the proportion 
of people receiving TB treatment also receiving 
antiretroviral therapy (ART) was 64%.(7) Uruguay 
reported 852 cases of TB in 2013, 14% of them 
involving co-infection with HIV.(8) Venezuela estimated 
the percentage of TB incidence among people with 
HIV as 18% in 2012,(40) Mexico had 512 people 
receiving both TB and ART treatment in 2013,(6) and 
Bolivia reported 168 people co-infected with TB 
and HIV.(20) Most Latin American countries offer HIV 
testing to anyone presenting with TB.  However, as in 
other	regions,	prevalence	figures	do	not	detail	what	
proportion of infections are among people who use 
drugs or who inject drugs. Moreover, while diagnosis 
services are available across the region, access to 
these is inconsistent for people who use drugs(11) and 
we are unaware of any TB services in Latin America 
that	specifically	target	this	community.
Antiretroviral therapy (ART)
Latin America has the highest international and 
domestic public spend on ART among low- and 
middle-income countries, at just under $US800 
million.(41) In 2010, it was reported that ART was 
being provided to 521,000 of the 820,000 people in 
need of treatment, representing 63% coverage for 
the region.(10) 14 of 31 countries and territories in the 
region reported at least one shortage of ART drugs 
in 2012, with prices varying by up to 77 times more 
depending on the country.(43) 
In 2013, Brazil reported 718,000 people living with 
HIV, with an estimated 5.82% HIV prevalence rate 
among people who inject drugs.(4) Although Brazil 
has a well-documented treatment system with high 
coverage rates and free ART, a 2011 study noted that 
many people who inject drugs had failed to initiate 
ART due to lack of access to HIV testing and stigma 
surrounding injecting drug use(42).  The criminalisation 
of drug use continues to greatly restrict access to 
services and treatment adherence among people 
who	inject	drugs,	although	figures	relating	to	rates	of	
service provision among key populations are severely 
lacking. Further research on the availability of ART 
for people who use drugs in Latin America is urgently 
needed.
Harm reduction in prisons
In most Latin American countries, the cultivation, 
distribution and personal use of drugs remain 
heavily criminalised. The pervasive ‘war on drugs’ 
in the region has led to large numbers of people 
who use drugs being incarcerated in severely 
overcrowded prisons. While there is a lack of data 
on the prevalence of HIV, viral hepatitis and TB 
in Latin American prisons, it is clear that prison 
populations are at increased risk of infection. In Peru, 
the estimated HIV prevalence rate among prison 
populations is 4.03% compared to 0.4% among the 
general population, and in Bolivia HIV prevalence is 
reported as 10% among prisoners compared to 0.2% 
among the general population.(44) In Argentina, TB 
patients with a history of incarceration were between 
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6 and 18 times more likely to test positively for HBV 
and HCV respectively.(45) 
Systematic research is required to provide a more 
accurate analysis of current HIV, viral hepatitis and TB 
epidemics and drug use in Latin American prisons. 
The available data suggests that there are currently 
no prison-based harm reduction services operating in 
the region.
Overdose
Data on the prevalence of overdoses is Latin America 
is extremely limited. Research in Colombia in 2012 in 
the cities of Pereira and Medellín reported that 25% 
and 33.3% respectively of people who inject drugs 
had experienced a non-fatal heroin overdose.(15) In 
both cities, six out of ten people revealed that they 
would not access healthcare services if they had 
another overdose episode for fear of referral to law 
enforcement authorities.(15)
There are currently no overdose prevention 
programmes established in the region.(11) Naloxone is 
registered in a number of Latin American countries, 
including Argentina, Brazil, Chile, Mexico, Paraguay, 
Peru, Uruguay and Venezuela. However, it is not yet 
available to people who use drugs or for medical 
emergencies in any of these areas. In Colombia, 
where heroin and opiate use is more widely reported, 
naloxone is available and its use is included in 
regional healthcare plans.(11)
Prevailing laws and the criminalisation of drug use 
continue to hamper the introduction of overdose 
prevention and treatment initiatives in the region, and 
further work on naloxone availability for people who 
use drugs is recommended.
Policy development for harm reduction
As reported in 2010(46) and 2012,(37) six Latin American 
countries include harm reduction in their national 
policies on HIV and/or drugs: Argentina, Brazil, 
Colombia, Paraguay, Peru and Uruguay. In 2013, 
Argentina made provision for a harm reduction 
approach in the National Mental Health Act 
2013.(11) As a result, the only national public institution 
dedicated to drug treatment, the Network Hospital 
Specialized in Mental Health and Addiction (formerly 
CENARESO), has now included both risk and harm 
reduction services within its programmes. (11) In Brazil, 
the Federal Drug Laws of 2000 and 2006 explicitly 
refer	to	harm	reduction.	Mexico	also	has	an	official	
statement that includes harm reduction strategies,(47) 
although it is claimed that few harm reduction 
initiatives are orientated towards people who use 
drugs but who do not inject.(48) 
Although there has been little progress in explicitly 
including harm reduction in national policies across 
the region, there has been a notable increase in 
debate on drug policy at national and international 
levels. Countries such as Chile Colombia, Costa Rica, 
Guatemala and Mexico have all declared the need for 
a new approach to drug policy, with greater emphasis 
on health principles rather than criminal sanctions.(11)
A major policy development occurred in Latin 
America in 2012when Bolivia denounced the 1961 
Single Convention on Narcotic Drugs, and then re-
acceded in 2013 with a reservation which would allow 
traditional uses of coca leaf domestically, enabling 
indigenous communities to legally cultivate and use 
the leaves, for example for chewing.(11) In 2013, the 
Government of Uruguay passed legislation to regulate 
state-controlled sales of cannabis.(11)  
A meeting hosted by AIDSTAR-One in Antigua, 
Guatemala, in September 2012, and supported by 
the United States President’s Emergency Plan for 
AIDS Relief (PEPFAR) and the Latin American and 
Caribbean Bureau of the United States Agency for 
International Development (USAID), helped raise 
awareness of the need for policy change in Latin 
America. During the technical consultation, entitled 
‘Substance use and HIV prevention, care and 
treatment in Latin America’, collaborating international 
agencies	–	including	the	United	Nations	Office	
on Drugs and Crime (UNODC), PAHO, the Joint 
United Nations Program on HIV/AIDS (UNAIDS), 
the Guatemalan department of health and human 
services, the Substance Abuse and Mental Health 
Services Administration (SAMSHA), the National 
Institute on Drug Abuse (NIDA) and the United States 
Centers for Disease Control and Prevention (CDC) – 
sought to improve planning for programmes related 
to substance use among key populations in Latin 
America. 
Civil society and advocacy 
developments for harm reduction
Civil society organisations in Latin America have 
played an increasingly important role in drug policy 
reform at both regional and national levels. In 2009, 
the	first	Latin	American	Conference	on	Drug	Policy	
was organised by Intercambios Civil Association in 
Buenos Aires, as a platform for discussing solution-
orientated proposals for drug policy in the region. 
The	fifth	Latin	American	Conference	on	Drug	Policy	
and	the	first	Central	American	Conference	on	Drug	
Policy took place in September 2014 in Costa Rica, 
organised by the Asociación Costarricense para el 
Estudio e Intervención en Drogas (ACEID) and the 
consortium CONFEDDROGAS, which is composed of 
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six	civil	society	organisations	committed	to	significant	
change in drug policy. 
In October 2012, the Latin American Network of 
People Who Use Drugs (LANPUD) was formed.(11) In 
2013, the 10th Hemispheric Forum of Civil Society 
and Social Actors held a special session with 
the Committee on Inter-American Summits 
Management and Civil Society Participation in the 
Organization of American States (OAS), and produced 
recommendations on harm reduction.(49) OAS plays an 
active role in promoting debate on drug policy in Latin 
America, publishing two reports in 2013 that called for 
open discussion on drug policy across the region.(50,51) 
In two successive declarations, the Declaration of 
Antigua adopted in June 2013, and the Declaration of 
Guatemala agreed in September 2014(11,52), OAS has 
also called for balanced drug policy that is respectful 
of health and human rights. Civil society organisations 
have	been	actively	engaging	with	and	influencing	
these regional processes.(13)
In November 2013, an open letter signed by 52 Latin 
American civil society organisations was handed 
to ministers at the Fourth Meeting of Ministers of 
Public Security of the Americas, urging them to get 
involved in the search for alternatives to current drug 
policy in the region, and calling for human rights, 
a reduction in violence and a minimisation of harm 
for people who use drugs.(54) Seventeen civil society 
organisations in the region also requested a hearing 
at a meeting of the Inter-American Commission on 
Human Rights (IACHR) in March 2014 in Washington 
D.C. to analyse the serious impact of current policies 
on human rights.(55)  The International Federation of 
Catholic Universities (IFCU) policy brief Drug Policy 
in Latin America and Asia: Towards the Construction 
of Responses Focused on Human Rights also makes 
an important contribution to harm reduction in 
Latin American, and is signed by academics from 
Catholic universities in Bolivia, Brazil, Colombia, 
India, Indonesia, Lebanon, Philippines and Thailand, 
together with Intercambios Civil Association.(53) 
Funding: developments for harm 
reduction
Multilateral agencies and international donors have 
continued to support harm reduction initiatives 
in Latin America. As in other regions, the Global 
Fund has allocated resources for harm reduction 
programmes in Argentina, Mexico, Paraguay 
and Uruguay,(11) and more recently Open Society 
Foundations, a key donor for harm reduction, has 
added harm reduction work in Latin America to its 
portfolio.(56) Caritas (Germany) has supported the 
activities of the Red Americana de Intervención en 
Situaciones de Sufrimiento Social (RAISSS) network, 
and the Levi Straus Foundation has continued its 
support for projects in Argentina. However, with 
donors including the Global Fund increasingly 
restricting resources for middle-income countries, the 
sustainability of many projects in Latin America is at 
risk.
Government support is essential for sustainable harm 
reduction programmes within the region. In addition, 
and particularly given the global economic crisis, 
support from international donors and multilateral 
agencies in the region remains critical to ensuring 
that harm reduction becomes an integral part of drug 
policy and public health responses.
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Table 2.6.1: : Epidemiology of HIV and viral hepatitis, and harm reduction responses in North America
Country/
territory
with reported
injecting
drug usei
People who
inject drugsi
Hiv prevalence
among people
who inject 
drugs (%)
Hepatitis C (anti-
HCv) prevalence
among people
who inject 
drugs (%)
Hepatitis B
(anti-HBsag)
prevalence among
people who  
inject drugs (%)
Harm reduction response
nSPii oSTiii DCRiv
canada
286,987 
(220,690–
375,173)(1)v 
11.2(2) vi 68(2) nk   
united States
6,612,488 
(4,583,188–
8,641,788)(3)
2.1(3) 43.13(3) 11.8 (3.5–20)(4) vii  (194)(5) viii  (>1,400)
(6)  
(b, bn, m)
x
 
i	 There	are	no	identified	reports	of	injecting	drug	use	in	Greenland.
ii	 The	number	in	brackets	represents	the	number	of	operational	NSP	sites,	including	fixed	sites,	vending	machines	and	mobile	NSPs	operating	from	a	vehicle	or	through	outreach	workers.
iii	 The	number	in	brackets	represents	the	number	of	operational	OST	sites,	including	publicly	and	privately	funded	clinics	and	pharmacy	dispensing	programmes.	(M)	=	methadone,	(B)	=	
buprenorphine,	(BN)	=	buprenorphine–naloxone	combination,	(O)	=	any	other	form	(including	morphine	and	codeine).
iv	 DCR	=	drug	consumption	room,	also	referred	to	as	a	safer	injecting	facility	(SIF).
v	 Year	of	estimate:	2004.
vi	 Figure	is	based	on	11	sentinel	sites.
vii	 Year	of	estimate:	1992.
viii	 These	services	operate	in	33	of	the	50	states,	which	include	Puerto	Rico	(see	page	68).
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NSP only
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Not known
DCR available
Map 2.6.1: Availability of needle and syringe exchange programmes (NSP) and opioid substitution therapy (OST)
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The USA, after China and Russia, has one of the 
highest estimated populations of people who inject 
drugs in the world,(1) with the combined total from 
all states estimated to be 46% of people who 
inject drugs globally.(2) In Canada, 17% of new HIV 
infections are attributed to unsafe injection drug use, 
and HIV prevalence among people who inject drugs 
ranges from 3—21%.(7) The HIV epidemic among 
people who inject drugs in both the USA and Canada 
mirrors broader disparities in the HIV epidemic, with 
racial and ethnic minorities in the USA and Aboriginal 
people in Canada disproportionately affected.(8,9) 
Although key harm reduction services such as needle 
and syringe exchange programmes (NSPs) and 
opioid substitution therapy (OST) are in place in both 
countries, provision remains uneven across smaller 
cities and rural areas. The Global State of Harm 
Reduction 2012: Towards an Integrated Response(10) 
reported increased overdose prevention and response 
programmes, including distribution of community-
based naloxone – a response that has continued to 
grow most dramatically in the USA. However, prison 
harm reduction remains underdeveloped in both 
countries. While OST provision is widely (if unevenly) 
available in both federal and provincial prisons in 
Canada, access is limited in the USA. Prison NSPs 
remain unavailable in North America. Canada still 
operates the only drug consumption room in North 
America, the INSITE project in Vancouver, British 
Columbia, with other cities stating their intention of 
opening these in the near future. 
Civil society organisations in the USA and Canada 
have actively engaged in activities around harm 
reduction and drug policy reform, and have been 
instrumental in the growing overdose prevention and 
community naloxone distribution programmes in 
both countries since 2012. Networking and activism 
among people who use drugs has also been growing 
stronger, particularly in the USA, where a new national 
umbrella association of drug user activist groups has 
been formed.
Developments in harm reduction 
implementation
Needle and syringe exchange programmes (NSPs)
NSPs are available in both countries. A 2014 review 
of coverage in the USA by the North American 
Syringe Exchange Network (NASEN) found 194 
NSPs operating in 33 states, the District of Columbia, 
the Commonwealth of Puerto Rico and the Indian 
Nations.(5) However, this data should be interpreted 
with some caution. The political climate and punitive 
legislation in a number of states discourages some 
programmes from making their information public. 
NSPs are available across Canada, although civil 
society reports that coverage varies from region to 
region, and even within regions, due to the unstable 
means by which the programmes are funded. While 
large urban centres tend to have strong networks of 
harm reduction services, rural areas, smaller centres 
and Aboriginal communities often face difficulties in 
establishing and maintaining services. For example, 
only six communities in Alberta have NSPs, and they 
are also unavailable in large parts of Manitoba and 
Ontario.(11) As in Canada, most NSPs in the USA are 
located in urban centres, with suburban and rural 
access being much less common.(5) 
National-level estimates of NSP coverage are not 
collected in Canada or the USA, making it difficult 
to monitor service provision levels accurately. The 
last available data, as reported in The Global State 
of Harm Reduction 2012, indicate that an average of 
23 syringes are distributed per person who injects 
per year across North America, amounting to low 
coverage compared to international targets.(12) This 
places North America behind other high-income 
regions such as Western Europe (59 syringes) and 
Australasia (202 syringes).(13) A 2012 survey of 142 
NSPs in the USA found a total of 39.2 million syringes 
distributed in that year by the 108 projects for which 
data was provided.(5) 
Civil society reports continue to suggest that funding 
is one of the most significant barriers to service 
provision and scale up in both countries. Since in the 
USA individual states determine the legality of syringe 
exchange or distribution, some states have only 
underground NSPs or none at all, which is largely the 
case throughout the southern region.(14) In Canada, 
the lack of federal support for NSPs means that 
harm reduction services are currently delivered by 
community agencies, non-governmental organisations 
(NGOs), municipalities, provinces and territories. 
The limited geographical reach and opening hours of 
available sites also pose barriers to access, especially 
for women who inject drugs, who also experience 
added stigma and fear of exposure to authorities 
because of strict child custody and welfare laws.(15) 
In Canada, confidentiality and fear of stigma pose a 
barrier to access in rural and remote areas, and on 
Aboriginal reserves, where those accessing harm 
reduction services may be easily identified.
Canada still operates the only drug consumption 
room in North America, the INSITE project in 
Vancouver, British Columbia. Following the failure 
of the federal government’s appeal to the Supreme 
Court in 2011 to force closure of the facility, other 
cities have approved proposals to establish safe 
injecting programmes, including Toronto and 
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Montreal.(16,17)	However,	establishing	the	projects	
will	still	require	approval	of	the	current	conservative	
federal	government.	In	2014,	the	federal	government	
introduced	legislation,	Bill	C-2,	which	would	make	
it	more	difficult	for	local	governments	to	set	up	
drug	consumption	rooms	(see	page	94,	Policy	
development	for	harm	reduction).		
Opioid	substitution	therapy	(OST)
OST	is	available	in	both	countries,	although	access	is	
by	no	means	universal.	Over	2,418	licensed	facilities	
provide	OST	in	the	form	of	methadone,	buprenorphine	
and	buprenorphine–naloxone	combination	across	the	
USA.(18)	The	most	recent	available	data	indicate	that	
in	the	USA	in	2009	there	were	640,000	individuals	
on	buprenorphine	or	buprenorphine–naloxone	
combination	for	maintenance	therapy	(up	from	
96,000	in	2005)	and	266,818	on	methadone	(up	
from	236,836	in	2005).(6)	All	ten	Canadian	provinces	
deliver	methadone	maintenance	therapy	(MMT)	
services	through	a	variety	of	models,	including	
government-funded	programmes,	for-profit	private	
clinics	and	family	practice,	but	the	number	of	sites	is	
unknown	due	to	lack	of	monitoring	as	part	of	national	
surveillance.(19)	Only	one	of	three	Canadian	territories	
provides	MMT,	and	buprenorphine	is	not	widely	used	
due	to	its	prohibitive	cost.(19)	In	Canada,	there	has	
also	been	an	increase	in	demand,	including	in	First	
Nation	communities	and	prisons.(19)	However,	the	lack	
of	doctors	who	can	prescribe	methadone,	and	limited	
provision	through	low-threshold	services,	remain	
a	significant	barrier	to	addressing	the	increasing	
demand	for	MMT	in	Canada.	
Limited	funding	options	and	budget	cuts	threaten	
the	quality	of	service	provision	in	Canada.	Additional	
obstacles	to	OST	access	include	geographical	
distance	from	sites,	stigma	and	misconceptions	
around	drug	dependence	at	every	level	of	the	
treatment	system.	As	with	NSPs,	confidentiality	issues	
present	a	further	obstacle,	especially	in	small	cities	
and	remote	areas.	Moreover,	there	is	often	powerful	
community	resistance	to	the	establishment	of	new	
programmes,	with	some	cities	amending	their	zoning	
by-laws	to	restrict	or	limit	programmes.	Civil	society	
reports	highlighted	a	need	for	more	low-threshold	
services	and	diversification	of	service	models,	as	
well	as	provision	of	integrated	psychosocial	and	
mental	health	support,	especially	among	First	Nation	
communities.	Some	attempts	are	being	made	to	
increase	the	availability	of	OST	through	low-threshold	
programmes.	
The	clinical	trial	‘Study	to	Assess	Longer-term	Opioid	
Medication	Effectiveness’	(SALOME)	is	currently	
underway	in	Vancouver.(20)	The	trial	is	investigating	the	
effectiveness	of	hydromorphine	(the	active	ingredient	
in	heroin)	compared	to	injectable	medical-grade	
heroin	(diacetylmorphine)	for	people	with	chronic	
opioid	dependence	for	whom	other	maintenance	
treatments	have	been	unsuccessful.	In	late	2013,	a	
group	of	patients	who	had	left	the	SALOME	project,	
along	with	their	doctors,	lodged	a	constitutional	
challenge	seeking	to	allow	them	to	continue	to	access	
prescription	heroin	even	though	they	were	no	longer	
part	of	the	project.	In	2014,	the	plaintiffs	won	the	
case,	and	the	doctors	began	prescribing	heroin	in	
November	2014(21) (see	page	94,	Policy	development	
for	harm	reduction)).		
In	the	USA,	growing	concerns	about	the	diversion	
of	buprenorphine(22)	have	the	potential	to	decrease	
access	to	the	medication.	Restrictions	arising	from	
these	concerns	include	mandatory	counselling	and	
urine	toxicology	tests,	as	well	as	requirements	by	
insurance	companies	for	prior	approval	of	each	
patient,	placing	greater	time	demands	on	doctors	
who	administer	buprenorphine	maintenance	
therapy.(22)	Additional	barriers	to	OST	access	in	the	
USA	include	uneven	Medicaid	coverage	across	
states,	leaving	many	uninsured	people	who	use	
drugs	unable	to	access	the	medication,	as	well	as	
many	doctors	opting	to	discharge	patients	for	poor	
attendance,	active	drug	use	or	not	participating	in	
counselling.	Methadone	clinics	in	the	USA	are	rarely	
low	threshold,	with	waiting	lists	of	at	least	six	months	
to	a	year,	or	longer,	outside	of	major	cities.	Barriers	
are	compounded	for	pregnant	women	who	use	drugs	
or	those	with	children,	as	they	are	at	risk	of	being	
reported	to	child	protection	services	and	losing	
custody	of	their	children	for	enrolling	in	treatment	
or	actively	using	drugs.	The	need	for	frequent	
attendance	(in	some	cases,	seven	days	a	week)	can	
be	further	complicated	by	childcare	difficulties	and	
increased	stigma.
Viral	hepatitis
Viral	hepatitis	prevalence	rates	among	people	who	
inject	drugs	are	high	in	both	the	USA	and	Canada.	
A	systematic	review	published	in	2011	reported	
prevalence	rates	of	hepatitis	C	(HCV)	among	people	
who	inject	drugs	of	over	60%	and	70%	in	Canada	
and	the	USA	respectively.(4)	Although	in	2014	HCV	is	
believed	to	have	declined	in	the	USA	(see	Table	2.6.1),	
the	rate	of	infection	among	this	population	group	is	
still	extremely	high.	For	example,	in	the	USA,	people	
who	inject	drugs	continue	to	account	for	up	to	50%	
of	new	HCV	infections(23)	and	approximately	80%	of	
new	HCV	infections	in	Canada.(24)	Both	countries	have	
significant	numbers	of	people	co-infected	with	HIV	
and	HCV.(25) 
The	extent	of	testing	and	treatment	for	viral	hepatitis	
among	people	who	inject	drugs	is	unclear.	In	the	
92 Global State of Harm reduction
USA,	access	to	testing	and	treatment	services	for	
viral	hepatitis	is	limited	by	several	factors,	including	
the	prohibitive	cost	of	treatment,	geographic	
distance	from	centres	that	may	offer	the	service,	
lack	of	an	effective	test	that	can	determine	current	
infection	status	instead	of	history	of	exposure,	and	
in	some	cases	the	requirement	that	a	person	must	
be	abstinent	from	drug	use	in	order	to	qualify	for	
treatment.(26)	In	Canada,	comprehensive	HIV	and	viral	
hepatitis	services	are	available	in	some	jurisdictions	
but	remain	limited	in	most	places	where	populations	
at	higher	risk	may	need	them	most,	such	as	on	
Aboriginal	reserves.	A	2011	study	estimated	that	
approximately	137,000	people	who	inject	drugs	will	
experience	HCV-related	disease	each	year	until	2026,	
and	it	will	cost	C$3.96	billion	to	provide	them	with	
treatment.	This	highlights	the	urgent	need	to	develop	
targeted	HCV	prevention	strategies	and	ensure	
adequate	allocation	of	resources	for	future	treatment	
needs	in	Canada.(27)
In	2014,	a	new	national	viral	hepatitis	action	plan	
was	released	in	the	USA	that	supports	the	provision	
of	both	NSP	and	OST	as	part	of	a	comprehensive	
HCV	prevention	package.	This	includes	support	
for	increased	access	to	HCV	prevention,	care,	and	
treatment	services	in	prison.(28)	In	Canada,	there	
is	no	national	hepatitis	strategy,	although	there	is	
a	2009	strategic	framework	for	action	sponsored	
by	the	Public	Health	Agency	of	Canada.	However,	
community-based	organisations	have	called	for	the	
development	of	a	true	national	HCV	strategy	that	
goes	beyond	the	limitations	of	and	gaps	in	the	current	
framework.(11) 
Tuberculosis
Integration	of	tuberculosis	(TB,)	viral	hepatitis	and	
HIV	services	vary	from	region	to	region	across	
Canada	and	the	USA.	The	lack	of	free	TB	testing	
and	treatment	targeted	at	people	who	inject	drugs,	
coupled	with	a	lack	of	awareness	of	the	relevance	
of	TB	as	an	issue,	hinder	many	from	seeking	these	
services.	The	US	Centers	for	Disease	Control	and	
Prevention	(CDC)	have	recently	launched	a	Program	
Collaboration	and	Service	Integration	(PCSI)	
mechanism	to	promote	increased	collaboration	and	
integration	of	testing,	treatment	and	surveillance	for	
HIV,	viral	hepatitis,	sexually	transmitted	infections	
(STIs)	and	TB	in	the	USA.	The	impacts	of	this	initiative	
are	yet	to	be	determined.
Antiretroviral	therapy	(ART)
An	estimated	40,334	people	who	inject	drugs	in	
Canada	and	308,208	in	the	USA	were	living	with	HIV	
in	2008.(8)	In	the	USA,	9%	of	new	HIV	infections	are	
among	people	who	inject	drugs.(9)	Racial	disparities	
in	HIV	infection	among	people	who	inject	drugs	are	
evident	in	both	countries.	According	to	the	CDC,	
African-Americans	are	ten	times	more	likely	to	be	
diagnosed	with	HIV	than	white	people	who	inject.(14) 
In	Canada,	aboriginal	people	(composed	of	First	
Nations,	Inuit	and	Métis)	are	more	likely	to	acquire	
HIV	via	unsafe	injecting	than	non-Aboriginal	people,	
and	unsafe	injecting	drug	use	accounts	for	more	
HIV	cases	among	Aboriginal	women	than	among	
aboriginal	men.(29)	Among	aboriginal	Canadians,	the	
estimated	proportion	of	new	HIV	infections	in	2008	
attributed	to	unsafe	injecting	was	66%;	almost	four	
times	higher	than	among	the	Canadian	population	as	
a	whole.(30) 
There	are	no	national-level	data	on	antiretroviral	
therapy	(ART)	coverage	among	people	who	inject	
drugs	in	either	Canada	or	the	USA.	Differing	
approaches,	targets	and	implementation	structures	
across	states,	provinces	and	jurisdictions	have	an	
impact	on	the	ability	to	monitor	service	provision.	It	
can	be	inferred	that	a	sizeable	proportion	of	those	
who	may	need	treatment	could	be	unaware	of	their	
HIV	status.	As	of	2008,	26%	of	the	estimated	65,000	
Canadians	living	with	HIV	were	unaware	that	they	
were	infected.(25)	Most	of	these	individuals	represent	
key	populations	at	higher	risk	of	HIV,	including	people	
who	inject	drugs.	Although	recent	data	indicate	
that	85.5%	of	people	who	are	injecting	drugs	took	
an	HIV	test	and	received	their	results	in	the	past	
12	months,(31)	this	proportion	is	substantially	lower	
among	sub-groups	at	higher	risk,	such	as	aboriginal	
people	and	women	who	inject	drugs.(9,29)
Civil	society	reports	in	the	USA	cite	the	lack	of	access	
to	antiretroviral	drugs	as	a	major	barrier	to	people	
who	inject	drugs	starting	ART,	especially	in	the	
southern	region	where	there	is	a	growing	waiting	list	
for	the	AIDS	Drug	Assistance	Program.(32)	Additionally,	
some	doctors	are	reported	to	initiate	treatment	only	
when	the	patient	abstains	from	drug	use.	In	Canada,	
the	cost	of	HIV	treatment	is	heavily	subsidised,	if	
not	completely	covered,	by	provincial	governments.	
However,	accessibility	to	ART	for	people	who	inject	
drugs	is	uneven	across	the	country.(11) 
Harm	reduction	in	prisons
The	USA	has	the	highest	prison	population	rate	
in	the	world,	with	a	recorded	2.24	million	people	
incarcerated.(33)	Despite	the	high	rate	of	detention,	the	
highest	estimated	population	who	inject	drugs,	and	
one	of	the	highest	prevalence	rates	of	HIV	among	this	
population,	harm	reduction	initiatives	in	the	prison	
setting	remain	extremely	limited.	Although	Canada’s	
prison	harm	reduction	programmes	are	more	
extensive	in	some	respects,	they	still	fall	far	short	of	a	
comprehensive	response.	
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High	rates	of	HIV,	viral	hepatitis	and	TB	among	
inmates	in	the	USA	have	been	recorded,	particularly	
among	those	who	are	released	from	prison	and	
re-incarcerated.(34)	This	suggests	the	urgent	need	
for	harm	reduction	provision	to	be	made	available.	
In	Canada,	HIV	and	HCV	prevalence	in	prison	is	at	
least	10	and	30	times	higher,	respectively,	than	in	the	
drug	user	community	as	a	whole.	Injecting	drug	use	
is	common,	with	one	in	six	people	in	federal	prisons	
reporting	injecting	in	prison	within	the	previous	six	
months.	Of	those	people	who	injected	drugs	in	
prison,	half	used	someone	else’s	used	syringe	and	
one-third	shared	a	needle	with	someone	with	HIV,	
HCV	or	unknown	infection	status.(35) 
OST	provision	is	available	in	only	a	small	number	
of	US	prisons	and	jails,	including	Rikers	Island	
(New	York),	the	Metropolitan	Detention	Center	(New	
Mexico)	and	jails	in	Baltimore	and	Rhode	Island.(32) 
In	2013,	indicative	of	a	gradual	shift	in	policy,	the	
US	Department	of	Justice	and	the	Bureau	of	Justice	
Assistance	co-sponsored	a	cross-disciplinary	training	
manual	on	OST	for	offender	populations	designed	
to	increase	knowledge	and	awareness.(36) Then in 
early	2014,	the	Substance	Abuse	and	Mental	Health	
Service	Administration	(SAMHSA)	released	a	report,	
Medication-Assisted Treatment and the Criminal 
Justice System,	three	years	after	hosting	an	expert	
committee	on	the	issue.
Unlike	the	USA,	OST	is	widely	available	in	Canadian	
federal	and	provincial	prisons.	In	most	jurisdictions,	
OST	continuation	is	available	to	prisoners	who	
were	prescribed	it	prior	to	their	arrest.	Only	the	
federal	prison	system	and	one	province	currently	
enable	prisoners	to	initiate	OST	treatment	while	
incarcerated,(37)	although	civil	society	reports	note	
that	difficulties	remain	in	initiating	OST	even	in	those	
jurisdiction	that	allow	it.(11) 
There	are	no	NSPs	operating	in	prisons	in	either	
Canada	or	the	USA,	although	in	2012	a	legal	
challenge	was	launched	in	Canada	by	a	former	
prisoner	and	four	HIV	organisations	to	the	failure	to	
make	sterile	injecting	equipment	available	in	prisons	
(see	box	below).	The	distribution	of	bleach	for	
cleaning	used	syringes	has	been	in	place	since	1996	
in	the	Canadian	federal	prison	system,	and	is	also	
available	in	some	provincial	systems,(37)	although	this	
is	a	suboptimal	harm	reduction	response	to	the	risk	of	
sharing	syringes.
Prisons	in	both	Canada	and	the	USA	have	ART	
provision.	Condom	provision	is	also	common	
although	uneven	across	the	Canadian	federal	and	
provincial	prisons,	with	most	jurisdictions	providing	
condom	access	to	some	degree,	although	concerns	
have	been	raised	about	barriers	to	access.(37) 
Condoms	are	largely	unavailable	in	US	prisons	and	
jails,	with	only	a	handful	of	jurisdictions	or	individual	
institutions	allowing	access.(38) 
Overdose
The Global State of Harm Reduction 2012	revealed	
a	steady	increase	in	reported	drug-related	overdose	
in	the	USA,(10)	and	it	is	still	the	leading	cause	of	death	
by	injury	in	the	country,	with	114	people	dying	as	
a	result	of	a	drug	overdose	every	day.(40)ix	In	2010,	
naloxone	(an	opioid	antagonist)	was	delivered	in	
188	opioid	overdose	prevention	programmes	in	
the	USA.(41)	Collectively,	these	have	trained	over	
50,000	individuals	in	naloxone	use,	resulting	in	
10,071	reported	overdose	reversals	between	1996	
ix	 This	includes	unintentional,	intentional	(suicide	or	homicide)	and	cases	of	undetermined	intent.
legal action on prison needle exchange 
in Canada
In	September	2012,	a	former	Canadian	prisoner	
and	four	community-based	HIV	organisations	
launched	a	joint	lawsuit	against	the	federal	
government	to	challenge	the	failure	to	provide	
access	to	sterile	injecting	equipment	in	prisons.	
The	lead	plaintiff	in	the	case	is	Steven	Simmons,	
a	former	prisoner	who	contracted	HCV	while	
incarcerated	between	1998	and	2010.	The	NGOs	
supporting	the	lawsuit	are	the	Canadian	HIV-
AIDS	Legal	Network,	Prisoners	with	HIV/AIDS	
Support	Action	Network	(PASAN),	the	Canadian	
Aboriginal	AIDS	Network	(CAAN)	and	CATIE,	a	
national	HIV	and	HCV	information	service.
The	lawsuit,	filed	in	Ontario’s	Superior	Court	of	
Justice,	claims	that	the	failure	of	the	state	to	
provide	access	to	NSPs	in	prisons	constitutes	a	
violation	of	the	Canadian	Charter	of	Rights	and	
Freedoms.	The	plaintiffs	are	seeking	a	judicial	
order	that	would	compel	the	government	to	
make	prison	NSPs	available	across	Canada.	
As	part	of	the	suit,	the	Canadian	HIV/AIDS	
Legal	Network	will	submit	affidavits	and	
testimonials	from	50	current	or	former	federal	
prisoners	from	across	the	country,	documenting	
their	experiences	of	injecting	drug	use	and	
needle	sharing	in	prisons.	Their	perspectives	
will	provide	evidence	of	the	harm	prisoners	
experience	when	they	are	denied	healthcare	
services	that	other	citizens	can	access.	
Developments	in	the	lawsuit	can	be	followed	at	
www.prisonhealthnow.ca.(39)
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and	2010.(40)	As	of	June	2014,	there	are	30	states	
plus	Washington	DC	that	have	at	least	one	point	of	
access	for	laypersons	to	obtain	naloxone	for	people	
who	use	drugs,	or	friends	and	family,(32)	with	over	600	
distribution	sites	and	13	states	that	have	at	least	one	
naloxone	co-prescription	in	place.(32)Co-prescription	
refers	to	the	practice	of	prescribing	naloxone	to	
someone	who	is	receiving	opioid	pain	medications	
from	their	doctor	for	a	chronic	pain	condition,	or	
for	a	patient	who	the	prescribing	doctor	otherwise	
feels	may	be	at	risk	of	overdose.	The	prescription	for	
naloxone	is	filled	through	the	pharmacy.	This	new	
development	is	intended	to	reach	prescription	opioid	
users	that	traditionally	have	not	been	well	served	by	
existing	naloxone	programmes,	which	are	primarily	
reaching	people	who	use	heroin	and	people	who	
inject	who	use	NSPs.(10)	A	2012	survey	of	NSPs	in	the	
USA	found	that	half	of	the	programmes	distributed	
naloxone	(60%	provided	injectable	naloxone	only,	
14%	intranasal	only	and	26%	provided	both).(5)
Over	the	past	few	years	there	has	been	a	significant	
increase	in	the	number	of	US	states	passing	laws	
enhancing	the	overdose	response.	Between	2012	
and	2014,	19	states	passed	laws	providing	immunity	
to	healthcare	workers	or	layperson	responders	
administering	naloxone,	making	a	total	of	27	states	
with	such	legislation.(42)	In	addition,	24	states	now	
have	passed	Good	Samaritan	laws	providing	legal	
protections	for	people	who	call	emergency	services	
for	help	in	the	event	of	an	overdose.	This	is	an	
increase	of	14	states	since	2012.(43) 
Until	recently,	naloxone	distribution	programmes	
in	Canada	existed	only	in	Edmonton,	Toronto	and	
Ottawa.	However,	since	2012	there	has	been	a	
rapid	scale	up	of	overdose	prevention	and	response	
programmes	in	British	Columbia,	sponsored	by	the	
BC	Centre	for	Disease	Control.	The	agency	has	
initiated	programmes	at	45	sites	in	the	province,	
with	1,215	naloxone	kits	being	distributed	and	more	
than	2,200	people	trained	to	recognise	and	respond	
to	an	opioid	overdose.(44)	Similar	community-based	
programmes	have	now	been	initiated	in	medium	and	
large	urban	centres	across	Ontario,	and	one	is	under	
development	in	Montreal,	Quebec.	Although	these	
programmes	are	not	yet	supported	by	the	federal	
government,	the	scale	up	and	initiation	of	naloxone	is	
a	positive	move	towards	fewer	deaths	by	overdose,	
and	also	serves	to	increase	awareness	of	the	issue.	
National-level	data	on	drug	overdoses	is	unavailable	
in	Canada.(11)
Policy	development	for	harm	reduction
Since	The Global State of Harm Reduction 2012 
there	has	been	significant	legislative	progress	in	
the	USA	on	the	issue	of	overdose	prevention.	As	
described	above,	19	states	have	passed	laws	since	
2012	providing	immunity	to	healthcare	workers	or	
layperson	responders	administering	naloxone,	and	14	
states	have	passed	Good	Samaritan	laws	providing	
legal	protections	for	people	who	call	emergency	
services	for	help	in	the	event	of	an	overdose.(42,43)	In	
April	2012,	the	director	of	the	Office	of	National	Drug	
Control	Policy	(ONDCP)	for	the	first	time	voiced	public	
support	for	the	distribution	of	naloxone,(45)	and	since	
that	time	ONDCP	and	other	federal	agencies	have	
continued	to	support	naloxone	programmes.	In	2014,	
the	National	Drug	Control	Strategy	was	released	
that	contains	supportive	language	for	both	naloxone	
and	NSPs.(46)	In	the	same	year,	the	Law	Enforcement	
Naloxone	Toolkit	was	released	by	the	Bureau	
of	Justice	Assistance	and	the	Opioid	Overdose	
Prevention	Toolkit(47)	by	SAMHSA,	both	in	response	to	
the	opioid	overdose	epidemic.
State	referenda	on	the	legal	regulation	and	sale	of	
cannabis	were	adopted	in	Washington	and	Colorado	
in	the	2012	elections,	and	similar	ballot	initiatives	
were	passed	by	voters	in	Oregon,	Alaska	and	the	
District	of	Columbia	in	2014.	These	referenda	have	
heightened	the	national	debate	on	drug	policy	reform	
within	the	USA.	
In	2013,	a	group	of	patients	and	doctors	initiated	a	
constitutional	court	challenge	to	proposed	changes	
to	Health	Canada’s	Special	Access	Programme,	
which	enabled	access	to	prescription	heroin	for	those	
who	had	participated	in	the	SALOME	heroin	trial	in	
Vancouver.	The	plaintiffs	sought	the	right	to	continue	
to	access	prescribed	heroin,	even	though	they	were	
no	longer	participants	in	the	SALOME	study.	In	
November	2013,	a	court	case	challenging	the	new	
federal	regulations	was	launched	by	the	Providence	
Health	Care	Society	and	four	former	participants	in	
the	trial,	who	were	represented	by	the	Pivot	Legal	
Society.	In	May	2014,	the	British	Columbia	Supreme	
Court	granted	an	injunction	to	the	participants,	
exempting	them	from	new	federal	regulations.	Then	
in	November	2014,	doctors	began	prescribing	heroin,	
making	Vancouver	the	first	city	in	North	America	
where	prescription	heroin	is	available	to	people	
outside	of	a	clinical	trial.(48,49) 
In	Canada,	there	have	been	further	developments	on	
the	issue	of	drug	consumption	rooms.	Following	the	
Canadian	federal	government’s	failed	2011	attempt	at	
the	Supreme	Court	to	close	down	the	INSITE	project	
in	Vancouver,	it	has	introduced	legislation	that	would	
substantially	limit	the	ability	of	other	municipalities	to	
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open	similar	safe	injecting	facilities.	The	legislation,	
known	as	Bill	C-2,	would	create	significant	barriers	
to	local	health	authorities	seeking	to	establish	drug	
consumption	rooms	in	their	own	cities.(50)	According	
to	the	Canadian	HIV/AIDS	Legal	Network,	“Bill	C-2	
would	introduce	an	unnecessary	series	of	obstacles	
and	a	biased	process	replete	with	opportunities	for	
misinformation	and	stigma	to	block	needed	health	
services.”	The	bill	is	currently	working	its	way	through	
parliament,	although	it	has	yet	to	be	approved.	Civil	
society	organisations	have	been	actively	opposing	the	
proposed	law.(51) 
Civil	society	and	advocacy	
developments	for	harm	reduction
Civil	society	organisations	working	for	harm	reduction	
and	drug	policy	advocacy	in	North	America	have	
been	increasingly	active	since	2012,	both	nationally	
and	internationally.	Grassroots	initiatives	have	played	
a	significant	role	in	expanding	access	to	naloxone	
in	both	the	USA	and	Canada.	The	Harm	Reduction	
Coalition	(HRC)	has	been	a	key	national	voice	in	the	
USA,	not	only	in	supporting	the	development	of	harm	
reduction	services	but	also	in	successfully	engaging	
the	Obama	administration	on	key	issues,	and	working	
with	international	partners	at	the	annual	Commission	
on	Narcotic	Drugs	meetings	and	on	preparations	for	
the	2016	United	Nations	General	Assembly	Special	
Session	(UNGASS)	on	drugs.	HRC	also	hosts	the	
biennial	national	harm	reduction	conference,	the	
major	meeting	place	for	harm	reductionists	and	
drug	user	activists	from	across	the	USA.	The	2014	
event	was	notable	for	a	keynote	speech	delivered	
by	the	US	‘drug	czar’	Michael	Botticelli,	ONDCP	
director,	in	which	he	explicitly	voiced	support	for	harm	
reduction	and	naloxone	–	the	first	time	a	high-level	
US	administration	official	has	addressed	the	harm	
reduction	conference.
In	Canada,	the	leading	national	organisations	include	
the	Canadian	Drug	Policy	Coalition,	an	independent	
civil	society	network	of	organisations	and	individuals	
advocating	to	improve	Canada’s	drug	policies;	
the	Canadian	HIV/AIDS	Legal	Network,	a	national	
organisation	actively	engaged	in	advocacy	on	legal	
and	human	rights	issues	surrounding	HIV;	and	
the	Canadian	Harm	Reduction	Coalition,	a	virtual	
forum	for	information	exchange	for	individuals	and	
organisations	working	in	the	areas	of	harm	reduction	
and	drug	policy.	Both	the	Canadian	Drug	Policy	
Coalition	and	the	Canadian	HIV/AIDS	Legal	Network	
have	been	particularly	active,	engaging	policymakers	
and	the	media	at	the	national	level	on	issues	such	
as	opposition	to	Bill	C-2,	drug	law	reform	and	harm	
reduction	in	prisons.	The	Canadian	Drug	Policy	
Coalition	and	the	Canadian	HIV/AIDS	Legal	Network	
are	also	active	on	the	international	stage,	working	
with	partners	at	United	Nations	forums	such	as	the	
Commission	on	Narcotic	Drugs.
In	Canada,	the	Pivot	Legal	Society	is	also	a	central	
player	in	promoting	legislative	change	to	support	
harm	reduction	and	drug	policy	reform.	Pivot	is	a	
legal	advocacy	project	committed	to	using	the	law	
to	address	the	root	causes	of	poverty	and	social	
exclusion,	and	it	has	been	centrally	involved	in	
a	number	of	key	court	decisions	in	recent	years,	
United States alliance of Drug User Unions
Drug	user	unions	began	to	form	in	the	USA	during	the	early	1990s,	and	the	drug	user	union	movement	
has	grown	slowly	since	then,	connected	to	the	international	drug	user	movement	via	the	International	
Network	of	People	who	Use	Drugs	(INPUD).		
In	2012,	following	a	drug	user	pre-conference	at	the	9th	National	Harm	Reduction	Conference	in	
Portland,	Oregon,	five	US	drug	user	unions	held	the	first	meeting	of	the	American	Federation	of	Drug	
Users	(AFDU).	The	groups	involved	were	the	San	Francisco	Drug	Users	Union,	VOCAL-NY,	the	New	York	
Users’	Union,	the	Urban	Survivors’	Union	(Seattle)	and	the	New	England	Users	Union.	At	this	meeting,	
each	union	nominated	a	representative	to	serve	as	a	link	person	between	AFDU	and	their	member	
organisation.	AFDU’s	first	formal	gathering	was	held	in	2013	in	Denver	at	the	Drug	Policy	Alliance	
Conference,	where	a	decision	was	made	to	change	the	name	of	the	group	to	the	United	States	of	
America	Drug	Users	Unions	(USADUU).			
USADUU	is	working	to	build	a	“national	drug	user	peer-based	organisation	promoting	drug	user	rights	
and	health,	de-stigmatisation	and	de-criminalisation	across	America”.	Among	its	core	objectives	are	“to	
unify	and	empower	Drug	User	Unions	across	America	to	collaborate,	thus	providing	a	united	platform	
giving	a	voice	to	American	drug	users	to	address	the	harm	created	by	the	war	on	drugs	at	both	a	
national	and	international	level”	and	“to	present	drug	users	and	the	drug	user	agenda	as	an	organised,	
strong,	and	unified	front	against	the	war	on	drugs”.	
At	the	10th	National	Harm	Reduction	Conference	in	Baltimore	in	2014,	USADUU	held	a	meeting	with	
over	30	activists	from	across	the	country.
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including	the	INSITE	case	in	2011,	the	SALOME	case	
(described	above),	and	a	recent	successful	Supreme	
Court	challenge	to	Canada’s	prostitution	laws.
Drug	user	organising	has	grown	significantly	in	the	
USA	since	last	reported	in	The Global State of Harm 
Reduction 2012,	with	well-established	networks	and	
associations	operating	in	New	York	(VOCAL,	New	You	
Users’	Union),	San	Francisco	(San	Francisco	Drug	
Users	Union),	Seattle	(Urban	Survivors’	Union)	and	
New	England	(New	England	Users	Union).	In	2012,	
these	five	unions	came	together	to	form	a	national	
umbrella	coalition,	the	United	States	Alliance	of	Drug	
User	Unions	(see	box	below).	
Organisations	of	people	who	use	drugs	operate	in	
a	number	of	cities	and	regions	in	Canada,	including	
Vancouver	(VANDU),	Victoria	(SOLID)	and	Toronto	
(TODUU).	Two	groups	–	the	BC-Yukon	Association	of	
Drug	War	Survivors	and	AAWARE	in	Alberta	–	operate	
at	the	regional	level.	Most	organisations	of	people	
who	use	drugs	are	small	and	have	minimal	budgets.	
The	Canadian	Association	of	People	who	Use	Drugs	
(CAPUD)	acts	as	an	umbrella	for	these	organisations.	
Formed	in	2010,	CAPUD’s	work	was	reinvigorated	
by	a	national	meeting	of	members	in	October	2013,	
and	it	has	since	formed	alliances	with	other	key	
national	partners,	including	the	Centre	for	Addictions	
Research	of	BC	(CARBC),	the	Canadian	Drug	Policy	
Coalition,	the	Canadian	HIV/AIDS	Legal	Network	and	
the	Canadian	AIDS	Society.		
Funding:	developments	for	harm	
reduction
Harm	reduction	in	Canada	is	largely	funded	by	
provinces	and	territories,	as	well	as	municipalities,	
and	covers	programming,	community-based	research	
and	direct	service	delivery.	Other	sources	of	funding	
include	MAC	AIDS	Fund	and	the	Open	Society	
Foundations.	
A	number	of	foundations	consistently	support	
harm	reduction	implementation	and	advocacy	in	
the	USA,	with	the	largest	percentage	of	funding	
going	to	direct	services.	In	the	absence	of	federal	
funding,	the	Syringe	Access	Fund	(SAF)	is	the	largest	
private	funding	source	for	syringe	access	in	the	
country,	comprised	of	AIDS	United,	Elton	John	AIDS	
Foundation,	Levi	Strauss	Foundation,	Open	Society	
Foundations,	Tides	Foundation,	Irene	Diamond	
Fund	(closed	in	2011)	and	NASEN.	A	2012	survey	of	
142	NSPs	in	the	USA	found	total	funding	of	$19.4	
million.(5)  
In	addition	to	the	contributions	made	by	SAF	
and	separate	funding	provided	by	individual	SAF	
partners,	ongoing	support	to	both	harm	reduction	
implementation	and	policy	advocacy	projects	has	
been	provided	by	MAC	AIDS	Fund,	amfAR,	Ford	
Foundation,	Broadway	Cares/Equity	Fights	AIDS	
and	the	Comer	Foundation.	In	response	to	the	
reinstatement	of	the	federal	funding	ban,	community	
and	corporate	foundations	that	fund	harm	reduction	
services	have	reported	an	increase	in	grant	requests	
from	public	health	departments	looking	to	offset	
projected	loss	of	federal	funding.
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Table 2.7.1: : Epidemiology of HIV and viral hepatitis, and harm reduction responses in Oceania
Country/
territory
with reported
injecting
drug use
People who
inject drugsi
Hiv prevalence
among people
who inject 
drugs (%)
Hepatitis C (anti-
HCv) prevalence
among people
who inject 
drugs (%)
Hepatitis B
(anti-HBsag)
prevalence among
people who  
inject drugs (%)
Harm reduction response
nSPii oSTiii DCRi
australia 89,200(1) 1.2(2) 54(2) 18.1(2) (3,000+) (P)iv (2,025)
(3)  
(b, m) 
1
fiji nk nk nk nk x x
new Zealand 12,840(4) 0.2(5) 50%(6) nk (192+) (P)(7)  (b, m)
Papua new 
Guinea
nk nk nk nk x x
Samoa nk nk nk nk x x
timor leste nk nk nk nk x x
 
i DCR is a drug consumption room (please refer to chapter for details), also referred to as a safer injection facility.
ii	 This	includes	all	operational	NSP	sites,	including	fixed	sites,	vending	machines	and	mobile	NSPs	operating	from	a	vehicle	or	through	outreach	workers.
iii	 (M)	=	methadone,	(B)	=	buprenorphine,	(O)	=	any	other	form	(including	morphine	and	codeine).
iv	 (P)	=	needles	and	syringes	reported	to	be	available	for	purchase	from	pharmacies	or	other	outlets.
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The	region	of	Oceania	includes	the	Pacific	Island	
countries	and	territories	(PICTs).v	However,	the	
regional	prevalence	of	injecting	drug	use	in	
countries	other	than	Australia	and	New	Zealand	is	
unknown.	Injecting	drug	use	has	been	reported	in	
the	PICTs,	but	little	research	has	been	undertaken	
and	no	harm	reduction	programmes	have	been	
initiated.(8)	Approximately	102,040	people	inject	
drugs	in	Australia	and	New	Zealand	combined,(1,4) a 
decrease	of	approximately	70,000	on	figures	from	
2012.(9) HIV	prevalence	among	them	is	relatively	low	
(1.2%(2)	and	0.2%(5)	respectively).	However,	hepatitis	C	
(HCV)	rates	have	remained	high,	at	54%(2)	and	50%(6) 
respectively.
Although	harm	reduction	services	in	the	form	of	
needle and syringe programmes (NSPs) and opioid 
substitution	therapy	(OST)	are	available	in	both	
Australia	and	New	Zealand,	there	is	a	disparity	of	
provision	and	uptake	among	Aboriginal	Australians	
and	Torres	Strait	Islanders.(10,11)	This is illustrated 
through	transmission	rates	among	newly	diagnosed	
HIV-positive	Aboriginal	people,	with	a	far	higher	
percentage reporting transmission through unsafe 
injecting	drug	use	(13%)	compared	to	non-Aboriginal	
people	living	with	HIV	(2%).(12)	Early implementation 
of	harm	reduction	programmes	in	the	1980s	has	
been	widely	credited	with	these	low	levels	of	HIV	
among injecting populations.(8) However,	there	are	still	
significant	ethnic	disparities	and	uneven	coverage	
among affected groups.(10,	13)
Civil	society	organisations	report	that	while	harm	
reduction	services	in	Australia	and	New	Zealand	
have	been	maintained,	they	have	not	been	increased.	
Without	additional	scale	up,	and	with	cuts	to	
current	funding,	this	situation	may	destabilise	the	
mechanisms	that	keep	unsafe	injecting	and	HIV	
infection	rates	low.(10,13)	In	Australia,	a	key	body	for	
the alcohol and other drugs sector, the Drug Council 
of	Australia,	was	defunded	on	25	November	2013.	
Other	groups,	such	as	the	Australian	Injecting	and	
Illicit	Drug	Users	League	(AIVL)	and	its	member	
organisations	representing	people	who	use	drugs,	
together	with	community	organisations	representing	
people	living	with	HIV,	have	reported	unstable	funding	
projections for the future.(10) The Anex Bulletin, 
a	publication	that	supported	the	harm	reduction	
workforce,	has	also	been	defunded.(11)
Among	the	smaller	islands	of	Oceania,	HIV	epidemics	
have	remained	limited.(14)	In	Fiji,	harmful	drug	use	
patterns	and	injecting	drug	use	are	reported,	but	
there is little analysis or structural response to 
address	the	range	of	social-	and	health-related	harms	
documented.(15)	A rapid assessment of drug use in 
Papua	New	Guinea	in	2005	found	that	high-potency	
cannabis	was	the	main	drug	used.(16)	In	2012,	two	
assessments	were	undertaken	to	explore	injecting	
drug	use,	treatment,	prevention	and	care,	yet	the	
extent	and	nature	of	injecting	practices	remain	
unclear.(17)	In	Samoa,	the	use	of	hallucinogens	is	
prominent among adolescents,(18)	and	poly-drug	use,	
particularly	involving	alcohol,	cannabis,	inhalants	and	
amphetamine-type	stimulants,	can	be	more	pervasive	
in	the	PICTs.(19)	There are presently no harm reduction 
services	in	the	PICTs,	with	most	approaches	to	drug	
use	or	poly-drug	use	being	abstinence	based.(19) 
Further	research	into	drug	use	in	the	PICTs	needs	to	
be	undertaken.	
Civil	society	organisations	have	noted	a	recent	
increase	in	use	of	amphetamine-type	stimulants	in	
both	Australia	and	New	Zealand.(10,13)	In	one	study	
looking	at	15	years	of	HIV	surveillance	in	Australia,	
31%	of	people	who	inject	drugs	had	recently	
injected	methamphetamine	(n=22,478),	whereas	
42%	had	recently	injected	heroin.(20) Another study 
between	2009	and	2013	showed	a	similar	increase	
in	methamphetamine	injecting	but	a	decrease	in	
heroin.(2)	Further	research	on	the	use	of	drugs	such	
as	methamphetamine	and	sexual	risk	behaviours	that	
have	been	associated	with	it(21)	should	be	undertaken	
to	improve	and	adapt	the	harm	reduction	response.	
Developments	in	harm	reduction	
implementation
Needle and syringe programmes (NSPs)
NSPs	have	a	long	history	in	Australia,	with	over	
3,000	NSP	outlets	now	in	operation,	including	mobile	
outreach	and	vending	machines.(8) The	low	rate	of	
HIV	transmission	among	people	who	inject	drugs	
has	often	been	attributed	to	the	early	implementation	
and	scale	up	of	NSP	services,	which	are	government	
supported	and	publicly	funded.	However,	since	
2012	there	has	been	no	significant	fiscal	increase,	
meaning	real	funding	for	NSP	services	has	decreased	
compared	to	inflation	and	increased	cost	of	sterile	
injecting equipment.(10) Although daily injecting 
decreased	between	2009	and	2013	from	a	reported	
50%	of	people	who	use	drugs	to	44%,	there	was	an	
increase	in	the	prevalence	of	injecting	performance	
and	image	enhancing	drugs	(PIEDs)	from	2%	to	7%	
during the same time period.(2)	The	number	of	PIEDs	
detected	at	the	Australian	border	increased	by	106%	
between	2009	and	2011,(22) indicating a need for 
Harm reduction in Oceania
v	 The	PICTs	comprise	22	countries	and	territories	subdivided	into	Micronesia,	Polynesia	and	Melanesia.	They	are	American	Samoa,	Cook	Islands,	Federated	States	
of	Micronesia,	Fiji,	French	Polynesia,	Guam,	Kiribati,	Marshall	Islands,	Nauru,	New	Caledonia,	Niue,	Northern	Mariana	Islands,	Palau,	Papua	New	Guinea,	Pitcairn	
Islands,	Samoa,	Solomon	Islands,	Tokelau,	Tonga,	Tuvalu,	Vanuatu,	and	Wallis	and	Futuna.
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Australian	NSPs	to	adapt	their	services	to	meet	the	
needs of these populations.  
Alongside	Australia,	New	Zealand	also	has	one	
of	the	highest	NSP	coverage	rates	in	the	world,	
annually	distributing	over	3	million	clean	needles	
to	people	who	inject	drugs,(23)	and	with	21	primary	
NSPs	and	approximately	170	pharmacies	offering	
NSP	services.(7)	In	both	countries,	NSPs	are	the	
primary mode of accessing safe injecting equipment, 
according	to	epidemiological	data.	In	New	Zealand,	
as	in	Australia,	the	low	rate	of	HIV	infection	among	
people	who	inject	drugs	has	been	attributed	to	the	
high	number	of	NSP	services	available.	However,	
also	like	Australia,	coverage	needs	to	be	more	
comprehensive	to	ensure	increased	access	and	
availability.(10,13)	Although	in	Australia	the	availability	of	
secure	dispensing	units	that	provide	sterile	injecting	
equipment	has	increased	since	2012,	other	models	
of	NSPs	have	been	scaled	down.	For	example,	the	
mobile	NSP	service	in	Victoria	is	no	longer	available	
24	hours	a	day,(11) and there are increasing strains on 
funding.(10,11)	
In	Australia,	as	previously	noted,	there	is	a	disparity	
of	service	provision	among	indigenous	communities,	
who	have	higher	rates	of	HIV	transmission	through	
unsafe injecting drug use. Although there are some 
small-scale	targeted	services,	such	as	dedicated	
peer-NSP	workers,	this	can	mean	that	in	small	
communities	a	service	provider	from	the	same	cultural	
background	is	likely	to	know	the	person	accessing	the	
service.	Confidentiality	issues	can	therefore	reduce	
the	desire	for	a	person	who	injects	drugs	to	seek	out	
this	service.(10) A more concerted effort is needed to 
ensure	greater	provision	and	uptake	by	Aboriginal	and	
Torres	Strait	Islander	communities.	
There	is	no	NSP	service	provision	in	any	of	the	
PICTs.	Injecting	practices	are	thought	to	occur	in	
Timor	Leste,	although	rates	of	HIV	infection	are	
unknown.(24)	Research	has	been	undertaken	in	Papua	
New	Guinea	but,	as	in	Timor	Leste,	injecting	practices	
are unclear.(17)	The	response	to	drug	use	is	based	on	
abstinence-only	interventions,	and	at	present	there	
are	no	plans	to	implement	harm	reduction	services	in	
these territories.
Opioid	substitution	therapy	(OST)
In	2013,	there	were	2,025	outlets	providing	OST	in	
Australia,(3)	a	reduction	of	107	outlets	from	2012.(9) 
The	ratio	of	clients	per	OST	prescriber	has	reduced	
from	26	in	2012	to	23	in	2013,	and	the	growth	in	
client	numbers	has	also	slowed	in	recent	years.(3)	
OST	is	mostly	provided	in	the	private	sector	(82%),(3)	
with	clients	paying	between	AU$14.70	and	AU$85	
per	week	for	medication,(28)	with	the	average	cost	
being	AU$35.(10)	This	burden	of	cost	can	be	extremely	
prohibitive	for	people	who	use	drugs,	and	has	yet	to	
be	addressed	in	the	country.
Although	OST	provision	is	high	in	Australia,	there	
has	been	little	change	since	2012.(10)	In	New	Zealand,	
current	levels	of	OST	provision	are	unclear,	but	in	
2009	it	was	estimated	that	approximately	4,600	
individuals	were	receiving	OST,	predominantly	in	
methadone form.(29)	The	only	forms	of	OST	available	
in	Australia	are	methadone	and	suboxone	film.	A	few	
people	in	Australia	are	allowed	to	remain	on	subutex	
if	their	doctor	agrees	they	cannot	take	suboxone	
for	medical	reasons.	However,	extra	restrictions	
are	often	applied	to	subutex,	such	as	no	takeaway	
doses.	Fewer	takeaway	doses	are	allowed	for	people	
on	methadone	than	on	suboxone	in	most	Australian	
states.(10) 
In	both	countries	there	are	restrictions	applied	to	
OST	provision,	creating	barriers	for	people	who	inject	
drugs,	and	service	provision	can	be	variable.(10,13)	In	
economic analysis: the value of needle and syringe programmes in australia
Australia’s	approach	to	harm	reduction	in	terms	of	NSP	provision	has	long	been	credited	with	keeping	
rates	of	HIV	low	among	people	who	inject	drugs,	and	economic	analysis	has	been	undertaken	to	illustrate	
the	cost-effectiveness	of	these	programmes.	It	is	estimated	that	between	2000	and	2009,	32,050	new	
HIV	infections	and	96,667	new	HCV	infections	were	directly	averted	through	provision	of	NSP	services,(25)	
reducing	the	incidence	of	HIV	by	34–70%.(26)
The	figure	attributed	to	healthcare	costs	saved	is	thought	to	be	AU$1.28	billion,	with	gross	funding	for	
NSP	services	costing	$243	million	Australian	dollars.(25)	Based	on	these	figures	and	the	continued	uptake	of	
NSP	services	among	people	who	inject	drugs,	the	projected	cost	savings	in	terms	of	healthcare	have	been	
stated	as	AU$340-950	million.(26)	Although	the	figures	are	impressive,	the	average	cost	per	person	who	
injects	drugs	per	occasion	of	service	is	AU$199.96,	which	one	study	believed	could	be	further	reduced	to	
$93.32	Australian	dollars	if	NSP	clinics	reached	peak	utilisation.(27)	
Maintaining	levels	of	NSP	funding	will	increase	healthcare	cost	savings	and	gains	in	life	years	of	the	person	
who	injects	drugs.(25,26)	However,	as	has	been	noted	by	civil	society	organisations,	there	is	some	uncertainty	
as	to	whether	funding	pools	for	NSP	services	will	remain	stable.(10) 
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New	Zealand,	one	of	the	main	barriers	to	OST	uptake	
is	over-adherence	to	urine	analysis,	with	people	
removed	from	OST	treatment	if	their	urine	is	found	
to contain illicit drugs(13)	–	a	theme	also	common	in	
some Australian states too.(10)	There	can	also	be	up	to	
a	six-month	wait	in	New	Zealand	to	access	an	OST	
service.(30)	However,	it	is	the	cost	of	prescriptions	that	
is	seen	to	be	the	primary	factor	deterring	people	who	
use drugs from turning to OST.(11)
Currently,	as	with	NSPs,	there	is	no	provision	of	OST	
in	the	PICTs.
Viral	hepatitis
Although	HIV	rates	among	people	who	inject	drugs	
in	both	Australia	and	New	Zealand	are	low,	HCV	
rates	have	remained	high	at	54%(2)	and	50%(6)	
respectively,	with	one	study	undertaken	in	Sydney	
finding	HCV	rates	as	high	as	62%.(21) Although there 
is	provision	for	HCV	testing	and	treatment	in	both	
countries,	the	cost	of	treatment	is	a	significant	barrier	
in	New	Zealand.(13)	In	Australia,	HCV	treatment	is	
relatively	affordable	and	available	on	a	government	
pharmaceutical	benefit	scheme.	Yet	it	is	thought	
that	only	1%	of	people	living	with	HCV	access	
treatment.(31)	As	with	HIV,	HCV	rates	have	also	
been	shown	to	be	notably	higher	among	Aboriginal	
and	Torres	Strait	Islander	populations	than	non-
Aboriginal	people	who	inject	drugs.(25)	Less	is	known	
about	hepatitis	B	in	Australia,	but	it	is	estimated	
that	approximately	50%	of	cases	(n=207,000)	are	
attributed	to	unsafe	injecting	drug	use.(32)
A	further	barrier	in	Australia	is	the	waiting	list	for	HCV	
treatment,	which	can	be	up	to	two	to	three	years.(10)	
There	are	also	restrictions	on	where	people	who	inject	
drugs	can	access	these	services,	as	they	are	often	
not	tailored	to	key	population	groups.(10)	It	has	been	
noted	that	HCV	government	expenditure	in	Australia	
is	inadequate,	and	represents	less	than	3%	of	harm	
reduction funding.(11)	Furthermore,	treatments	have	
been	linked	to	unpleasant	side	effects,	meaning	
uptake	can	be	low.	
In	New	Zealand,	it	is	thought	that	over	50,000	
people	have	been	exposed	to	HCV,	many	of	whom	
contracted	the	virus	through	unsafe	injecting	drug	
use.(30)	However,	provision	for	testing	and	treatment	
remains	extremely	low,	with	a	nurse	specialising	in	
HCV	visiting	only	once	a	month	in	one	area	of	New	
Zealand,	and	a	GP	testing	for	HCV	closing	down	due	
to	a	lack	of	funding.(30)	As	can	be	seen	from	these	
data,	there	is	strong	evidence	in	both	countries	of	the	
need	for	an	urgent	change	in	the	way	HCV	is	treated.
As	is	the	case	with	HIV	and	injecting	drug	use,	there	
is	little	to	no	data	on	hepatitis	in	the	PICTs,	and	further	
research on this is needed.
Tuberculosis
Tuberculosis	(TB)	rates	remain	extremely	low	in	both	
Australia	and	New	Zealand,	with	between	5	and	6	
cases	per	100,000	people	in	Australia(33)	and	10	cases	
per	100,000	people	in	New	Zealand.(34)	
HIV	is	seen	to	be	an	insignificant	contributor	to	TB	
in	New	Zealand,(23)	and	although	it	is	covered	to	
some	extent	in	harm	reduction	policies,(13)	there is no 
evidence	to	suggest	it	is	increasing	among	people	
who	inject	drugs.	This	finding	is	echoed	in	Australia,	
although there is little information on rates of TB 
infection	among	people	who	inject	drugs	both	in	
the	country	and	surrounding	PICTs.	However,	TB	is	
seen	to	be	of	increasing	concern	within	the	general	
population	of	Papua	New	Guinea.(8)
Antiretroviral	therapy
The	prevalence	of	HIV,	like	TB,	among	people	who	
inject	drugs,	remains	low	in	Australia	and	New	
Zealand,	at	1.2%(2)	and	0.2%(5) respectively.	However,	
as	stated	previously,	the	proportion	of	Aboriginal	
people	in	Australia	who	have	reported	transmission	
of	HIV	through	unsafe	injecting	drug	use	is	9%	higher	
than	non-Aboriginal	people	living	with	HIV	who	inject	
drugs.(12)
In	New	Zealand,	80%	of	people	living	with	HIV	are	
thought	to	be	receiving	antiretroviral	therapy	(ART).(23)	
There	are	thought	to	be	12,800	people	receiving	ART	
in Australia,(2)	although	it	is	unclear	how	many	of	them	
inject	drugs.	Many	PICTs	provide	access	to	ART,	but	
again	it	is	unclear	how	many	of	those	who	receive	
treatment also inject drugs, as there is little research 
available.
Harm reduction in prisons
Unsafe	injecting	practices	have	been	widely	reported	
in	Australian	prisons.	In	a	recent	study,	it	was	shown	
that	of	47,196	opioid-dependent	people,	37%	had	
experienced	at	least	one	episode	of	incarceration.(35) 
Approximately	one	in	three	people	who	inject	drugs	
who	were	incarcerated	reported	injecting	drug	use	in	
prison	in	all	years	between	2009	and	2013,(2) and in 
a	sample	of	415	prison	entrants	who	injected	drugs,	
HCV	was	prevalent	in	57.2%.(36)	The	prevalence	
of	HCV	has	consistently	been	higher	among	
respondents reporting imprisonment,(2)	highlighting 
an	important	need	for	harm	reduction	interventions	in	
Australian prisons.  
There	are	presently	no	NSP	services	available	in	
prisons	in	either	Australia	or	New	Zealand.	In	one	
prison	in	Canberra,	NSP	funding	had	been	provided	
by	local	government	and	a	model	had	been	agreed	for	
its	implementation.	However,	prison	staff	had	signed	a	
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workplace	agreement	that	NSP	services	would	not	be	
implemented	without	their	consent.	Negotiations	are	
currently	ongoing	with	staff	to	assess	the	options	for	
legally implementing an NSP.(10)	
In	Australia	and	New	Zealand,	OST,	ART	and	
condom	provision	are	available	in	prisons	in	most	
states.(10,13) There is little information on harm 
reduction	interventions	in	the	PICTs,	but	it	has	been	
reported that prisoners are not routinely screened on 
entry	into	prisons	in	Papua	New	Guinea	for	diseases	
such as TB and hepatitis.(17)
Overdose
There	were	279	cases	of	heroin-related	fatal	
overdose	reported	in	Australia	in	2013.(2)	Since	2012,	
Australia	has	implemented	naloxone	programmes	
on	a	pilot	basis	for	people	who	use	drugs	in	four	
states (Australian Capital Territory, Western Australia, 
Victoria	and	New	South	Wales),	and	evaluations	of	
the	peer-distribution	programmes	have	so	far	shown	
a high degree of success.(10)	There are also models 
of	naloxone	distribution	using	primary	healthcare	
workers	in	place.(11)	However,	both	programmes	face	
challenges in meeting demand.(11) Australia has a 
medically	supervised	injecting	centre	(also	known	as	
a	DCR	–	please	refer	to	Table	2.7.1),	which	provides	
sterile injecting equipment alongside a range of 
additional	services	for	people	who	inject	drugs.	It	has	
been	found	to	significantly	reduce	calls	to	ambulance-
attended	opioid-related	overdoses	in	the	small	area	
of	Sydney	where	it	is	located.(37)	In	2012,	after	more	
than	ten	years	of	positive	evaluations,	the	centre	has	
now	been	moved	from	a	pilot	programme	to	a	legal	
entity.(10)
In	New	Zealand,	no	overdose	prevention	programmes	
exist	in	the	form	of	naloxone	distribution	among	
peers.	Instead,	overdose	prevention	is	handled	
through	drug	helplines	and	emergency	services.(13)	In	
the	PICTs,	information	on	overdose	and	prevention	is	
unknown.
Policy	development	for	harm	reduction
In	Australia,	one	of	the	most	important	policy	changes	
in	recent	years	relates	to	HCV,	with	recognition	that	
prevention,	treatment	and	care	provision	varies	
for	key	populations,	and	recommendations	on	
improving	access	for	people	who	inject	drugs,	with	
particular	emphasis	on	those	within	prison	settings.(38) 
Within	the	2014–2017	HCV	strategy	there	are	also	
recommendations	for	NSP	services	to	become	
available	in	prison	settings,	and	for	further	peer-
led harm reduction programmes to operate among 
Aboriginal	and	Torres	Strait	Islander	people	due	to	
a	disproportionate	prevalence	of	HIV	and	HCV	in	
these communities.	(38) These policy changes are 
an	important	step	towards	recognising	the	impact	
of harm reduction programmes in the region, and 
understanding the shortcomings in Australia’s 
approach	to	reducing	HCV	transmission	among	
people	who	inject	drugs.
People	who	inject	drugs	are	mentioned	as	a	priority	
group	in	Australia’s	national	HIV	strategy,(39)	HCV	
strategy,(38)	hepatitis B strategy(32)	and	Aboriginal	and	
Torres	Strait	Islanders	blood-borne	viruses	strategy.(40)	
Civil	society	is	represented	on	committees	working	on	
drug	strategies	within	the	region.(10)
As detailed in The Global State of Harm Reduction 
2012,	the	New	Zealand	Law	Commission	produced	
144	recommendations	for	reforming	the	Misuse	of	
Drugs	Act	1975,(9) and	encouraged	greater	investment	
in harm reduction, education and addiction 
treatment,	amendment	of	drug	paraphernalia	laws	
and decriminalisation of small amounts of drug 
possession.(41)	
Within	the	PICTs,	in	countries	such	as	Fiji,	drug	
policy	strategies	are	closely	linked	to	mental	health	
promotional	activities,(42) and many responses to drug 
use	have	been	law	enforcement	rather	than	harm	
reduction centred.(19)	As	reported	in	2012,	a	lack	of	
research on injecting drug use in the region hampers 
policy reform.(9)
Civil	society	and	advocacy	
developments	for	harm	reduction
In	Australia,	civil	society	organisations	continue	to	
play	a	key	role	in	the	harm	reduction	response	for	
people	who	inject	and	use	drugs.	One	particular	
organisation,	the	Australian	Injecting	&	Illicit	Drug	
Users	League	(AIVL),	has	played	an	integral	role	in	
ensuring,	through	their	involvement	on	government	
committees, that harm reduction and policy 
reform	issues	have	been	heard.(10)	AIVL	is	currently	
conducting research and programming on stigma 
and	discrimination	towards	people	who	use	drugs,	
and	has	developed	a	training	module	focusing	on	
healthcare	workers,	social	workers,	university	and	
other	tertiary	students,	and	other	organisations	with	
the	potential	to	impact	on	the	lives	of	people	who	use	
drugs.(10)	
The	New	South	Wales	Users	and	AIDS	Association	
(NUAA)	has	developed	a	book	advocating	for	
NSPs	in	prisons,	incorporating	interviews	with	
people	who	have	been	imprisoned	to	inform	
their	advocacy.	The	Canberra	Alliance	for	Harm	
Minimisation	and	Advocacy	(CAHMA)	has	also	been	
integral	to	advocacy	for	NSP	services	in	a	prison	in	
Canberra.(10)	In	addition,	Australia	has	a	national	harm	
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reduction	network,	Anex,(43)	established	in	1995,	that	
promotes	evidence-informed	policy	and	practice,	
particularly in relation to NSPs, and also a national 
advocacy	organisation,	Family	and	Friends	for	Drug	
Law	Reform	(FFDLR).(44)
International	Overdose	Awareness	Day,	an	annual	
initiative	of	the	Pennington	Institute	in	Australia,	
highlights	the	need	for	greater	prevention	awareness	
around	the	issue	of	drug	overdose,	alongside	
remembrance	of	those	who	have	died.	This	event	has	
grown	since	2012	and	is	now	known	internationally.(11)	
In	New	Zealand,	civil	society	organisations	provide	
the	majority	of	advocacy	activities	for	people	who	
inject drugs.(13)	In	August	2013,	the	New	Zealand	
Drug	Foundation	gathered	together	almost	100	
people	representing	over	50	organisations	to	help	
reshape	New	Zealand’s	alcohol	and	drug	policy.	This	
culminated	in	the	Wellington	Declaration	for	better	
cooperation	and	collaboration	between	everyone	
affected	by	drugs	and	drug	policy.(45) 
The Global State of Harm Reduction 2012 reported 
on	the	PICTs’	more	visible	presence	in	civil	society	
forums,	but	noted	their	lack	of	engagement	in	regional	
forums	advocating	harm	reduction.(9) Although the 
PICTs	do	have	the	Pacific	Drug	&	Alcohol	Research	
Network	(PDARN),	the	last	meeting	was	held	in	
August	2011.(46)	There	has	been	a	small	increase	in	
research	in	these	territories,	but	further	data	gathering	
and	advocacy	should	be	undertaken	regarding	harm	
reduction	approaches	and	drug	use,	particularly	with	
the	increase	in	amphetamine-type	stimulants.	
Funding:	developments	for	harm	
reduction
Historically,	financial	support	for	harm	reduction	
services,	and	organisations	working	with	people	who	
inject	drugs,	has	been	provided	by	the	Australian	
federal	government.	However,	support	for	non-
governmental	organisations	and	advisory	boards	has	
diminished	since	the	recent	change	in	government,	
destabilising	the	future	of	the	harm	reduction	
response.	Furthermore,	the	department	of	foreign	
affairs	and	trade,	which	has	now	absorbed	the	
Australian	aid	development	programme,	has	recently	
received	significant	cuts	to	its	aid	budget.(10)	
AIVL,	the	main	representative	of	people	who	use	
drugs	in	Australia,	has	been	given	a	six	month	
extension	of	government	funding	for	its	programmes	
but	has	no	guarantee	of	ongoing	funding.(10)	
International/multilateral	funding	also	faces	an	
uncertain	future,	with	programmes	such	as	the	HIV/
AIDS	Asia	Regional	Program	(HAARP)	and	the	HIV	
Cooperation	Programme	for	Indonesia	(HCPI)	now	
coming to an end, and nothing in place for their 
continuation.(10)	In	a	2013	report	by	the	National	
Alcohol	and	Drug	Research	Centre,	it	was	found	that	
actual	spending	on	harm	reduction	has	been	greatly	
reduced in Australia,(47)	a	troubling	fact	considering	its	
history and success in reducing the harms for people 
who	inject	drugs.
1072.7 Oceania
1.	 Australian	Institute	of	Health	and	Welfare.	2010 National Drug Strategy Household Survey Report.	Canberra:	2011.
2.	 Iversen	J,	Maher	L.	Australian Needle and Syringe Program National Data Report 2008-2012.	The	Kirby	Institute,	University	of	New	South	Wales:	2013.
3.	 Australian	Institute	of	Health	and	Welfare.	National	opioid	pharmacotherapy	statistics	2013.	Drug Treatment Series	23.	Canberra:	2014.
4.	 New	Zealand	Ministry	of	Health.	The 2007/08 New Zealand Alcohol and Drug Use Survey: online data tables.	[Online].	2010.	Available	from:	http://www.health.
govt.nz/publication/2007-08-new-zealand-alcohol-and-drug-use-survey-online-data-tables	[Accessed	9th	October	2014].
5. New	Zealand	Doctor.	Study shows lowest HIV rates ever among injecting drug users in New Zealand.	[Online].	2014.	Available	from:	http://www.nzdoctor.co.nz/
news/2014/july-2014/22/new-zealand-intravenous-drug-users-have-lowest-hiv-rate-ever.aspx	[Accessed	9th	October	2014].
6. UNODC.	World Drug Report 2014.	Vienna:	2014.
7.	 Needle	Exchange	Programme.	Informative information.	[Online].	2014.	Available	from:	http://www.needle.co.nz/informative_info.html/189	[Accessed	11	
November	2014].
8. Vumbaca	G.	Global State of Harm Reduction 2014 Survey Response.	Australian	National	Council	on	Drugs:	28	May	2014.
9. Stoicescu C. The Global State of Harm Reduction 2012: Towards an Integrated Response.	London:	2012.
10.	 Morrison E. Global State of Harm Reduction 2014 Survey Response.	Australian	Injecting	&	Illicit	Drug	Users	League:	23	June	2014.
11.	 Ryan	J.	Global State of Harm Reduction 2014 Survey Response.	Penington	Institute:	22	October	2014.
12.	 The	Kirby	Institute.	HIV, Viral Hepatitis and Sexually Transmissible Infections in Australia: Annual Surveillance Report 2013.	Sydney:	2013.
13.	 Henderson C. Global State of Harm Reduction 2014 Survey Response.	New	Zealand	Needle	Exchange	Programme:13	August	2014.
14.	 WHO,	UNAIDS,	UNICEF.	Global HIV/AIDS Response: Epidemic Update and Health Sector Progress Towards Universal Access. Progress Report 2011.	Geneva:	
2011.
15.	 Puamau	ES,	Roberts	G,	Schmich	L,	Power	R.	Drug	and	alcohol	use	in	Fiji:	a	review.	Pacific Health Dialogue.	2011;17(1):165-71.
16.	 McDonald	D.	A	rapid	situation	assessment	of	drug	use	in	Papua	New	Guinea.	Drug and Alcohol Review.	2005;24(1):79-82.
17.	 Kelly	A,	Mathers	B,	Kawage	T,	Vallely	A.	Emerging HIV Risk in Papua New Guinea. Two Assessments: Alcohol and Injecting and Other Drug Use, and HIV Risk, 
Prevention, Treatment and Care in Closed Settings.	Papua	New	Guinea	Institute	of	Medical	Research:	2012.
18.	 Odden	HL.	Alcohol,	tobacco,	marijuana	and	hallucinogen	use	in	Samoan	adolescents.	Drug and Alcohol Review.	2012;31(1):47-55.
19.	 TB	Institute.	Situational analysis of drug and alcohol issues and responses in the Pacific 2009-09.	Canberra:	2010.
20.	 Topp	L,	Day	CA,	Iversen	J,	Wand	H,	Maher	L,	Collaboration	of	Australian	NSPs.	Fifteen	years	of	HIV	surveillance	among	people	who	inject	drugs:	the	Australian	
Needle	and	Syringe	Program	Survey	1995-2009.	AIDS.	2011;25(6):835-42.
21.	 Islam	MM,	Topp	L,	Conigrave	KM,	Haber	PS,	White	A,	Day	CA.	Sexually	transmitted	infections,	sexual	risk	behaviours	and	perceived	barriers	to	safe	sex	among	
drug users. Australian and New Zealand Journal of Public Health.	2013;37(4):311-5.
22.	 Dunn	M,	McKay	FH,	Iversen	J.	Steroid	users	and	the	unique	challenge	they	pose	to	needle	and	syringe	program	workers.	Drug and Alcohol Review. 
2014;33(1):71-7.
23.	 UNAIDS.	Global AIDS Response Progress Reporting: New Zealand.	2014.
24.	 UNESCO.	A Situation-Response Analysis of the Education Sector’s Response to HIV, Drugs and Sexual Health in Timor-Leste June 2012.	Jakarta:	2012.
25.	 Wilson	D,	Kwon	A,	Anderson	J,	Thein	H,	Law	M,	Maher	L,	et	al.	Return on investment 2: Evaluating the cost-effectiveness of needle and syringe programs in 
Australia.	National	Centre	in	HIV	Epidemiology	and	Clinical	Research:	2009.
26.	 Kwon	JA,	Anderson	J,	Kerr	CC,	Thein	HH,	Zhang	L,	Iversen	J,	et	al.	Estimating	the	cost-effectiveness	of	needle-syringe	programs	in	Australia.	AIDS. 
2012;26(17):2201-10.
27.	 Islam	MM,	Shanahan	M,	Topp	L,	Conigrave	KM,	White	A,	Day	CA.	The	cost	of	providing	primary	health-care	services	from	a	needle	and	syringe	program:	a	case	
study. Drug and Alcohol Review.	2013;32(3):312-9.
28.	 Rowe	J.	A Raw Deal? Impact on the Health of Consumers Relative to the Cost of Pharmacotherapy.	Melbourne:	2008.
29.	 Deering	DE,	Sheridan	J,	Sellman	JD,	Adamson	SJ,	Pooley	S,	Robertson	R,	et	al.	Consumer	and	treatment	provider	perspectives	on	reducing	barriers	to	opioid	
substitution	treatment	and	improving	treatment	attractiveness.	Addictive Behaviors.	2011;36(6):636-42.
30.	 New	Zealand	Drug	Foundation.	Where there is life, there is hope.	[Online].	2013.	Available	from:	http://www.drugfoundation.org.nz/matters-of-substance/where-
there-is	[Accessed	10	October	2014].
31.	 Hepatitis Australia. Providing ready access to new hepatitis C treatments.	Australia:	2014.	Available	from:	http://static.squarespace.com/
static/50ff0804e4b007d5a9abe0a5/t/52ca335fe4b0ef830a2404d6/1388983135971/Providing%20ready%20access%20to%20new%20hepatitis%20C%20
treatments%202014-01%20(revised_HT).pdf	[Accessed	9	October	2014].
32.	 Australian	Government	Department	of	Health.	Second National Hepatitis B Strategy 2014-2017.	Canberra:	2014.
33.	 Lumb	R,	Bastian	I,	Carter	R,	Jelfs	P,	Keehner	T,	Sievers	A.	Tuberculosis	in	Australia:	bacteriologically	confirmed	cases	and	drug	resistance,	2010.	A	report	of	the	
Australian	Mycobacterium	Reference	Laboratory	Network.	Communicable Diseases Intelligence Quarterly Report.	2013;37(1):E40-6.
34.	 New	Zealand	Ministry	of	Health.	Guidelines for Tuberculosis Control in New Zealand 2010.	Wellington:	2010.
35.	 Degenhardt	L,	Larney	S,	Gisev	N,	Trevena	J,	Burns	L,	Kimber	J,	et	al.	Imprisonment	of	opioid-dependent	people	in	New	South	Wales,	Australia,	2000–2012:	a	
retrospective	linkage	study.	Australian and New Zealand Journal of Public Health.	2014;38(2):165-70.
36.	 Reekie	JM,	Levy	MH,	Richards	AH,	Wake	CJ,	Siddall	DA,	Beasley	HM,	et	al.	Trends	in	HIV,	hepatitis	B	and	hepatitis	C	prevalence	among	Australian	prisoners	-	
2004,	2007,	2010.	Medical journal of Australia.	2014;200(5):277-80.
37.	 Salmon	AM,	van	Beek	I,	Amin	J,	Kaldor	J,	Maher	L.	The	impact	of	a	supervised	injecting	facility	on	ambulance	call-outs	in	Sydney,	Australia.	Addiction. 
2010;105(4):676-83.
38.	 Australian	Government	Department	of	Health.	Fourth National Hepatitis C Strategy 2014-2017.	Canberra:	2014.
39.	 Australian	Government	Department	of	Health.	Seventh National HIV Strategy 2014-2017.	Canberra:	2014.
40.	 Australian	Government	Department	of	Health.	Fourth National Aboriginal and Torres Strait Islander Blood-borne	Viruses and Sexually Transmissible Infections 
Strategy 2014-2017.	Canberra:	2014.
41.	 New	Zealand	Law	Commission.	Controlling and Regulating Drugs: A Review of the Misuse of Drugs Act 1975.	Wellington:	2011.
42.	 Veitata	L.	Global State of Harm Reduction 2014 Survey Response.	Ministry	of	Health,	Fiji:	28	May	2014.
43.	 Anex.	Home.	[Online].	2014.	Available	from:	www.anex.org.au	[Accessed	30	October	2014].
44.	 Families	and	Friends	for	Drug	Law	Reform.	About us.	[Online].	2014.	Available	from:	http://www.ffdlr.org.au/	[Accessed	11	November	2014].
45.	 New	Zealand	Drug	Foundation.	Reshaping New Zealand’s Alcohol and other Drug Policy Declaration. [Online].	2013.	Available	from:	http://www.drugfoundation.
org.nz/wellington-declaration	[Accessed	14	October	2014].
46.	 PDARN. Meetings: 2011.	[Online].	Available	from:	http://www.pdarn.org/meetings.html	[Accessed	14	October	2014].
47.	 Ritter	A,	McLeod	R,	Shanahan	M.	Government	drug	policy	expenditure	in	Australia	–	2009/10.	Drug Policy Modelling Program Monograph 24.	Sydney:	2013.
References
108 Global State of Harm reduction
Middle East and North Africa2.8
ReGional oveRview
109
110 Global State of Harm reduction
Table 2.8.1: Epidemiology of HIV and viral hepatitis, and harm reduction in the Middle East and North Africa
Country/
territory
with reported
injecting
drug use
People who
inject drugs
Hiv prevalence
among people
who inject drugs
(%)
Hepatitis C (anti-
HCv) prevalence
among people
who inject drugs
(%)i
Hepatitis B
(anti-HBsag)
prevalence among
people who  
inject drugs 
(%)ii
Harm reduction response
nSPiii oSTiv
algeria nk nk nk nk x x
bahrain nk 55.8(1)v nk nk x  (m)vi
egypt 100,000(2) 6.5–6.8(3) 49.4 (35.8–63) 13.5 (10.9–16) (11)(4)vii x
iran 185,000(5) 15.07(6) 50.2 (34.5–65.9) 17.3 (3.7–30.9) (682)(4, 6) (4275)(6)
iraq 34,673(7)viii nk nk nk x (P) x
israel nk nk 67.6 2.8 (0.-5.5) (5)(8)  (b.m)
Jordan nk 6(9) nk nk (2)(4)ix x
Kuwait nk nk nk nk x x
lebanon nk 1(10) 52.8(11) nk (2)(4)x xi 
libya 7,206(7)xii 87(12)xiii 94(12) 5(12) x x
morocco 18,500(13)xiv 11.4(2) 51(14) nk (>8)(15) (6)(15) (m)
oman nk 3.8(16)xv nk nk x x
Palestine nk 0(3) nk 1(17) (1)(18) x
Qatar nk nk nk nk x x
Saudi arabia 10,000(19) 3.5(20)xvi 49.8 (14.1–85.4)(15) 18.5(17) x x
Syria 10,000(17) nk 60.5(15) nk x x
tunisia 9,000(2) 3(2) nk nk (3)(8) x
united arab 
emirates (uae)
nk nk nk nk x (m)xvii 
Yemen nk nk nk nk x x
 
i Unless otherwise stated, data is sourced from Nelson et al. (2011) Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet, 378(9791) 
pp.571-83 
ii Unless otherwise stated, data is sourced from Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject 
drugs: results of systematic reviews. Lancet. 2011;378(9791):571-83.
iii	 This	includes	all	operational	NSP	sites,	including	fixed	sites,	vending	machines	and	mobile	NSPs	operating	from	a	vehicle	or	through	outreach	workers.
iv (M) = methadone, (B) = buprenorphine, (O) = any other form (including morphine and codeine).
v People who inject drugs are only reached through post-rehabilitation or prison programmes (n=244), which may not be representative of the total number of people who inject drugs.
vi Methadone is only available in rehabilitation facilities.
vii  Figure does not relate to the number of sites but the 11 known organisations providing NSPs in Egypt.
viii  Based on a literature review between 1998 and 2005. 
ix Figure does not relate to the number of sites but the two known organisations providing NSPs in Jordan.
x	 Figure	does	not	relate	to	the	number	of	sites	but	the	two	known	organisations	providing	NSPs	in	Lebanon.
xi OST only available in the ministry of health.
xii  Based on a literature review between 1998 and 2005.
xiii  Based on sub-national data in the city of Tripoli.
xiv	 	This	figure	has	been	queried	by	civil	society	organisations	as	ranges	vary	from	5,000	to	18,500.
xv	 	This	figure	has	been	queried	by	civil	society	organisations	as	there	are	great	discrepancies	in	data	published	by	other	organisations.
xvi	 	2013	data	from	three	detoxification	centres	in	Riyadh,	Jeddah	and	Daman,	which	may	not	be	representative	of	the	total	number	of	people	who	inject	drugs.
xvii  Methadone is only available in rehabilitation facilities.
Middle East and North Africa
1112.8 Middle East and North Africa
MOROCCO
LEBANON
BAHRAIN
ALGERIA
LIBYA EGYPT
SAUDI ARABIA
IRAN
YEMEN
OMAN
IRAQ
SYRIATUNISIA JORDAN
ISRAEL
UAE
QUATAR
PALESTINE
KUWAIT
Both NSP and OST available
OST only
NSP only
Neither available
Not known
DCR available
Map 2.8.1: Availability of needle and syringe exchange programmes (NSP) and opioid substitution therapy (OST)
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The Middle East and North Africa (MENA) is a 
region where HIV infections continue to rise.(2) Within 
MENA,	people	who	inject	drugs,	men	who	have	sex	
with	men	and	female	sex	workers	are	still	the	most	
affected groups in terms of HIV, hepatitis C (HCV) 
and hepatitis B (HBV) infection.(2) Although the region 
has seen an increase in HIV research,(21) there is still 
a lack of reliable size estimates for populations who 
inject drugs in most countries, and the availability of 
evidence remains weak.
An estimated 626,000 people inject drugs in MENA 
(range 335,000–1,635,000),(5) with injecting drug use 
appearing as the primary mode of transmission of HIV 
in Bahrain,(1) Iran(6) and Libya.(22) With 80% of the global 
opium production occurring in Afghanistan,(13) and 
the price of heroin markedly lower than in other parts 
of the world,(13) the geographical location of many of 
the surrounding territories means that injecting drug 
use remains high. In recognition of this, there have 
been	significant	policy	developments	and	a	scale	
up of harm reduction programmes since 2010, with 
the	Middle	East	and	North	Africa	Harm	Reduction	
Association	(MENAHRA)	being	a	central	catalyst	for	
increased government and civil society attention 
around the issue. 
Although there is a high prevalence of people 
who inject drugs in the region, there are highly 
heterogeneous	findings	in	terms	of	the	distribution	
geographically in certain countries.(5) For	example,	
prevalence of drug use in Iran is the highest in the 
region	at	approximately	185,000.(5) However,	the	figure	
is estimated to be 0% in some areas(23) and as high as 
44.7% in others.(24)	Libya	has	an	extremely	high	rate	
of	HIV	attributed	to	unsafe	injecting,	but	these	figures	
relate only to Tripoli.(12) In Morocco, many of the data 
relating to the prevalence of HIV among people who 
inject drugs is concentrated in the northern part of 
the	country,	with	figures	reaching	17.9%.(25) This is 
considerably	higher	than	the	national	figure	of	11.4.(2) 
The above evidence suggests that, although data 
gathering regarding injecting drug use and HIV/
hepatitis surveillance in the region has greatly 
improved, there are still wide gaps in knowledge.(3) 
There also appears to be a greater gender division in 
MENA countries than in other parts of the world, with 
the most common route of HIV among males (82%) 
in people who inject drugs in Iran, and 18.5% HIV 
transmission as the most common rate among men 
who inject drugs in Tunisia.(26) Again, this may not be 
representative of the whole region, but it is important 
to note in terms of tailored responses for women who 
may not be accessing services.
The sharing of needles and syringes is also highly 
variable within the MENA region. Although there is 
little information on injecting drug use in Palestine, 
a bio-behavioural survey undertaken in 2010 found 
that among 199 people who inject drugs, 90.4% 
reported	using	sterile	injecting	equipment	last	time	
they injected(27) – a similar number to those in Iran, 
at 91.72%.(6) These two countries appear in the top 
quartile	in	terms	of	safe	injecting	practices.	However,	
in Morocco, a study undertaken in 2005 reported 
that 63.9% of people who inject drugs would share 
syringes,(28) and in Egypt only 45.5% of people who 
inject	drugs	reported	using	sterile	injecting	equipment	
in 2013.(29) 
There is currently limited data on people who inject 
drugs in Bahrain, with information from mandatory 
testing on admission to rehabilitation facilities in 
2011	finding	4.6%	HIV	prevalence	among	people	
who inject drugs.(1) A survey of university students in 
2006 found that 25% of a sample of 2,200 shared 
needles. However, there is no provision for needle and 
syringe programmes (NSPs) and opioid substitution 
therapy (OST) in the country, and current interventions 
for people who use drugs are abstinence based, 
with clean needles and syringes only available from 
pharmacies on prescription.(1) There is limited research 
done among key populations in Kuwait, Oman, 
Saudi Arabia, Syria, Yemen, Lebanon and Jordan.(4,5) 
However, in places such as the Amman region in 
Jordan, unsafe injecting drug use is reported.(9) 
Information from focus groups in Kuwait shows that 
unsafe injecting drug use is present,(30) and at the 
end of 2013 there was an estimated 3.8% rate of 
HIV prevalence among people who inject drugs in 
Oman.(16) In the Daman district of Saudi Arabia, there 
was an estimated 3.5% rate of HIV prevalence among 
people who inject drugs.(20) With	figures	such	as	these	
emerging in MENA territories and no harm reduction 
interventions in place, it seems imperative that further 
research is undertaken alongside the scale up of harm 
reduction services to limit the transmission of viruses 
such as HIV and hepatitis.
There has been a steady increase in use of 
amphetamine-type stimulants (ATS) among people 
who use drugs noted in Iran.(6,31) This is not only 
leading to health problems, but also negatively 
affecting the use of methadone for treatment 
among	people	who	inject	drugs	(specifically	heroin)	
by ameliorating some of the side effects such 
as	psychological	energy,	sexual	functioning	and	
cognitive performance.(31) In a study of prisoners 
in Iran undertaken in 2012/2013, it was found that 
11.6% of prisoners had used ATS within the last 
month and 27.98% of those had injected.(6) ATS 
seizures have also been reported in Jordan, Saudi 
Arabia, Lebanon and Syria,(4, 13) indicating a need for 
further mapping and research to understand ATS use 
and appropriate responses to it. 
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Developments in harm reduction 
implementation
Needle	and	syringe	exchange	programmes	(NSPs)
Iran	has	consistently	experienced	the	highest	rate	
of HIV prevalence in the region,(32,33) and prevalence 
rates remain high in 2014.(6) Although clean needle 
and syringe provision has doubled since 2012 (from 
6,022,834 in 2012 to 12,626,021 in 2014), funding 
for harm reduction activities seems to have slowed 
down,(4,6) which appears contradictory to coverage 
reports. In 2012, The Global State of Harm Reduction 
reported that coverage of needle and syringes was 
between 26 and 35 per person who injects drugs per 
year.(8) This has since increased to between 55 and 
77.(6) This evidence therefore contradicts the steady 
increase in rates of HIV among people who inject 
drugs. Unless others factors are at play that have not 
been	identified,	such	as	sexual	risk	behaviours	or	an	
increase in refugees who inject drugs unsafely, it is 
difficult	to	ascertain	the	facts	about	infection	rates	
among this population in Iran.
There has been no change in the number of 
countries providing NSP services in MENA since 
2012.(32) Although a previous pilot NSP in Oman 
is	no	longer	operating,	MENAHRA	initiated	a	pilot	
NSP and condom distribution service in the Jarash 
area of Jordan through Friends of Development and 
Investment Society (FDIS) in 2012. This pilot has 
since	expanded	to	areas	outside	of	the	main	city,	
as well as in Amman and other surrounding areas 
during 2014 through the Forearms of Change Center 
to Enable Community.(4)	In	2012,	MENAHRA	provided	
a four-month grant to the Association of Friends of 
HIV+ (FHIV+), an Egyptian organisation in the Minya 
governorate. During this period, the organisation 
distributed 5,995 clean needles and syringes.(4) 
Funding in Egypt was then halted for two years while 
the volatile situation in the country interrupted service 
delivery. Then in August 2014, FHIV+ and two other 
organisations	were	funded	through	MENAHRA	to	
implement NSP distribution outreach activities in the 
governorate of Minya and in greater Cairo.(4) 
In early 2012, plans were underway to operate a 
pilot NSP service in Syria, with funding through the 
Global Fund,(32) but this has been postponed due 
to the security situation in the country.(4) There is 
little published data on Lebanon, but NSP services 
are thought to be in operation,(32) with reports from 
Soins	Infirmiers	et	Développement	Communautaire	
(SIDC), a non-governmental organisation (NGO) 
in Lebanon providing this service, indicating that 
coverage	was	extremely	low,	at	approximately	1.6	
clean syringes per person per year.(8) Between 2012 
and 2014, two organisations in Lebanon, SIDC and 
Skoun, distributed over 16,000 syringes to people 
who inject drugs.(4) In Tunisia, there are three NSP 
sites in operation, with 142 people who inject drugs 
accessing the service and 3,944 clean syringes 
distributed	during	a	six-month	period	in	2013.(4) 
NSP services also operate in Morocco,(34) Israel and 
Palestine, but there is limited information on these 
programmes. In one study of 211 people who inject 
drugs in Morocco, it was found that 85.2% of them 
shared needles and syringes,(34) highlighting the need 
for scale up of NSP provision. 
Although the primary mode of HIV transmission in 
Bahrain is unsafe injecting drug use, there is no NSP 
provision in the country.(1) People who inject drugs 
in Bahrain are reached through post-rehabilitation 
or prison programmes, and the services offered are 
abstinence based.(1) In Kuwait, the rate of sharing 
of needles and syringes is thought to be high. 
However, the only services available for people who 
inject	drugs	are	detoxification	and	rehabilitation	at	
the Addiction and Psychiatric Hospital, which is 
insufficient	compared	to	need.(30) In Qatar, according 
to	government	figures,	only	18	cases	of	HIV	have	
been reported among the whole population.(35) In 
Saudi Arabia, there is evidence of injecting drug use 
but there are no NSPs in operation in the country. 
The same is true of the United Arab Emirates, Algeria, 
Yemen,	Iraq	and	Kuwait.
Barriers to accessing NSP services in countries where 
there is availability are similar to those found in other 
regions, with low coverage in rural areas, cultural 
stigma related to injecting drug use (particularly 
experienced	by	women	who	inject	drugs),	and	a	fear	
of arrest due to punitive laws.(4)
Opioid substitution therapy (OST)
Six	MENA	countries	provide	OST	to	different	degrees:	
Bahrain, Iran, Israel, Lebanon, Morocco and United 
Arab Emirates. In some countries such as Bahrain(1) 
and the United Arab Emirates,(36) OST is only available 
through	detoxification	and	rehabilitation	facilities,	
with people who inject drugs being reached through 
post-rehabilitation or prison programmes. In other 
countries, OST provision is not based on punitive 
measures	or	rehabilitative/detoxification	programmes.	
The	best	example	of	this	is	Iran,	where	OST	is	offered	
to people who inject drugs in 4,275 centres, 4,038 of 
which are privately operated.(4,6) This represents an 
increase of 902 sites since 2012.(32) However, there 
remains	a	need	to	expand	OST	services	to	meet	
increasing	demand	within	the	country,	and	to	find	
a	solution	to	the	shortage	of	financial	and	human	
resources for OST provision.(4)  
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In Lebanon, multiple OST services have been funded 
by	MENAHRA	since	2012	and	provided	through	
Skoun and SIDC. Since 2012, Lebanon has included 
OST provision for people who inject drugs within its 
national strategic plan, with the service dispensed 
by the ministry of health. There are currently over 
1,000 people who inject drugs receiving OST in 
the form of Buprenorphine in Lebanon.(4,37) There is 
limited information on OST programmes in Israel. 
In	Morocco,	there	are	six	OST	sites	operational(15) 
accessed	by	approximately	300	people	who	inject	
drugs.	Since	over	1,000	requests	have	been	made,(38) 
a further three OST sites are planned in the country 
in response.(15) Kuwait is due to begin a pilot OST 
service in 2014,(4,30) and government permission has 
been given to begin a pilot OST service in Oman.(16)
In	2014,	the	United	Nations	Office	on	Drugs	
and Crime (UNODC) convened a national opioid 
substitution therapy taskforce, commissioning a 
feasibility study to select, approve and procure the 
most appropriate controlled substances for piloting 
OST in Egypt. In preparation for introducing this 
service to people who inject drugs, training of service 
providers	across	six	governorates	in	Egypt	has	been	
initiated.(29)  
Although bio-behavioural surveillance of people who 
inject drugs has improved in the MENA region, actual 
coverage	estimates	for	OST	provision	are	still	difficult	
to	ascertain.	Iran	is	the	only	exception	to	this,	with	an	
estimated 64,000 people receiving OST.(6) Barriers to 
accessing OST services remain throughout the region, 
with fear, stigma and discrimination surrounding 
people who use drugs, together with criminalisation 
by governments.(4,38) To combat some of the stigma 
that	women	who	inject	drugs	may	encounter,	five	
pilot centres were established in Iran in 2007 offering 
the	management	of	sexually	transmitted	infections	
(STIs), psychological counselling and harm reduction 
services, provided by female staff.(39) A follow-up 
study	six	months	later	found	that	those	using	the	
service had responded well and showed a reduction 
in HIV risk behaviour.(40) Although it was reported that 
the	female-specific	programmes	had	been	expanded	
to 27 sites in 2012,(32) it is not known whether they are 
still	in	existence.
Viral hepatitis
There is little data on the prevalence of viral hepatitis, 
either HCV or HBV, among people who inject drugs in 
MENA.	The	figures	in	Table	2.8.1	date	from	estimates	
taken in 2008, with some estimates dating back to 
1988/89 (e.g. Israel).(17) Morocco has the most up-
to-date HCV estimate from a study undertaken in 
2010, but is based on sub-regional data in northern 
Morocco only.(14) The eight countries that do have 
available data, although unlikely to be representative 
of present rates of infection among people who inject 
drugs, had HCV prevalence close to 40% and above. 
The majority of countries in the region have a viral 
hepatitis	policy,	with	the	exception	of	Algeria,	Libya	
and Yemen. However, only Bahrain, Kuwait and Iran 
specifically	mention	services	targeted	at	people	who	
inject drugs.(4,38,41) 
In the United Arab Emirates, 44% of people who 
inject drugs who were admitted to the national 
rehabilitation centre tested positive for HCV,(42) and 
data from the two main drug treatment centres in 
Jordan showed prevalence rates among people who 
use drugs at 5.4% for HCV and 0.6% for HCB.(9) In 
the East Jerusalem governorate region of Palestine, 
a biological behavioural survey in 2010 among 199 
people who inject drugs found that 40.3% tested 
positive for HCV.(27) However, treatment availability 
for people who inject drugs is these countries 
remains	unclear.	Bahrain,	Egypt,	Iraq,	Jordan,	Kuwait,	
Lebanon, Qatar and Syria do have publicly funded 
HCV treatment.(4) A treatment clinic for HCV has 
been recently introduced at the Mubarak hospital in 
Kuwait,(30) but whether it can be accessed by people 
who inject drugs is unknown.
HCV	diagnosis	and	treatment	is	a	significant	issue	
for people who inject drugs in Egypt.(43) However, 
with an estimated 10% of the population living 
with the disease (8–10 million people), and unsafe 
injecting practices among people who use drugs 
contributing to increasing numbers, WHO launched 
a new global injection safety initiative in December 
2014.(44) Together with provision of new, affordable 
treatment, the initiative will hopefully have an impact 
on hepatitis rates for people who inject drugs in the 
region. However, an urgent need remains for data on 
viral hepatitis among people who inject drugs in the 
MENA region.
Tuberculosis
Like hepatitis, there is very little data on tuberculosis 
(TB) among people who inject drugs in MENA. As 
far as we are aware, only one recent study has been 
undertaken in the region looking at the burden of 
HIV	among	TB	patients	since	2007,	finding	a	3.8%	
rate of HIV co-infection among 3,133 patients in Iran 
and 1.6% HIV co-infection in Yemen.(26) In 2011, data 
from Libya indicated 731 new TB cases, 128 of which 
included	HIV	co-infection.	In	2010,	approximately	
14,000 people were affected by TB, but it is not 
known what proportion of these cases is attributable 
to unsafe injecting drug use.(8)
According to UNAIDS 2011 Universal Access 
Reporting,	coverage	of	treatment	for	people	with	TB/
HIV co-infection in MENA ranges from less than 10% 
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in	five	countries,	to	between	25%	and	55%	in	another	
four, to nearly full coverage in Oman and Algeria.(25) 
There is believed to be routine testing of TB in Algeria 
and Syria, and TB screening for people living with 
HIV in Bahrain, Egypt, Iran, Jordan, Morocco, Oman, 
Saudi Arabia and the United Arab Emirates,(4) but 
there is little evidence on TB testing and treatment 
services tailored for people who inject drugs. Further 
data is needed on the levels of TB among people 
who inject drugs in MENA to assist with developing 
an appropriate harm reduction response that is 
integrated	into	existing	services.
Antiretroviral	therapy	(ART)
Data on HIV prevalence, testing and antiretroviral 
therapy	(ART)	in	the	region	is	mostly	based	on	
detoxification	centres,	police	registers	and	prison	
records.	As	a	result,	available	figures	in	many	MENA	
countries tend to be underestimates or susceptible 
to	reporting	bias.	ART	provision	has	not	increased,(2) 
despite a steady rate of HIV among people who 
inject drugs within the region. There are currently an 
estimated	19,424	adults	receiving	ART,(2) although 
rates	of	ART	provision	among	people	who	inject	
drugs is unknown. 
Coupled with this is the relative lack of information 
on HIV prevalence among people who inject drugs. 
In Egypt in 2010, 6.8% of people who inject drugs in 
Cairo were found to have contracted HIV, and 6.5% 
in	Alexandria	were	HIV	infected.	Lower	rates	of	2.4%	
HIV prevalence among people who inject drugs were 
observed in Tunisia in 2011 (0–2.7%), while surveys 
undertaken in Jordan, Lebanon and Palestine found 
no HIV cases among people who inject drugs.(26) In 
Morocco, people who inject drugs were thought to 
contribute to 7% of new HIV injections.(45) In Egypt 
1,171	people	were	receiving	ART	in	2013,(29) but it 
is not known how many of them were injecting. In 
Kuwait, people who inject drugs are only tested for 
HIV when arrested or admitted to the addiction and 
psychiatric hospital, and an HIV diagnosis often does 
not result in counselling in these services.(30) In Oman, 
there	are	15	sites	at	which	people	can	access	ART	
treatment, with an estimated 821 people receiving 
ART	in	2013.(16) In	Lebanon,	ART	is	not	available	for	
people who inject drugs unless they are on OST.(4)
Voluntary counselling and testing (VCT) is available 
in several MENA countries. However, most of these 
services	do	not	specifically	target	people	who	inject	
drugs. In Algeria, 68,779 individuals were tested for 
HIV in 2013, but the proportion who were injecting 
drugs is unknown.(4) In Lebanon, VCT is available 
through a mobile unit of the organisation SIDC, as 
well as 60 VCT centres around the country run by 
NGOs.(4) VCT is also available in Egypt, and 29% of 
newly reported cases of HIV in 2012 were found to 
be among people who inject drugs.(46) In Jordan, VCT 
is available and there are plans to offer this service 
within the newly implemented NSP service.(4) In 
Morocco, VCT uptake has increased from 70 in 2010 
to 385 in 2013, although VCT coverage for people 
who inject drugs remains limited.(4)
Like	NSP	and	OST	provision,	even	where	ART	or	VCT	
services are available, people who inject drugs often 
face barriers to accessing them, such as a fear of 
breach	of	confidentiality	and	stigma	related	to	drug	
use. 
Harm reduction in prisons
Punitive drug laws in much of the MENA region 
means a high proportion of people who use drugs 
are incarcerated. However, information on injecting 
drug use among the prison population is limited. In 
2005, a study found that 45.9% of people who inject 
drugs had a history of incarceration for drug use, and 
19.8% had unsafely injected drugs while in prison.(28) 
In 2010, Iran reported HIV prevalence among people 
imprisoned for injecting drug use as 5.42%,(6) yet it is 
the only country in the region that has an NSP service 
available.(47) It is also the only country that provides 
OST in prisons, with 40,000 prisoners receiving 
access.(6) However, since an estimated 120,000 need 
OST,	an	expansion	of	this	service	is	required	in	Iranian	
prisons.(6) In Morocco, an OST pilot programme was 
initiated in one prison in 2013,(15) and in Lebanon 
there are plans to initiate OST services in the prison 
setting(4,10,48) 
In Egypt between 2009 and 2012, a Drosos 
Foundation-funded project, in collaboration with the 
Egyptian ministries of interior affairs, health and social 
affairs, launched four VCT sites inside four Egyptian 
prisons as part a call to improve HIV prevention 
among prison populations.(4) However, generally within 
the	region,	access	to	ART	provision	varies	greatly.	In	
Algeria, although there is testing and treatment for 
STIs	in	prisons,	there	is	no	specific	mention	of	ART.(49) 
In	Bahrain,	eligible	prisoners	are	provided	with	ART	
through a link to a central hospital,(1) and there is 
ART	provision	for	the	prison	population	in	Jordan,(9) 
Iran(6) and Lebanon.(10) Although	ART	is	available	in	
Kuwait, Oman, the United Arab Emirates and Yemen, 
it is uncertain whether prisoners have access to 
treatment.	Libya	also	provides	ART,	but	due	to	the	
volatile situation in the country, supplies are thought 
to be limited for the general population, indicating 
that vulnerable populations may not have access to 
ART.(4) In terms of condom provision, as far as we are 
aware only Algeria and Iran supply condoms within 
the prison setting.(6,49)
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Overdose
Data on the occurrence of fatal and non-fatal 
overdose	remain	extremely	limited	in	the	region,	and	
responses	to	overdose	limited.	Naloxone,	a	highly	
effective opioid antagonist that reverses the effect of 
overdose, is not available for peer distribution in the 
community in any of the MENA countries. However, 
isolated initiatives addressing overdose as part of 
broader interventions have been documented in some 
instances. 
Policy development for harm reduction
Although monitoring of injecting drug use has 
improved marginally in the region, many MENA 
countries	still	make	no	explicit	mention	of	harm	
reduction in their national strategies. Algeria’s national 
strategic plan does not refer to harm reduction,(49) 
and it is also absent from Bahrain’s national strategy.
(1) In Oman and Kuwait, there is also presently no 
mention of harm reduction, but there are plans to 
revise these documents to include key populations, 
including people who inject drugs.(4) In Jordan(9) and 
Saudi Arabia,(20) the need to strengthen HIV prevention 
for key populations at high risk is acknowledged but 
people who inject drugs are not. However, Egypt,(29) 
Iran,(6) Morocco, Syria and Tunisia all refer to harm 
reduction in their national strategic plans.(5)
In November 2012, a technical meeting to develop 
an	Arab	AIDS	strategy	took	place	in	Riyadh.	The	
meeting was organised by the League of Arab 
States in coordination with UNAIDS, and served as a 
technical forum for facilitating the development and 
implementation of the strategy. The Council of Arab 
Ministers of Health endorsed the Arab AIDS Strategy 
(2014–2020) during its session at the League of Arab 
States.(50) The strategy acknowledges people who 
inject drugs, and urges the need to scale up HIV 
testing and harm reduction programmes as part of an 
integrated package of services for people who inject 
drugs.
In 2013, UNODC and partners selected 24 high-
priority countries where more concentrated efforts will 
be focused on HIV prevention, including people who 
inject drugs and other key population groups.(51) This 
initiative will affect three of the most-affected MENA 
countries – Iran, Egypt and Morocco – and hopefully 
will improve harm reduction efforts. In 2012, a regional 
technical committee on harm reduction was formed 
to enhance coordination among key actors working 
on the topic and/or engaging with people who inject 
drugs.	The	committee	was	led	by	MENAHRA	and	
includes WHO, UNODC and UNAIDS representatives 
as core members.(4)          
Civil society and advocacy 
developments for harm reduction
Civil society organisations in MENA have consistently 
played an active role in advocating and implementing 
harm reduction approaches. In November 2013, 
MENAHRA	held	its	2nd	Regional	Conference	on	Harm	
Reduction	in	Beirut.	Hosted	by	the	Lebanese	ministry	
of public health, the three-day event brought together 
over 224 delegates from 24 countries to discuss, 
debate and advocate for harm reduction policies 
and practices. During the conference, delegates 
shared	findings,	achievements	and	challenges	to	
harm reduction in MENA. A pre-conference donors’ 
meeting highlighted MENA’s harm reduction needs, 
ensuring that the region remains an integral part of 
donors’	agendas.	A	film	festival	also	took	place	over	
two	days,	during	which	14	films	and	documentaries	
illustrated harm reduction issues in the region.(4) 
MENA also has a Middle East and North Africa 
Network of People who Use Drugs (MENAPUD), 
formed	at	the	International	Harm	Reduction	
Association’s Conference in Beirut in 2011. Lacking 
a coordinating body, this network of people who use 
drugs,	or	who	previously	used	drugs,	at	first	had	
relatively low levels of engagement. 
Harm reduction and the Regional 
Religious leaders Group 
In December 2012, a regional advocacy meeting 
on harm reduction was held for religious leaders. 
Eighteen participants attended, representing 
different religions and sects from Lebanon, 
Syria, Jordan, Egypt, Tunisia, Morocco and 
Bahrain. It was an important move forward for 
harm reduction in the region, as religious leaders 
can be important stakeholders. In addition to 
advocating with policymakers and government 
officials,	advocating	with	religious	leaders	
to promote acceptance of harm reduction 
programmes is often central to increasing 
tolerance of harm reduction. The religious 
leaders	who	attended	had	previous	experience	
of HIV and AIDS, and most were part of the 
CHAHAMA	network	(Arab	Religious	Leaders	
Network	Responding	to	AIDS).	As	a	result	of	
this meeting, participants formed a group on 
harm reduction and issued a declaration on the 
rights of people who use drugs and on harm 
reduction.(52) The group are presently preparing a 
manual,	Harm	Reduction	for	Religious	Leaders,	
which will be completed by the end of 2014.
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Then in March 2014 funds were secured by 
MENAHRA	to	appoint	a	coordinator	and	re-activate	
the network. Since April 2014, MENAPUD members 
and the coordinator have been working, with 
MENAHRA’s	support,	on	structuring	the	network	
through capacity-building and mentorship. In addition, 
the group has been involved in a number of activities 
to increase the representation and participation of 
the community of people who use drugs within the 
region,	such	as	a	graffiti	event	in	Beruit.(4)
In	February	2014,	the	Second	Regional	Consultative	
Meeting towards Networking of Drug Demand and 
Harm	Reduction	NGOs	was	held	in	Tehran.	Multiple	
regional and international organisations were in 
attendance to help draft the network’s constitution. 
Presentations and plenaries took place, and harm 
reduction, networking and advocacy issues were 
discussed. At the end of the meeting, the proposed 
constitution was approved by members and Iran was 
designated the network’s secretariat.(53) 
MENAHRA	also	became	a	primary	recipient	of	
a	Global	Fund	Round	10	grant	to	advocate	for	a	
conducive environment for implementing harm 
reduction activities, advocacy and capacity-building 
work in 13 MENA countries. At the end of 2013, 
MENAHRA	underwent	a	round	of	negotiations	for	
Phase 2 of the grant, receiving approval to initiate 
activities for the following three years (2014–2016).(4)
In 2013, Drosos funded the Network of Associations 
for	Harm	Reduction	(NAHR)	in	Egypt,	a	coalition	
of civil society organisations and stakeholders 
supportive of and dedicated to harm reduction 
initiatives. Its aim is to strengthen collaborations 
among civil society organisations to improve 
implementation of harm reduction activities, as well as 
reduce	stigma	and	discrimination	experienced	by	key	
populations.(54) 
Funding: developments for harm 
reduction
The	Global	Fund	is	one	of	the	most	significant	
contributors to the funding of harm reduction in 
MENA. Aside from Iran, where almost 95% of OST 
services are provided by the private sector and civil 
society organisations,(4) funding for harm reduction 
services in Morocco, Lebanon, Jordan, Egypt and 
Tunisia	stems	from	MENAHRA	during	Phase	1	of	the	
Global	Fund	grant,	extended	through	negotiating	
for Phase 2 funding from the New Funding Model.
(4) With the Global Fund’s support, advocacy and 
scoping missions have also been funded. In 2012, 
two advocacy missions were conducted in Oman and 
Jordan, and in 2013 two advocacy missions were 
conducted in Egypt and Libya. However, Jordan has 
recently	been	classified	as	ineligible	for	Global	Fund	
grants because of its status as a middle-income 
country, and alternative donors must be sought. 
The	Global	Fund,	through	MENAHRA,	has	funded	
knowledge hubs in Morocco and Lebanon, delivering 
multiple trainings on advocacy. There is also a 
knowledge hub in Iran called KH-INCAS, although 
there have been issues relating to the receipt of funds 
due to international sanctions placed on Iran.(4) The 
regional	Global	Fund	grant	(Round	10)	managed	by	
MENAHRA	ends	in	2016.	As	the	major	source	of	
funding for harm reduction services in a number of 
MENA countries, an alternative is urgently needed to 
ensure that services continue and that pilots begin in 
countries	where	no	services	exist.(4) Drosos funding for 
NAHR	in	Egypt	ends	in	2017,	and	again,	alternative	
funding must be secured before the grant ends so as 
to not adversely affect the harm reduction initiatives 
underway in the country.
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Table 2.9.1: Epidemiology of HIV and viral hepatitis, and harm reduction responses in sub-Saharan Africa
Country/
territory
with reported
injecting
drug use
People who
inject drugs
Hiv prevalence
among people
who inject drugs
(%)
Hepatitis C (anti-
HCv) prevalence
among people
who inject drugs
(%)
Hepatitis B
(anti-HBsag)
prevalence among
people who  
inject drugs 
(%)
Harm reduction 
response
nSPi oSTii
burkina faso nk nk nk nk x (1)
côte d’ivoire nk nk nk nk x x
djibouti nk nk nk nk x x
Gabon nk nk nk nk x x
Ghana nk nk nk nk x x
Kenya 18,327(2) 18(2) 51.4 (42.2–60.6)(3) 6.4(3) (10)(22) x
malawi nk nk nk nk x x
mauritius 10,000(4) 44.3(4) 97.3(5) 9(3) (52)(4) (16) (m, o)
nigeria 11,692 4.2(6) nk nk x x
Senegal 1,324(7) iii 9.1(8) nk nk (1) x
Seychelles 345(9) 5.8(9) 53.5(9) 0.1(9) x (9)
Sierra leone nk nk nk nk x x
South africa 67,000(10) 19.4(10) nk nk (1)iv (m, b)v
tanzania 30,000(11) 33.9(11) 28(11) nk (7) (3) (m, o)
uganda nk 16.7(12) vi nk nk x x
Zambia nk nk nk nk x x
 
i	 This	includes	all	operational	NSP	sites,	including	fixed	sites,	vending	machines	and	mobile	NSPs	operating	from	a	vehicle	or	through	outreach	workers.
ii	 (M)	=	methadone,	(B)	=	buprenorphine,	(O)	=	any	other	form	(including	morphine	and	codeine).
iii	 This	is	based	on	sub-national	data	from	the	Dakar	region.
iv	 This	is	a	small-scale	community-based	outreach	programme	delivering	needles	and	syringes.
v	 In	the	Western	Cape	there	is	one	government-funded	OST	demonstration	project,	but	as	both	private	and	public	clinics	provide	OST	we	are	unable	to	cite	an	actual	figure.
vi	 Based	on	a	study	conducted	in	Kampala	in	2012	with	a	sample	of	54	people	who	inject	drugs.
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An	estimated	23.5	million	people	are	living	with	HIV	in	
sub-Saharan Africa, representing 69% of the global 
HIV	burden.(13)	In	2012,	75%	of	all	new	HIV	infections	
globally	occurred	in	the	region.(14)	Although reliable 
information	on	injecting	drug	use	in	sub-Saharan	Africa	
is	very	limited,	estimates	suggest	that	there	may	be	
1,020,000	people	who	inject	drugs,	with	an	extremely	
wide	range	of	between	300,000	and	6,240,000,(15) of 
which	5	to	10%	are	thought	to	be	living	with	HIV.(14)	
There	is	some	understanding	of	HIV	prevalence	among	
people	who	inject	drugs	in	certain	countries	in	sub-
Saharan	Africa.	However,	due	to	the	different	methods	
of	calculating	prevalence,	and	figures	often	stemming	
from	sub-national	data,	the	numbers	cited	should	be	
viewed	with	caution.	The	reported	prevalence	of	HIV	
among	people	who	inject	drugs	in	Tanzania	in	2012	
was	42%,(10)	which	has	since	dropped	to	an	estimated	
33.9%.(11)	Research	in	Kampala,	Uganda,	found	16.7%	
HIV	prevalence	among	people	who	inject	drugs.
(12)	This	is	believed	to	be	the	first	study	of	its	kind	to	
map	prevalence	among	key	populations	in	Uganda,	
producing	a	pledge	from	government	to	prioritise	
innovative	approaches	for	people	who	inject	drugs.(12)	
In	Senegal,	HIV	prevalence	among	people	who	inject	
drugs	is	approximately	9.1%.(8)	It	has	recently	been	
reported	that	a	small-scale	community-based	needle	
and	syringe	programme	(NSP)	has	been	initiated,(16) 
which	is	the	only	government-run	harm	reduction	
programme	in	West	Africa.(8) 
Although	services	are	generally	lacking,	the	initiation	
of	research	and	emerging	harm	reduction	policies	
are	positive	steps	forward,	particularly	in	light	of	
the	documentation	of	high-risk	injecting	practices,	
including	that	of	flashbloodvii	occurring	in	Tanzania	and	
Zanzibar.(17)	Moreover,	because	of	the	geographical	
location	of	countries	such	as	Tanzania	and	Zanzibar	
along	key	transit	points	for	the	trafficking	of	heroin,	
cocaine	and	other	drugs,	there	is	increased	availability	
of	these	drugs	in	this	part	of	the	region.(18) South 
Africa	has	also	seen	a	marked	increase	in	stimulant	
use(19)	that	is	evidenced	in	research	into	increased	
risk	behaviours	for	sexual	transmission	of	HIV.(20)	In	
Western	Cape	Province,	the	proportion	of	admissions	
to	drug	treatment	facilities	for	methamphetamine	as	
the	primary	drug	used	increased	from	0.8%	in	2001	to	
52%	in	2011.(21) 
Programmatic	scale	up	of	harm	reduction	services	in	
a	few	sub-Saharan	countries	has	marginally	improved	
since	2012.	However,	it	has	not	grown	in	proportion	
to	the	HIV	epidemic	among	people	who	inject	drugs.	
NSPs	have	been	implemented	in	Kenya(22) and scaled 
up	in	Tanzania	from	one	site	in	2012	to	seven	sites	in	
2014,	including	one	mobile	outreach	programme.(23)	
The	recent	establishment	and	scale	up	of	community-
based	opioid	substitution	therapy	(OST)	in	Tanzania	is	
an	important	step	forward	for	the	region,	as	the	first	of	
its	kind	in	East	Africa.	
As	Table	2.9.1	shows,	there	is	a	serious	need	to	close	
the	evidence	gaps	on	the	epidemiology	of	HIV	and	viral	
hepatitis	among	people	who	use	drugs	in	sub-Saharan	
Africa.	Ghana	is	set	to	undertake	a	study	in	2014	on	
people	who	inject	drugs	to	ascertain	an	accurate	
picture	of	trends.(24)	A	study	in	2011	documented	
injecting	drug	use	among	males,	but	did	not	make	
reference	to	females	who	inject	drugs.(25)	Research is 
also	scheduled	in	Somalia(26)	and	Senegal.(7)	In	South	
Africa,	the	Centres	for	Disease	Control	and	Prevention	
(CDC)	have	contracted	civil	society	organisations	to	
work	on	increasing	services,	awareness	and	education	
on	harm	reduction,	with	a	demonstration	project	
planned	for	Cape	Town,	Durban	and	Pretoria.(19) 
However,	other	countries,	such	as	Zambia,	which	has	
one	of	the	highest	HIV	prevalence	rates	in	the	world,(27)	
have	no	verified	data	on	injecting	drug	use	and	HIV,	
and	no	research	planned.	Other	countries,	such	as	
Rwanda,	claim	that	injecting	drug	use	is	not	present	
and	therefore	do	not	target	people	who	use	drugs	in	
their	HIV	strategy,	despite	data	collected	in	2007/2008	
identifying	injecting	drug	use.(28)	However,	there	is	a	
proposal	from	the	Global	Fund	to	increase	data	and	
research	for	East	Africa.
Recent	civil	society	initiatives	include	establishing	the	
Kenya	Network	of	People	who	Use	Drugs	(KeNPUD)	
in	2012,	followed	by	the	Eastern	African	Harm	
Reduction	Network,(22,	30)	which	met	in	March	2013	
to	share	experiences	and	strengthen	organisational	
development	for	a	resilient	regional	harm	reduction	
network.(31)		Also	in	2013,	a	countrywide	harm	reduction	
network	was	implemented	in	Uganda,(29)	and an 
advocacy	group,	the	Tanzania	Network	of	People	Who	
Use	Drugs	(TANPUD),	was	introduced,(23)	advocating	
and	educating	for	the	health	and	human	rights	of	
people	who	use	drugs.(32)	Most	recently,	in	June	2014,	
ReAct,	an	independent	peer-led	network	of	people	who	
use	drugs,	was	established	in	Tanzania.(33) 
The	limited	services	in	the	region,	coupled	with	the	
criminalisation	of	drug	use	and	minor	possession,	
do	little	to	reduce	HIV	risks	faced	by	people	who	
inject	drugs,(34)	and	do	not	meet	international	
recommendations.While	there	are	significant	structural	
factors	involved	beyond	service	provision,	drug	policy,	
criminal	laws,	law	enforcement	and	political	priorities	
relating	to	drugs	present	significant	hurdles	to	access	
and	scale	up	of	programmes,	with	many	countries	
continuing	to	focus	primarily	on	supply	reduction	and	
law	enforcement	rather	than	public	health.	There	is	also	
Harm	reduction	in	sub-Saharan	Africa
vii	 Flashblood	is	a	high-risk	blood-sharing	practice	that	carries	a	very	high	probability	of	HIV	transmission.	One	user	draws	blood	back	into	the	syringe	after	
injecting	heroin	and	then	passes	the	syringe	on	to	a	peer,	who	injects	the	3ml	to	4ml	of	blood.
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a	need	in	the	region	to	include	people	who	use	drugs	
in	harm	reduction	initiatives	and	research	in	order	to	
obtain	a	more	accurate	picture	of	various	types	of	
substance	use.(35)
Developments	in	harm	reduction	
implementation
Needle	and	syringe	exchange	programmes	(NSPs)
NSPs	are	generally	unsupported	both	financially	and	
politically	by	governments,	with	civil	society	providing	
the	majority	of	services	in	the	region.(19,	22,	23,	30,	36)	
Historically	Mauritius	has	been	the	only	exception,	
but	in	2012	the	Kenyan	government	announced	the	
initiation	of	NSPs	within	the	country,(28)	resulting	in	2014	
in	ten	newly	operational	sites	(four	in	Nairobi,	three	
in	Kilifi,	two	in	Mombasa	and	one	in	Kwale)	reaching	
4,500	people	who	inject	drugs.(22)	It	is	estimated	that	
51.6%	of	people	using	NSP	service	provision	in	Kenya	
now	report	using	sterile	injecting	equipment.(2)	There 
has	also	been	a	scale	up	of	NSPs	in	Dar	es	Salaam,	
Tanzania,	increasing	from	one	site	in	2012	to	seven	in	
2014,	with	one	mobile	NSP	visiting	people	who	inject	
drugs	approximately	once	a	week.(23)	On	average,	155	
syringes	were	distributed	per	person	per	year	in	Dar	
es	Salaam,	with	84.2%	of	people	who	inject	drugs	
reporting	using	sterile	injecting	equipment	in	areas	
where	there	is	NSP	provision.(37)	In	South	Africa,	there	is	
presently	only	one	NSP	site	focused	on	men	who	have	
sex	with	men	who	inject	drugs.	(19) 
By	far	the	greatest	coverage	of	NSPs	in	the	region	
is	to	be	found	in	Mauritius.	On	average,	44	syringes	
were	distributed	per	person	per	year	in	Mauritius,	
with	83.8%	of	people	who	inject	drugs	reporting	
using	sterile	injecting	equipment	in	2013.(4)	However,	
Mauritius	has	remained	static	in	terms	of	NSP	sites,	
and	although	generally	people	who	inject	drugs	are	
moving	towards	OST,	a	growing	number	are	injecting	
drugs	and	accessing	services.	Consequently,	there	
are	often	insufficient	facilities	to	meet	the	need,	which	
is	negatively	affecting	the	quality	of	service,	with	long	
waiting	times	and	lack	of	equipment.(30)
In	Nigeria,	9%	of	new	HIV	infections	are	attributed	to	
unsafe	injecting	drug	use(38)	and	there	are	currently	
no	known	NSPs.	However,	70.89%	of	people	who	
inject	drugs	reported	using	sterile	injecting	equipment	
between	2005	and	2010(6)	due	to	widespread	
availability	via	pharmacies.(38)	In	the	Seychelles,	a	high	
percentage	of	people	who	inject	drugs	have	reported	
practising	unsafe	injecting,	and	OST	has	been	newly	
introduced,	along	with	a	recognition	by	government	
of	a	need	for	NSP	service	provision.(9)	In	Senegal,	
NSP	provision	on	a	small	scale	has	recently	been	
established.(16)
Despite	increases	in	the	number	of	NSP	sites	in	
sub-Saharan	Africa,	coverage	of	existing	services	
still	remains	disproportionately	low	compared	to	
international	coverage	targets.(39) There are also 
numerous	legal	and	policy	barriers,	coupled	with	
intense	social	stigma	associated	with	injecting	drug	
use.	This	can	force	people	who	inject	drugs	to	hide	
injecting	equipment	and	engage	in	unsafe	injecting	
practices.	Even	in	areas	where	it	is	legal	to	purchase	
needles	and	syringes,	police	harassment	and	fear	
of	arrest	for	carrying	drug	paraphernalia	may	deter	
individuals	from	accessing	services.(19,	23,	29,	30) 
These	barriers	lead	to	poor	health-seeking	behaviour.(19)
women who inject drugs: adapting the service response in sub-Saharan africa
As	in	many	other	parts	of	the	world,(40,	41)	women	who	inject	drugs	often	experience	disproportionately	
higher	levels	of	negative	health	outcomes,(11,	39,	42)	with	HIV	prevalence	for	women	who	inject	being	5	
to	15%	higher	than	their	male	counterparts	in	Nigeria(43)	and	55	to	68%	higher	in	Tanzania.(44)	A	study	
looking	specifically	at	gender	inequalities	in	harm	reduction	services	in	Dar	es	Salaam	found	that	only	
8%	of	those	accessing	the	services	were	women.(45)	In	another	study	undertaken	in	South	Africa,	less	
than	20%	of	women	who	use	drugs	reported	any	awareness	of	drug	treatment	programmes.(34) 
Gender	inequality,	alongside	lower	purchasing	power	and	dependence	on	their	male	partners,(43)	mean	
that	some	women	who	inject	drugs	participate	in	extremely	high-risk	injecting	practices.	However,	
awareness	of	the	heightened	barriers	that	women	who	use	drugs	encounter	in	accessing	services	is	
increasing	with	the	development	of	gender-sensitive	services	in	some	countries.(22,	23)	In	Kenya,	for	
example,	NSP	services	are	using	community-based	outreach	that	will	enable	women	who	do	not	wish	
to	seek	services	publicly	to	access	NSP	provision,(22)	and	mobile	units	are	in	operation	in	Tanzania	and	
Mauritius.(23,	30)	The	demonstration	project	planned	in	South	Africa (see	page	122),	although	not	yet	
implemented,	has	also	built	in	harm	reduction	approaches	for	women,	using	female	peers	and	other	
female	staff	members	in	outreach	programmes	to	support	women	who	are	fearful	of	attending	services.
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Opioid	substitution	therapy	(OST)
As	illustrated	in	Table	2.9.1,	OST	remains	largely	
unavailable	throughout	sub-Saharan	Africa,	with	the	
exception	of	Mauritius,	(30)	where	over	6,000	people	
access	services,	and	newly	initiated	programmes	
in	Tanzania. Methadone	maintenance	therapy	has	
increased	in	Tanzania,	which	is	a	significant	step	
forward,	rising	from	one	site	to	three	in	the	city	of	
Dar	es	Salaam.(23)	This	makes	the	OST	programme	in	
Tanzania	the	largest	government-run	programme	in	the	
region,	with	over	1,200	people	receiving	methadone	
in	2013	and	outreach	workers	making	contact	with	
around	20,000	people	who	use	drugs.(8)	However,	
takeaway	doses	remain	unavailable,	and	the	cost	of	
transport	to	OST	sites	for	people	who	inject	drugs	
has	been	cited	as	a	barrier	to	access.	In	Mauritius,	
people	who	inject	drugs	and	wish	to	access	OST	
must	complete	a	two-week	induction	period,	either	
as	an	inpatient	or	outpatient.	This	requirement	has	
been	cited	as	a	barrier	for	those	in	employment,	those	
who	do	not	wish	to	disclose	to	their	family	that	they	
inject	drugs,	and	for	women	who	cannot	find	or	afford	
childcare.(30) 
In	Kenya,	methadone	OST	is	in	development,	with	
funding	from	the	US	government	and	technical	
support	from	the	United	Nations	Office	on	Drugs	
and	Crime	(UNODC),	and	is	due	to	be	situated	in	
government	hospitals	in	Mombasa,	Malindi	and	
Nairobi.(22)	However,	OST	in	a	community	setting	
remains	unavailable,	and	due	to	a	long	process	of	
service	development	and	preparation,	it	is	unlikely	
to	be	established	in	the	near	future.	In	Senegal,	an	
OST	site	within	a	drug	treatment	centre	is	currently	
being	built	in	Dakar,(16)	and	OST	provision	is	reportedly	
available	in	Burkina	Faso,	although	limited	information	
is	available.(1)
There	are	OST	sites	in	operation	in	South	Africa	and	
plans	to	increase	this	service.	However,	available	data	
indicates	that	this	is	restricted	to	just	one	government-
funded	site,	with	private	OST	provision	available	
in	clinics.(19)	While	other	government	hospitals	use	
methadone,	it	should	be	noted	this	is	for	detoxification	
services	only.	Due	to	the	cost	of	treatment	and	the	
inability	of	many	people	who	inject	drugs	to	obtain	
private	health	insurance,	coverage	remains	low	in	the	
country.(19) 
In	many	of	the	other	sub-Saharan	African	countries	
where	injecting	drug	use	has	been	reported,	such	as	
Nigeria	and	Uganda,	OST	has	yet	to	be	established.	
 
Viral	hepatitis
Hepatitis	C	(HCV)	and	hepatitis	B	prevalence	in	
sub-Saharan	Africa	is	generally	quite	high,	and	more	
elevated	still	among	people	who	inject	drugs.	For	
example,	Kenya	reports	over	50%	HCV	prevalence	
among	people	who	inject	drugs,	and	Mauritius	over	
97%.(46,	47)	However,	data	relating	to	viral	hepatitis	in	
people	who	inject	drugs	is	sparse.	Within	the	five	
countries	where	data	is	available,	HCV	prevalence	is	
thought	to	be	significantly	higher	than	HIV	prevalence.	
The	estimate	of	HCV	prevalence	for	people	who	
inject	drugs	in	Tanzania	is	28%,(23) an increase of 
approximately	5%	from	2012.		
The	cost	of	treatment	and	testing	is	one	of	the	central	
problems	in	addressing	HCV.	In	Tanzania,	the	cost	of	
treatment	for	HCV	is	more	than	€10,000	per	patient.(23) 
In	Kenya,	HCV	treatment	is	also	very	limited.	People	
can	be	referred	to	research	institutes	or	government	
hospitals.	However,	referral	rates	are	extremely	low,	
and	people	who	inject	drugs	report	rarely	being	
offered	a	rapid	HCV	test	and	generally	having	little	
to	no	access	to	treatment.(22)	Barriers	to	access	for	
testing,	treatment	and	care	are	evident	in	Uganda	and	
South	Africa.	In	Mauritius,	HIV	and	HCV	testing	are	
offered	together,	but	as	in	most	countries	in	the	region,	
treatment	is	unavailable	for	people	who	inject	drugs,	
even	though	97%	of	them	are	HCV	positive.	
In	2014,	Nigeria	developed	a	programme	to	enable	
HCV	testing	for	people	who	use	drugs,	but	the	policy	
has	only	recently	been	published	and	is	yet	to	be	
implemented.	As	in	most	countries	in	the	region,	HCV	
treatment	is	unavailable,	not	only	for	key	populations	
but	for	anyone.	New	HCV	direct	acting	antiretroviral	
medications	have	been	hailed	as	“revolutionary”,	
and	it	is	hoped,	will	ensure	greater	adherence	and	
clearance	rates	of	HCV.	However,	the	extremely	high	
cost	of	these	new	drugs	puts	them	out	of	reach	for	
low-	and	middle-income	countries.	However,	Gilead,	
a	pharmaceutical	company	that	has	developed	
medicines	suitable	for	treating	viral	hepatitis,	is	
working	with	regional	partners	to	introduce	low-cost	
generic	Sovaldi®	(one	of	the	new	WHO-recommended	
HCV	treatment	drugs)	for	use	in	low-	and	middle-
income	countries.(48)
Tuberculosis
Prevalence	of	tuberculosis	(TB)	in	sub-Saharan	Africa	
is	extremely	high,	with	more	than	75%	of	HIV	co-
infection	with	TB	based	in	this	region.(14) There is a 
paucity	of	data	related	to	TB	prevalence	among	people	
who	inject	drugs.	While	the	majority	of	those	who	have	
been	diagnosed	will	not	develop	active	TB	disease,	
people	who	inject	drugs,	together	with	prisoners,	are	
more	vulnerable	to	progressing	to	active	TB	due	to	
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increased	HIV	co-infection	among	people	who	inject	
drugs,	and	prison	conditions	in	some	countries.(49) 
Where	available,	TB	rates	per	100,000	in	the	
population	were	reported	to	be	highest	in	South	
Africa	(981)	and	Zimbabwe	(633),	with	Mozambique	
(544)	and	the	Democratic	Republic	of	Congo	(327)	
also	reporting	substantial	rates.(49) Although there 
are	services	for	testing	and	treatment	of	TB	in	most	
countries	in	the	region,	stigma,	discrimination	and	
treatment	adherence	impede	any	advances	in	tackling	
TB	among	people	who	inject	drugs.	In	the	Temeke	
district	of	Dar	es	Salaam	in	Tanzania,	a	national	
patient-led	organisation	focusing	on	TB	and	HIV,	called	
MUKIKUTE,	has	been	established,	integrating	TB	
and	HIV	low-threshold	centres	for	people	who	inject	
drugs.(23)	It	is	the	only	service	reported	that	delivers	
coordinated	TB	and	HIV	services	in	Tanzania.	Although	
TB	diagnosis	and	treatment	are	available	and	free,	the	
high	prevalence	rate	among	people	who	use	drugs	
means	that	clinics	may	face	difficulties	in	accepting	all	
requests.(23) 
A	similar	problem	is	apparent	in	Kenya	and	South	
Africa,	with	treatment	available	but	detection	among	
people	who	inject	drugs	remaining	an	issue.	In	South	
Africa,	however,	it	is	hoped	that	this	will	be	addressed	
with	the	implementation	of	a	multi-site	programme	
that	came	into	operation	during	2014	as	part	of	
national	health	screening.(19)	There	are	few	TB	cases	in	
Mauritius,	but	diagnosis	and	treatment	are	available	for	
people	who	use	drugs.(30)	There	are	no	TB	programmes	
for	people	who	inject	drugs	in	Nigeria,	but	a	
programme	is	available	for	the	general	population.(36)
Antiretroviral	therapy	(ART)
In	2012	there	were	an	estimated	6,991,492	adults	
receiving	antiretroviral	therapy	(ART)	in	sub-Saharan	
Africa,(14)	representing	60%	of	those	living	with	HIV.	
However,	the	data	on	numbers	of	people	who	inject	
drugs	receiving	ART	within	this	region	remain	limited.	
In	2008,	the	Reference	Group	to	the	United	Nations	
on	HIV	and	Injecting	Drug	Use	reported	that	just	38	
people	who	inject	drugs	in	Kenya	and	138	people	who	
inject	drugs	in	Mauritius	were	receiving	ART.	These	
estimates	represented	less	than	1%	of	HIV-positive	
people	who	inject	drugs	in	Kenya	and	1.1%	of	people	
who	inject	drugs	in	Mauritius	receiving	ART.(50) There 
is	no	up-to-date	government	data	in	the	region	on	the	
number	of	people	receiving	ART	who	inject	drugs,	
making	it	difficult	to	calculate	ART	coverage	among	
this	population.
In	Tanzania,	reports	have	shown	that	people	who	use	
drugs	have	been	discriminated	against	and	denied	HIV	
testing	from	certain	government	hospitals.	However,	
non-governmental	organisations	(NGOs)	also	provide	
testing	services	and	sensitisation	programmes,	
and	training	among	providers	is	being	rolled	out	in	
government	hospitals	to	improve	access	for	people	
who	use	drugs.(23)	In	Kenya,	all	people	who	use	drugs	
who	have	a	CD4	count	of	less	than	350	are	eligible	
for	ART;	otherwise	they	are	provided	with	prophylactic	
cotrimoxazole	–	an	antibiotic	seen	to	reduce	morbidity	
in	adults	with	HIV.(22,51)	In	Mauritius,	ART	is	available	
for	people	who	inject	drugs	at	the	HIV	public	hospital.	
ART	is	available	in	South	Africa,	but	services	are	not	
explicitly	aimed	at	people	who	inject	drugs.(19) 
Harm	reduction	in	prisons
The	criminalisation	of	possession	of	drugs	and	
drug use in sub-Saharan Africa contributes to a 
high	proportion	of	people	who	inject	drugs	being	
incarcerated.	Evidence	suggests	that	the	prison	
setting	may	be	contributing	considerably	to	
accelerating	HIV	transmission	with	high-risk	injecting	
practices.(34)	In	2008,	a	study	undertaken	in	Ghana	
found	that	35%	of	people	in	prison	reported	a	history	
of	injecting	drug	use.(52)	
In	Africa,	OST	in	prisons	is	available	only	in	Mauritius	
and	is	limited	to	male	prisons.(30)	In	addition,	men	who	
are	incarcerated	on	the	island	and	who	do	not	have	
ID	cards	are	refused	access	to	this	service.	There	has	
been	some	improvement	in	OST	provision	in	that	it	
is	now	available	for	prisoners	who	were	not	receiving	
OST	before	they	were	in	custody.(30)	In	the	rest	of	the	
region,	harm	reduction	services	in	the	form	of	OST	and	
NSPs	are	unavailable	in	prison	settings.	While	Nigerian	
government	objectives	outline	a	commitment	to	
increased	access	for	people	who	inject	drugs	to	a	full	
range	of	harm	reduction	measures,	planned	services	
in	prisons	are	limited	to	drug	treatment,	telephone	
hotlines	and	drop-in	centres	providing	information	and	
referrals.(53) 
ART	is	available	in	Kenyan	prisons,(22)	with	
approximately	77%	of	Kenyan	detainees	reporting	
being	tested	for	HIV.(54)	Uganda	also	provides	ART	
to those incarcerated,(29) and South Africa is due 
to	provide	ART	provision	across	prison	settings	
following	a	court	decision.(19)	In	Tanzania,	it	has	been	
reported	that	ART	should	be	available	in	prisons,	
but	it	is	unclear	whether	this	service	is	actually	being	
offered.	In	addition,	the	government	has	justified	
the	non-availability	of	condoms	for	male	prisoners	
by	citing	the	illegality	of	sodomy.	Indeed,	condom	
provision	in	prisons	throughout	the	region	is	limited	
to	South	Africa,	where	availability	is	inconsistent.(19) 
The	UK	Department	for	International	Development	
has	published	plans	for	a	regional	project	aimed	at	
making	condom	provision	in	prisons	more	politically	
acceptable	in	Southern	Africa.(67)
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Overdose
There	is	little	data	on	the	prevalence	of	and	response	
to	overdose	in	sub-Saharan	Africa.	Data	from	
2011	indicated	that	overdose	cases	in	Kenya	were	
estimated	to	be	83–90%	higher	in	Nairobi	than	in	the	
coastal	areas,	and	approximately	58%	of	people	who	
injected	drugs	in	Kenya	reported	knowing	at	least	
one	person	who	had	experienced	a	fatal	overdose.(55) 
Naloxone,	a	highly	effective	opioid	antagonist	used	
to	reverse	the	effects	of	opiate	overdose,	is	now	
available	in	Kenya,	although	the	success	of	this	
provision	has	yet	to	be	evaluated.(22)  
Naloxone	is	also	available	in	hospitals	in	Tanzania,(56) 
but	there	is	still	no	access	to	overdose	treatment	
for	the	wider	population;	for	example,	friends	and	
family	of	the	person	injecting	drugs.	Civil	society	and	
government	in	Tanzania	are	in	discussion	regarding	
naloxone	peer-distribution	programmes.(23)		
Mauritius,	South	Africa	and	Nigeria	currently	have	no	
overdose	prevention	system	in	operation.(19,30,36) 
Policy	development	for	harm	reduction
Since	2012,	seven	sub-Saharan	countries	have	
adopted	a	specific	reference	to	harm	reduction	in	
national	HIV	policy	documents.	Harm	reduction	is	
currently	endorsed	in	the	Tanzanian	National	Strategy	
for	Non-Communicable	Diseases	2009–2015(57) and 
the	Tanzania	Third	National	Multi-Sectoral	Strategic	
Framework	for	HIV	and	AIDS.(58)	It	is	also	a	component	
of	HIV	policy	frameworks	in	Kenya	and	Mauritius.(30,42) 
The	2011–2015	National	AIDS	Programme	in	Senegal	
also	makes	explicit	reference	to	people	who	inject	
drugs	as	a	priority	target	group.(59)	The	government	
of	Mauritius	has	also	stated	that	it	will	re-establish	
a	harm	reduction	committee,	conduct	frequent	
harm	reduction	awareness	programmes,	and	aim	to	
decriminalise	the	distribution	and	use	of	syringes.(4) 
In	Uganda,	where	there	are	currently	no	active	harm	
reduction	services,	the	United	Nations	Development	
Programme	(UNDP)	has	invited	the	Uganda	Harm	
Reduction	Network	(UHRN)	to	participate	in	
consultations	to	develop	a	model	for	a	regional	
framework	based	on	HIV	prevention,	treatment	and	
care	among	key	populations.(29)	The	Department	of	
Health	in	South	Africa	is	also	drafting	operational	
guidelines	for	HIV,	sexually	transmitted	infections	
and	TB	for	key	populations,(19)	and	advocating	for	
prescribed	medication	and	substitution	therapies	for	
opiate	dependence.(60)	
The	Seychelles	National	Strategic	Framework	2012–
2016	for	HIV	and	AIDS	and	STIs	prioritises	the	needs	
of	key	populations	at	higher	risk	of	HIV	exposure,	
including	people	who	inject	drugs,	recognising	the	
need	for	harm	reduction	services	such	as	NSPs	on	
the	island.(61)	In	2009,	harm	reduction	was	included	
in	the	National	Policy	on	HIV/AIDS	in	Nigeria,	where	
the	government	committed	to	“Increase	access	of	
drug	users	to	[a]	full	range	harm	reduction	measures	
and	to	service	providers	offering	treatment	for	drug	
dependence,	sexually	transmitted	infections,	AIDS	
and	tuberculosis.”(62)	
Despite	these	advances,	policies	for	most	countries	
in	the	region	continue	to	focus	on	supply	reduction	
and	the	criminalisation	of	drugs,	overshadowing	
any	harm	reduction	responses.	Despite	progress	in	
implementing	NSPs	in	Tanzania,	for	example,	the	
possession	of	needles	is	still	illegal	in	the	country.(11) 
A	small	step	forward	was	taken	in	Mauritius	when	
the	Dangerous	Drugs	Act	was	amended	in	2013	to	
make	provision	for	the	decriminalisation	of	“synthetic	
Cannabinoids	and	their	derivatives”,(30)	illustrating an 
increased	tolerance	towards	certain	forms	of	drug	use	
in	the	country.	
During	the	5th	African	Union		Conference	of	Ministers	
of	Drug	Control		in	2012,	a	new	Plan	of	Action	on	
Drug	Control	was	agreed	for	2013–2017.	This	signals	
an	important	step	forward,	with	a	balanced	approach	
that	includes	(in	the	accompanying	Implementation	
Matrix)	an	explicit	commitment	to	implement	the	
UNODC/UNAIDS/WHO	comprehensive	package	
of	harm	reduction	services,	as	well	as	providing	
alternatives	to	incarceration.	At	the	6th	Conference	
in	2014	–	under	the	bold	heading	‘Drugs	Kills,	But	
Bad	Policies	Kill	More’	–	countries	reviewed	progress,	
recommitted	to	harm	reduction,	and	held	important	
discussions	on	drug	policy	reform	in	the	region.(63)   
In	2013,	the	former	United	Nations	Secretary-General,	
Kofi	Annan,	convened	the	West	Africa	Commission	
on	Drugs	to	address	the	issue	of	drugs	and	security	
in	the	region.	The	commission	comprises	11	regional	
leaders	from	the	worlds	of	politics,	civil	society,	
health,	security,	law	enforcement	and	the	judiciary.	
It	is	chaired	by	former	Nigerian	president,	Olusegun	
Obasanjo.(8)	After	18	months	of	debate,	outreach	
and	consultation,	the	commission	launched	its	
report	in	2014,	recommending	the	adoption	of	a	
harm	reduction	and	public	health	approach	across	
the	region,	and	the	integration	of	harm	reduction	
into	national	drug	policies.(8) The report also 
called	for	broad	drug	policy	reform,	including	the	
decriminalisation	of	people	who	use	drugs,	and	for	
a	balanced	approach	to	drug	policy	that	prioritises	
health	and	human	rights.
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Civil	society	and	advocacy	
developments	for	harm	reduction
With	the	emerging	scale	up	of	harm	reduction	
services	in	Tanzania	and	Kenya,	and	a	plan	to	
initiate	these	in	Uganda,	civil	society	organisations	
in	the	region	have	helped	to	secure	small	but	
vital	improvements	in	harm	reduction	provision.	
Through	the	Community	Action	on	Harm	Reduction	
(CAHR)	programme,	additional	funding	for	the	NSP	
programme	was	secured	from	the	Open	Society	
Foundations	and	Mainline.(64)	In	the	continuing	
absence	of	local	government	support,	the	inception	
of	the	Eastern	African	Harm	Reduction	Network	may	
have	the	potential	to	contribute	to	a	coherent	regional	
harm	reduction	strategy,	with	the	synergy	of	civil	
society	organisations	giving	harm	reduction	a	stronger	
voice	in	a	part	of	the	world	where	for	too	long	it	has	
been	muted.
Collectif	Urgence	Toxida	(CUT),	the	national	harm	
reduction	network	in	Mauritius,	together	with	the	
Kenyan	AIDS	NGOs	Consortium	(KANCO)	and	other	
national	actors,	TanPUD,	Youth	RISE	Nigeria,	ZDCLU	
in	Zimbabwe	and	KenPUD	have	used	the	‘Support.	
Don’t	Punish’	campaign(65)	as	a	platform	for	people	
to	talk	publicly	about	drug	policy	reform.(23,29,30) This 
has	helped	to	draw	attention	to	the	need	for	harm	
reduction	services,	harm	reduction	funding,	and	drug	
policy	reforms	across	the	region.	
In	South	Africa,	the	CDC	has	contracted	civil	society	
organisations	to	set	up	a	pilot	programme	providing	
medication-assisted	treatment	to	people	who	are	
dependent	on	heroin.	The	demonstration	project	
planned	for	Cape	Town,	Durban	and	Pretoria	(see 
page	122)	will	provide	a	package	of	services	for	
people	who	inject	drugs.	It	aims	to	reach	50%	of	this	
population	in	the	areas	where	the	project	is	initiated,	
although	only	a	few	areas	of	these	municipalities	will	
be	targeted.(19)	Closer	collaboration	with	government	
authorities	is	also	evident	in	Uganda,	where	UHRN	
has been selected to represent the interests of 
people	who	use	drugs	on	a	ministry	of	health	national	
technical	committee.(29)	And	in	March	2013,	an	
inception	meeting	to	formulate	the	Eastern	Africa	
Harm	Reduction	Network	was	convened,	with	an	
application	put	forward	to	the	Global	Fund	to	support	
both	initiation	and	scale	up	of	harm	reduction.		
Funding:	developments	for	harm	
reduction
Multilateral	agencies	and	donor	NGOs	provide	the	
majority	of	HIV	and	AIDS	funding	in	sub-Saharan	Africa.	
In	Tanzania,	Médecins	du	Monde-France	received	a	grant	
from	the	Elton	John	AIDS	Foundation	(EJAF)	to	scale	up	
harm	reduction	programmes	in	Dar	es	Salaam.(23) The 
Open	Society	Foundations	have	also	been	supporting	
capacity-building	and	advocacy	in	the	country,	and	
funding	from	the	French	Development	Agency	has	
continued	to	assist	harm	reduction	programmes	in	Dar	
es	Salaam.(23)	CDC	has	also	supported	OST	in	Tanzania.	
In	2014,	the	Tanzanian	government	formed	a	resource	
mobilisation	committee	to	raise	awareness	of	harm	
reduction,	mobilise	resources	and	hold	a	workshop	with	
mayors	and	councillors	from	Dar	es	Salaam,	in	the	hope	
of	increasing	harm	reduction	funding.	At	present,	there	
is	no	available	data	on	the	contribution	of	government	
funding	for	harm	reduction	in	Tanzania.	However,	the	
Tanzanian	government	does	provide	HIV	tests	and	
condom	distribution,	with	more	funds	being	released	
to	build	a	centre	specifically	aimed	at	key	population	
groups.	
Kenya	received	an	one-year	extension	to	continue	harm	
reduction	programming	through	the	Dutch-funded	
CAHR	project	implemented	by	the	International	HIV/
AIDS	Alliance	in	December	2014.(22)	The	Global	Fund	
has	taken	over	funding	of	some	activities.(16)	The	Kenyan	
government	began	a	major	initiative	in	2014	to	introduce	
OST	to	people	who	inject	drugs	in	order	to	prevent	HIV	
and	increase	their	access	to	HCV	treatment	and	ART,	
while	promoting	respect	for	their	human	rights.	This	
initiative	is	the	result	of	a	unique	partnership	between	
the	ministry	of	health,	country	governments	in	Nairobi	
and	coastal	provinces,	UNODC	and	USAID.(66)	However,	
without	a	sustainable	plan	to	continue	the	funding	stream,	
any	progress	made	in	Kenya	for	provision	of	sterile	
injecting	equipment	and	OST	is	likely	to	be	reversed.	A	
similar	outcome	is	probable	in	Mauritius,	whichto	date	
has	received	US$9,668,292	in	harm	reduction	funding	
from	the	Global	Fund,	as	funding	will	cease	over	the	
coming	two	to	three	years.	The	Mauritian	government	
has	pledged	to	invest	in	some	national	projects,	but	it	is	
unclear	if	civil	society	(currently	funded	through	the	Global	
Fund)	will	benefit	from	this	support.	
In	Uganda,	funding	for	harm	reduction	has	generally	
been	viewed	as	a	low	priority	by	government,	although	
there	has	been	an	increased	focus	from	multilaterals	and	
donor	NGOs.	The	International	Treatment	Preparedness	
Coalition	(ITPC)	has	also	provided	US$20,000	for	two	
years	in	Uganda.(29)	Multilaterals,	including	UNODC,	
UNAIDS,	WHO,	and	agencies	such	as	PEPFAR,	have	
been	working	alongside	civil	society	organisations	in	
South	Africa	to	raise	harm	reduction	awareness,	but	large	
funding	gaps	remain.(19) 
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about this Publication
In 2008, Harm Reduction International released the Global State of Harm Reduction, a report that 
mapped responses to drug-related HIV and hepatitis C epidemics around the world for the first time. 
The data gathered for the report provided a critical baseline against which progress could be measured 
in terms of the international, regional and national recognition of harm reduction in policy and practice. 
Since then, the biennial report has become a key publication for researchers, policymakers, civil society 
organisations and advocates, mapping harm reduction policy adoption and programme implementation 
globally.
The Global State of Harm Reduction 2014 continues to map the response to drug-related HIV, viral 
hepatitis and tuberculosis. It also integrates updated information on harm reduction services into each 
regional chapter, including on needle and syringe programmes (NSPs) and opioid substitution therapy 
(OST) provision; harm reduction services in the prison setting; access to antiretroviral therapy for people 
who inject drugs; regional overdose responses; policy developments; civil society developments; and 
information relating to funding for harm reduction.
This report, and other global state of harm reduction resources, are designed to provide reference 
tools for  wide range of audiences, such as international donor organisations, multilateral and bilateral 
agencies, civil society and non-governmental organisation, including organisations of people who use 
drugs, as well as researchers and the media.
If you would like to find out more about Harm Reduction International
and how you can support our work, please contact us at:
Harm Reduction International
Unit 2C09, South Bank Technopark
90 London Road, London, SE1 6LN
Phone:  +44 (0)207 7171 592
Email: info@ihra.net
Web: www.ihra.net
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